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1 PREFACE 
Cancer research targeting Ras 
The oncogenic protein Ras is a key cancer promoting molecule in many tumours. 20-30% of 
all human cancers display mutations in the Ras encoding genes resulting in uncontrolled cellular 
growth. Therefore, the Ras protein has been a central target for pharmaceutical research within 
the last decades. Unfortunately, none of these research efforts has resulted in effective 
medication directly targeting Ras.  
Only recently it was realized how the cancer promoting effect of Ras is connected to the 
localization of Ras in the cell. The protein PDEδ has emerged as the central transporting agent 
for Ras. PDEδ regulates the cellular localization of Ras and Ras-dependent signal transduction. 
PDEδ has therefore been proposed as a novel target for suppressing oncogenic Ras signaling. 
Due to their favourable pharmacological properties, small organic molecules are often required 
for the treatment of deadly diseases like cancer. Decades of research on small molecule 
inhibitors of Ras have not lead to success, therefore novel approaches for targeting Ras are of 
particular value. In this thesis, targeting the Ras-PDEδ interaction will be explored as a novel 
means of suppressing oncogenic Ras signaling. The rational development of small molecule 
inhibitors blocking this interaction and their impact on Ras signaling will be described in detail.  
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2 INTRODUCTION 
2.1 Ras-GTPases  
GTPases are proteins that bind and hydrolyze guanosine triphosphate (GTP). The  Ras (rat 
sarcoma) GTPases regulate important cellular processes such as growth, differentiation and 
apoptosis.1 Ras proteins bind GDP and GTP with very high affinity and display low intrinsic 
GTPase activity and nucleotide exchange rates.2-4 By cycling between an inactive GDP- and an 
active GTP-bound state, Ras proteins act as molecular switches (Figure 1, a). The nucleotide 
binding state of Ras proteins is controlled by guanosine nucleotide exchange factors (GEFs) 
and GTPase activating proteins (GAPs).  
 
 
Figure 1: Biological switch function of Ras proteins.2 a) Ras acts as molecular switch by cycling between the 
GDP- and GTP bound state, which is regulated by GAPs and GEFs. Inactive, GDP-bound Ras is activated by 
guanine nucleotide exchange factors (GEF), which induce GDP/GTP exchange. GTP loading changes the Ras 
protein confirmation which results in binding to effectors via their Ras-binding domains (RBDs). The active state 
of Ras is regulated by its very slow intrinsic GTPase activity, which can be accelerated strongly by the interaction 
with a GTPase-activating protein (GAP); b) Mechanism of the Ras/Raf-1/Erk pathway which is frequently 
dysregulated in Ras dependent cancer. The adaptor protein GRB2 binds to active receptor tyrosine kinases (RTK) 
and to the GEF son of sevenless (SOS). SOS is therefore recruited to the plasma membrane where it can activate 
Ras. Ras binds RAF1 and stimulates its kinase activity, which results in downstream signaling cascades ending in 
activation of transcription factors like ELK.2,5 
 
RTK 
a b 
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The binding of GTP to Ras induces a conformational change, which allows Ras proteins to 
interact with effector proteins triggering different downstream signaling cascades. Ras proteins 
regulate cellular growth for example via the Ras/Raf/Mek/Erk pathway (Figure 1, b). In this 
signal transduction pathway binding of a growth factor to the extracellular part of a receptor 
tyrosine kinase (RTK) activates the cytoplasmic kinase activity. The adaptor protein GRB2 
binds to active, phosphphorylated RTK and recruits the GEF (SOS) to the plasma membrane. 
Upon activation by SOS, Ras binds RAF1 and stimulates its kinase activity, leading to the 
activation of phosphorylation cascades. Ultimately, transcription factors are activated which 
results for example in stimulation of cellular growth.  
Due to this crucial role in the regulation of growth and proliferation, mutations in Ras-encoding 
genes are strongly associated with cancer development. Mutations can lock the Ras proteins in 
a GTP-bound active state, mainly by preventing the hydrolysis GTP catalyzed by GAPs.1 As a 
result, the cycling of Ras between the active and the inactive state is impaired and Ras signaling 
pathways are permanently active, which may result in uncontrolled cellular growth.  
Owing to the eminent role of Ras proteins in cancer development, oncogenic Ras signal 
transduction has been a major target in anti-cancer therapy for the last thirty years. However, 
despite intense efforts not a single therapeutic has reached the market.6 This failure in 
generating anti-Ras drugs can be at least partially attributed to the lack of a hydrophobic, 
druggable cavity, that allows efficient binding of small molecules. Only recently fragment based 
approaches have generated low affinity binders of Ras that may lead to biologically useful, high 
affinity compounds in the long run.7,8 Furthermore, selective inactivation of a particular Ras 
mutant (G12C) with covalent inhibitors has stirred novel interest in the modulation of Ras 
signaling by direct small molecule modulators of the GTPase.9,10 
2.1.1 Ras GTPases localization and spatiotemporal signaling 
All Ras isoforms (K-Ras4A, K-Ras4B, N-Ras, H-Ras) feature a highly conserved G-domain 
and a lipidated C-terminal hypervariable region (HVR, Figure 2a). The biological function of 
Ras proteins is strictly linked to their dynamic, subcellular localization.11-13 Correct Ras 
localization is mediated by posttranslational modifications at the HVR, which is different for 
all four Ras isoforms. All Ras isoforms are modified through a series of processing reactions 
including cysteine S-farnesylation (farnesyltransferase, FTase), proteolysis (RCE1) and C-
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terminal carboxymethylation (ICMT, Figure 2a). These modifications, however, are not 
sufficient for ensuring stable binding to lipid double layers. H-Ras and N-Ras undergo 
additional, reversible S-palmitoylation at one or two cysteine residues (Figure 2b). A 
re/depalmitoylation cycle of N-Ras and H-Ras allows for reversible binding to endomembranes 
and regulates the dynamic cellular localization of these isoforms.11,14,15 K-Ras on the other hand 
is expressed as two isoforms K-Ras4A and K-Ras4B which are results of alternative splicing. 
K-Ras4A features a palmitoylation site, K-Ras4B on the other hand displays a poly lysine 
stretch in the HVR which facilitates membrane binding. Due to the positive charge of the 
polylysine sequence and the C-terminal farnesylation, K-Ras4B localizes primarily to the 
negatively charged plasma membrane (Figure 2a). 
K-Ras4B is arguably the most important isoform for anti-cancer research. Mutations of the K-
Ras gene occur frequently in lung, colorectal and pancreatic cancer. Impressively, in the very 
deadly pancreatic cancer more than 90% of all patients feature K-Ras mutations. Since 
K-Ras4B is more widely expressed than K-Ras4A, this splice variant is generally believed to 
be the key oncogenic protein in K-Ras driven tumours.16 
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Figure 2  Posttranslational processing of Ras isoforms.17 H-Ras, N-Ras, K-Ras-4A/B all possess a highly 
homologous G-domain and a C-terminal hypervariable region (HVR). While the conserved G-domain is involved 
in nucleotide binding and effector interactions, the HVR undergoes a series of posttranslational modifications to 
enable stable membrane binding. (a) All Ras proteins are farnesylated (F, orange) by farnesyltransferase (FTase) 
at the C-terminal cysteine, Ras-converting enzyme1 (RCE1) cleaves the three C-terminal AAX residues of the 
CAAX box (C = cysteine, A = aliphatic amino acid and X = variable amino acid) and isoprenylcysteine 
carboxylmethyltransferase1 (ICMT1) transforms the C-terminal carboxylate into a methyl ester (red). In the case 
of K-Ras4B, electrostatic interactions of a poly lysine stretch with the negatively charged plasma membrane enable 
stable binding to the target membrane. The other isoforms are additionally modified by protein acyltransferases 
(PATs) with one or two palmitoyl groups (P, blue) at their C-terminal cysteines to enable stable binding to the target 
membrane. Palmitoylation is reversible and acylprotein thioesterases (APT1/2) release the Ras protein from the 
target membrane. The prenyl binding protein PDEδ additionally controls association of all Ras isoforms with lipid 
bilayers; (b) Posttranslational modifications for the four different Ras isoforms and chemical structures of the 
products of S-palmitoylation (left) and S-farnesylation (right). 
  
PDEδ PDEδ 
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2.1.2 Impairment of Ras spatiotemporal signaling with small molecules 
The postranslational modifications of Ras proteins regulate localization of Ras in the cell and 
thereby control Ras dependent signaling.11,13,18,19. Initially interference with Ras localization, 
and signaling seemed to be readily possible by targeting processing enzymes like 
farnesyltransferase. Farnesyltransferase inhibitors suppress S-farnesylation of GTPases,5,20 and 
treatment of cells results in a cytosolic enrichment of non-functional Ras. A number of farnesyl 
transferase inhibitors have been tested in clinical trials, but ultimately failed to affect oncogenic 
Ras signaling mostly due to alternative prenylation pathways.21 Hence, if farnesyltransferase is 
inhibited, Ras becomes a substrate for geranylgeranyl transferase (GGTase) which results in 
retained membrane affinity. Treatment of cells with a combination of FTase and GGTase 
inhibitors to avoid alternative geranylgeranylation or dual prenylation inhibitors lead to toxicity 
and lacked the desired efficacy in clinical trials.22,23 Additionally, it is unclear whether a 
significant portion of the in vitro anti-cancer effect of farnesyl transferase inhibitors is due to 
inhibition of Ras signaling or due to relocalization of other GTPases. Targeting of the protease 
RCE161,62 and the methyltransferase ICMT163 by small molecules has also been explored, but 
the overall anti-proliferative effect of these inhibitors was less pronounced compared to farnesyl 
transferase inhibitors.  
In addition to targeting processing enzymes, farnesyl cysteine mimetics have been designed to 
compete with the interaction of Ras and prenyl-binding proteins. Unfortunately, these 
molecules were largely ineffective in clinical trials.24-26 Phenotypic screening approaches have 
revealed compounds which interfere with Ras localization, but the targets of the identified 
compounds remain unclear to date and therefore rational compound optimization is not 
possible.27,28 In summary, no clinically effective approach for impairment of oncogenic Ras 
signaling by means of subcellular relocalization of Ras has been developed. In particular, no 
approach that targets the most oncogenic isoform K-Ras4B has been reported and is available 
for the treatment of cancer patients. 
2.2 PDEδ a prenyl-binding molecular chaperone 
The Pde6d gene encodes a 17 kDa protein (PDEδ, PDE6D or PrBP/δ) which was originally 
identified as the soluble δ-subunit of phosphodiesterase 6 (PDE6) in photoreceptor cells, where 
it detaches PDE6 from the membrane and thereby desensitizes the phototransduction 
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cascade.29,30 In subsequent studies PDEδ was found to function as a ubiquitously expressed, 
molecular chaperone for the transport of prenylated proteins.31 PDEδ is part of the 
UNC119/PDEδ/RhoGDI protein family, which share a common lipid binding motif. Each of 
the proteins features a beta-barrel fold that contains a large hydrophobic cavity which can 
accommodate lipid groups. While PDEδ and RhoGDI both preferentially interact with prenyl 
groups, UNC119a and UNC119b shuttle myristoylated proteins in the cell. 32-36 
In virtually all animals including the nematode C. elegans, orthologs of PDEδ were identified. 
29,37 Sequence identities of over 97% were observed between mouse, bovine, and human PDEδ 
by sequence similarity search. The amino acid sequence of PDEδ shows at least 70% sequence 
identity within vertebrates and around 50% sequence identity among invertebrates.30 The 
conserved primary sequence suggests an eminent role of PDEδ in the trafficking of prenylated 
proteins like K-Ras4B inside the cell. 
2.2.1 The prenyl-dependent interaction between Ras-GTPases and PDEδ 
Biochemical and cellular studies have revealed crucial interactions between farnesylated 
GTPases, most notably K-Ras4B, and PDEδ.38 PDEδ binds Ras family proteins and sequesters 
them from membranes thereby regulating specific localization of these proteins in the cell. 
K-Ras4B is enriched at the plasma membrane, however, until recently it was unclear how K-
Ras4B is transported to the plasma membrane after synthesis and posttranslational modification 
at the endoplasmic reticulum. The prenyl-binding protein PDEδ was shown to mediate this 
transport of K-Ras4B to the plasma membrane (Figure 3).18 
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Figure 3 PDEδ (cyan) funtions as a shuttle protein for Ras family proteins (shown here for K-Ras4B). Ras proteins 
are posttranslationally processed at the endoplasmatic reticulum, and PDEδ transports for example K-Ras4B to 
the plasma membrane where it can exert its biological function. 
The effect of PDEδ on Ras signal transduction has been investigated by siRNA. Knockdown of 
the Pde6d gene led to a significant decrease in Erk phosphorylation.18,39 This finding was 
attributed to an unspecific relocalization of Ras proteins in the cell in the absence of PDEδ. 
The interaction between Ras proteins and PDEδ was also recently investigated at a molecular 
level. A biophysical investigation into the binding of PDEδ to several farnesylated peptides and 
semisynthetic Ras proteins revealed that the carboxymethylated, farnesylated C-terminal K-
Ras4B-dodecapeptide binds to PDEδ with a higher affinity than a simple farnesylated cysteine 
methyl ester.40 A semisynthetic K-Ras4B-protein does not display higher affinity for PDEδ than 
the C-terminal K-Ras4B-dodecapeptide, thus suggesting that PDEδ recognizes mainly the C-
terminus of the lipidated protein.40 Subsequently, the cocrystal structure of the Ras family 
protein Rheb in complex with PDEδ showed that the two proteins interact exclusively via the 
S-farnesylated C-terminus and the following 5-10 amino acids of Rheb (Figure 4, a). The crystal 
structure revealed a large, hydrophobic cavity of PDEδ which is occupied by the farnesyl group 
(Figure 4, b). The binding between Rheb and PDEδ is mediated by a few, key polar interactions. 
Arg61 of PDEδ shows a cation  interaction with a farnesyl double bond and Tyr149 forms a 
hydrogen bond with a backbone amide group of the Rheb C-terminus. 
Plasma membrane 
K-Ras4B 
PDEδ 
endomembranes 
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Figure 4 Interactions of farnesylated GDP-bound Rheb (red) in complex with PDEδ (cyan). a) PDEδ/Rheb overall 
structure, showing no protein backbone interations; b) surface representation of hydrophobic cavity surrounding 
the farnesyl group; c) key hydrogen bond of Rheb C-terminus backbone amide with Tyr149.  
2.2.2 Arl2/3-GTP and PDEδ regulate a transport system for prenylated cargo which 
controls the localization of Ras family proteins 
The binding of farnesylated proteins to PDEδ is regulated by Arl2 and Arl3, which belong to 
the Arl (ADP-ribosylation factor-like) family of GTPases.41-43 PDEδ is an effector of Arl2/3, 
which interacts exclusively with the GTP bound form. The crystal structure of the PDEδ/Arl2 
complex revealed that the interaction is mediated by a series of parallel inter-protein β-sheet 
contacts (Figure 5).41 
Tyr149 
Arg61 
Glu78 
c 
b a 
Rheb 
PDE 
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Figure 5 Structural analysis of the Arl2-PDEδ interaction a) Cocrystal structure of Arl2-GppNHp (green) with 
PDEδ (cyan) (PDB: 1KSG). GTP-bound Arl can be biochemically mimicked by using the non-hydrolysable GTP 
analog GppNHp. GppNHp is shown as ball and sticks; b) Surface representation of PDEδ: The farnesyl binding 
pocket is closed in the presence of Arl2-GppNHp (left, farnesyl is modeled into the structure) and open in the 
presence of farnesylated proteins (right).44 
The binding site of Arl2/3 on PDEδ is therefore distinct from the binding site of farnesylated 
proteins like Rheb, and suggests a mechanism of allosteric control. It was demonstrated by 
Wittinghofer and coworkers that Arl proteins actively displace farnesylated protein cargo from 
PDEδ.44 A short-lived, ternary complex between farnesylated proteins like Rheb, PDEδ and 
Arl2 thus mediates the release of farnesylated cargo at a specific location in the cell. The cargo 
system is reminiscent of the RhoGDI/Rho transport mechanism because RhoGDI preferentially 
binds the GDP bound form of Rho and acts as a solubilizing factor that sequesters and buries 
the lipid moiety.33,45 In the case of Rheb, PDEδ and Arl2, however, the nucleotide dependent 
interaction is observed between Arl2 and PDEδ and not between the Rho homologue Rheb and 
PDEδ. PDEδ has therefore been described as a GDI-like solubilizing factor (GSF).18 
a b 
Arl2 
PDEδ 
PDEδ–Arl2: closed 
prenyl binding cavity 
PDEδ-RheB: open  
prenyl binding cavity 
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Figure 6 Ternary structure model of PDEδ/Arl2/Ras homologue (Rheb) generated from the PDB entries 1KSH 
and 3T5G. For Rheb (red) the farnesyl group is shown in ball and sticks. GppNHp bound to Arl2 is also shown in 
ball and sticks. 
Recently, cellular experiments demonstrated how K-Ras localization and thus signaling is 
controlled by both PDEand the release factor Arl2 (Figure 7).13 Interestingly, electrostatic 
interactions alone cannot account for enrichment of K-Ras at the plasma membrane (compare 
Figure 3), due to the very large relative surface area of endomembranes in the cell. Instead K-
Ras is sequestered continuously from endomembranes by PDE and delivered to perinuclear 
membranes where it is unloaded by Arl2. Electrostatic interactions transfer K-Ras to the 
negatively charged surface of the recycling endosome. Vesicular transport is then responsible 
for the observed enrichment of K-Ras at the plasma membrane.  
Arl2 
PDE 
Rheb 
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Figure 7 K-Ras localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular 
transport.13 K-Ras is sequestered continuously from endomembranes by PDE and delivered to perinuclear 
membranes where it is unloaded by Arl2. Electrostatic interactions transfer K-Ras to the negatively charged surface 
of the recycling endosome. Vesicular transport leads to the observed enrichment of K-Ras at the plasma membrane.  
2.2.3. Interactions between PDEδ and other prenylated proteins 
In addition to the Ras GTPases, also other prenylated GTPases were identified as targets of 
PDEδ in yeast-two hybrid screens and proteomics experiments (Figure 8, left).38 Due to its high 
expression levels in the retina, PDEδ plays an essential role in maintaining the spatial 
organization of prenylated proteins in photoreceptor cells.37 PDEδ interacts with prenylated 
PDE6 subunits, farnesylated rhodopsin kinase (GRK1) and geranylgeranylated GRK7 in these 
cells (Figure 8, right).46  
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Figure 8 Interaction map of PDEδ with prenylated (farnesyl, f or geranylgeranyl, gg) and non prenylated proteins. 
Small GTPases are shown in the left column, other proteins on the right. 
PDEδ binds to the GTPases Arl2/3 and the Retinitis Pigmentosa GTPase regulator (RPGR, 
RCC1 domain) via protein backbone interactions in a non-prenyl dependent fashion.47,48 It is of 
note that a number of the validated PDEδ interaction partners (RPGR, Arl3, INPP5E, Rab8a, 
Rab28, PDE, PDEGRK1) are involved in diseases which involve the dysfunction of the 
primary cilium, a small organelle that protrudes from the cell body. 
2.2.4 PDEδ, cilia and signaling 
Cilia are specialized organelles which protrude from the cell surface of almost all mammalian 
cells.49 Proteins that localize to cilia are often prenylated. Prenylated, ciliary proteins include 
the phosphoinositide phophatase INPP5E, Phosphodiesterase 6 α and β subunits and the 
rhodopsin kinase GRK1. Mutations in the corresponding genes can lead to photoreceptor 
degeneration, MORM and Joubert syndrome in humans.50-53 Due to the involvement of the 
primary cilium in these diseases, they are often called ciliopathies. PDEδ controls the ciliary 
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targeting of prenylated proteins like the inositol phosphatase INPP5E.54,55 A homozygous 
mutation of PDEδ in Joubert syndrome impairs targeting of farnesylated INPP5E to the 
cilium.56 Interestingly, the homozygous mutation blocks the binding of lipidated proteins and 
Arl2/3 to PDEδ and thus inactivates its function as a shuttle protein. While a PDEδ knockout 
mouse phenotypically only displays retinal degeneration and weight reduction, multi organ 
dysfuntion is observed in humans with Joubert syndrome carrying mutant PDEδ.37 Strikingly, 
the highest expression levels of PDEδ in human embryos were observed in the nervous system, 
kidney tubules and epithelial cells of the respiratory tract (Figure 9).  
 
Figure 9 PDEδ expression in human embryos.56 The protein is ubiquitously expressed within human tissues. PDEδ 
is most abundant in the entire central nervous system (prosencephalon (Pro), mesencephalon (Mes) and 
rhombencephalon (Rh) (a,b), in renal tubules (c) and in epithelial cells of the bronchus (d). PDEδ also localizes to 
the limb bud mesenchyme (e) and to the neural layer of the optic cup (future neural retina) (f). Br, bronchus; Cb, 
cerebellum; H, heart; L, lens; nR, neural retina; pR, pigment layer of retina; R, Rathke’s pouch; sc, spinal cord; tg, 
tongue; Tu, renal tubules.56 
These organs are commonly affected by ciliopathies.56 Within ciliated cells PDEδ localizes 
primarily to the basal body of the primary cilium.56 The transport of prenylated proteins like 
INPP5E to primary cilia is largely not understood, however the involvement of PDEδ in this 
interaction network suggests the possibility to use small molecule binders of PDEδ to 
understand the underlying mechanisms.54  
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2.2.5 Hedgehog signaling pathway 
The Hedgehog signaling pathway is critically involved in the development of embryonic cells, 
but also plays a vital role in adult cells for example in cancers like basal cell carcinoma.57   
Briefly, Sonic Hedgehog  (SHH) is a secreted, lipidated protein that binds to the patched 
receptor (PTC), which localizes in and around the primary cilium.57 Upon binding of SHH to 
PTC, the smoothened receptor (SMO) relocalizes to the primary cilium and transcription factors 
(GLI) are activated which leads to transcription of the target genes (Figure 10).  
  
Figure 10 Hedgehog signaling pathway in vertebrates around the cilium.57 a) off state: in the absence of ligand, 
PTCH1 localizes to the cilium and is thought to block the entry of  Smoothened (SMO) to the cilium; b) on state: 
upon binding of Hedgehog protein (Hh) to PTCH1, SMO relocalizes to the ciliary membrane and activates GLI 
transcription factors like GliA which leads to activation of the target genes in the nucleus.57 
Since Hedgehog signaling in vertebrates requires the primary cilium,57 and PDEδ plays a vital 
role in ciliopathies like Joubert syndrome, it can be reasoned that PDEδ has a general role in 
Hedgehog signaling. Additionally, the PDEδ interaction partner K-Ras has been shown to 
activate Hedgehog signaling in pancreatic tumor cells.58,59 
  
cilium cilium 
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2.3 Small molecule binders of PDEδ 
So far, no rational design strategy has been employed to find small molecules that target the 
prenyl binding cavity of PDEδ. Proteomics and phage display experiments, however, 
accidentally revealed small molecules binder of PDEδ.  
In an effort to identify unknown binding partners of marketed drugs, the company Ambit 
Biosciences found that the clinically used HMG-CoA reductase inhibitor Atorvastatin (1) binds 
to PDEδ (Figure 11).60 The penta-substituted pyrrole core structure of Atorvastatin was 
identified as the pharmacophore for PDEδ binding, and a library based on this core structure 
was synthesized. However, none of the synthesized molecules showed significantly better 
binding affinities than Atorvastatin. In addition to the originally reported pyrrole compounds, 
thiophenes, furans and imidazoles were patented for the use as PDEδ binders and the treatment 
of stroke.60 By an elegant combination of yeast-three hybrid screening and affinity 
chromatography, Johnsson and coworkers could clearly show that Atorvastatin indeed targets  
PDEδ and that among the statin drug class only Atorvastatin interacts with PDEδ.61 
In a different study proteomics experiments by Heck and coworkers revealed that the nanomolar 
PDE5 inhibitor PF-4540124 (2) also shows off-target binding to PDEδ with an approximate 
affinity of 1-10 µM (Figure 11).62,63 Subsequently, four derivatives of PF-4540124 were 
synthesized and two of them showed stronger binding to PDEδ than to PDE5, as judged by 
quantitative proteomics experiments with immobilized compounds.64 However, no absolute 
affinities for these compounds were reported. 
 
Figure 11 Structures of previously reported binders of PDEδ. 
.
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3 AIMS 
Due to its eminent role in cancer, the Ras proteins have been a major target of pharmaceutical 
research. While numerous attempts have been made to find direct binders of Ras proteins that 
impair oncogenic signaling, not a single drug has emerged from these efforts. Oncogenic Ras 
signaling is tightly linked to the subcellular location of the Ras proteins. The spatial 
organization of Ras family proteins, and in particular of K-Ras, is maintained by the prenyl 
binding protein PDEδ. SiRNA mediated knockdown of the Pde6d gene results in 
mislocalization of K-Ras and a decrease in the phosphorylation of downstream ERK-kinase. 
Knockdown of Pde6d impairs oncogenic K-Ras signaling, thus validating the K-Ras- PDEδ 
interaction as an interesting target for the development of novel anti-cancer therapeutics. 
Since PDEδ features a large hydrophobic and therefore potentially druggable prenyl binding 
cavity, it seems feasible to find small molecules that interfere with the K-Ras-PDEδ interaction 
and thus impair oncogenic K-Ras signaling. Hence, the main aim of this work is the validation 
of the PDEδ-K-Ras interaction as a target for drug discovery aimed at cancers with mutations 
in K-Ras and the development of small molecules which are able to block this interaction. 
For the identification of these inhibitors a biochemical assay that is amenable to high-
throughput screening has to be designed and potential hit molecules have to be validated with 
other biophysical methods like isothermal titration calorimetry (ITC) and thermal shift assays. 
Hit compounds should be cocrystallized with PDEδ and then rationally improved by structure-
guided design. Selected compounds shall be tested for their ability to break the K-Ras-PDEδ 
interaction in the living cell and for their impact on oncogenic Ras signaling. Since K-Ras 
mutations are observed in >90% of pancreatic cancers, the most promising molecule shall be 
evaluated in mice bearing K-Ras-dependent, human pancreatic cancer cell lines.  
Although siRNA mediated knockdown of PDEδ yielded clear evidence that Ras signaling is 
dependent on PDEδ, the overall biological role of the prenyl binding protein is still debated. It 
is, for example, still unclear whether PDEδ only shuttles farnesylated proteins like Ras in the 
cell, or whether it can also transport geranylgeranylated proteins. Therefore biochemical model 
studies using differently prenylated peptides with the same sequence could reveal whether there 
is a prenyl specifity of PDEδ. 
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Previously, it was shown that the Arl2/3 GTPases allosterically regulate binding of prenylated 
proteins to PDEδ by interaction with a binding site distinct from the hydrophobic prenyl binding 
cavity. Arl2/3 GTPases can actively release cargo proteins from the prenyl binding cavity of 
PDE Since prospective small molecule inhibitors of the K-Ras-PDEδ interaction are expected 
to bind into this hydrophobic cavity, it is of interest whether the mode of action of these 
molecules can be reversed by binding of Arl2/3. 
Arl2/3 do not only regulate binding of prenylated cargo to PDEδ they also control cargo release 
from the closely related myristoyl binding proteins UNC119a and UNC119b. Similar to PDEδ, 
UNC119a/b feature large lipid binding cavities. Therefore, rational design of UNC119a/b 
inhibitors targeting this binding site seems feasible and selected compounds/peptides should be 
evaluated in biochemical assays for their ability to interact with UNC119a/b. 
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4 RESULTS AND DISCUSSION 
A two-pronged strategy was employed for the identification of small molecule K-Ras-PDEδ 
inhibitors (Figure 12). The major focus was to develop a high throughput screening assay to 
identify novel scaffolds that bind to PDEδ. In a parallel approach it was also attemped to 
synthesize Sildenafil and Atorvastatin derivatives and evaluate them for their ability to break 
the K-Ras-PDEδ interaction.  
 
Figure 12 Approach for the identification PDEδ inhibitors. A two-pronged approach for entering the cycle of 
structure-guided design (blue) was followed: High-throughput screening was accompanied by the synthesis of 
Sildenafil and Atorvastatin derivatives. 
4.1 Development of a high-throughput screening assay of the K-Ras4B-PDEδ 
interaction 
Due to the size of the MPI Dortmund in-house library (ca. 200000 compounds), a high-
throughput screening assay was needed to test these compounds for their ability to break the 
K-Ras4B-PDEδ interaction. Alpha technology has emerged as a powerful tool for studying 
biological interactions and for screening large compound libraries. As a bead-employing 
proximity assay, this technology is based on the generation of singlet oxygen upon excitation 
with visible light and its subsequent transfer from a donor to an acceptor bead, when both beads 
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are within 200 nm distance (Figure 13). As a result, the singlet oxygen causes a 
chemoluminescent ring opening reaction on the acceptor bead. For screening purposes Alpha 
technology has two advantages: a) There is a delay between excitation and detection of the 
emitted light and b) the emitted light has a shorter wavelength than the excitation source. 
Therefore, the intrinsic, short lived fluorescence of many compounds in the screening collection 
does not interfere with the assay. 
 
 
Figure 13 Alpha screening assay for the detection of small molecule inhibitors of the K-Ras4B-PDEδ interaction. 
a) The proximity based assay relies on a chemiluminescent reaction triggered by singlet oxygen. A donor bead 
recognizes the biotinylated K-Ras4B-peptide and an acceptor bead binds to the His-tagged protein. Upon 
excitation with visible light, singlet oxygen is produced at the donor bead. Due its limited lifetime the singlet 
oxygen can only reach the acceptor bead if the K-Ras4B peptide and PDEδ interact. b) In the presence of an 
inhibitor no emission between 520-600 nm is observed. 
b 
a 
 RESULTS AND DISCUSSION 
21 
 
The K-Ras4B-PDEδ interaction is restricted to the last 5-10 C-terminal amino acids of 
K-Ras4B, therefore it is not necessary to work with full length, farnesylated K-Ras4B protein 
(KD C-terminal K-Ras4B peptide 227 nM, KD full-length K-Ras protein 302 nM).44 In contrast 
to the full length protein, farnesylated K-Ras4B-peptides are readily available in milligram 
amounts by solid phase peptide synthesis. Owing to the bead-based assay setup both interaction 
partners, K-Ras4B and PDEδ, have to be affinity tagged. It was thus envisaged to synthesize a 
biotinylated, C-terminal K-Ras4B peptide and in parallel express His6-tagged PDEδ in E.coli.  
4.1.1 Synthesis of a C-terminal, biotinylated K-Ras4B peptide 
The Waldmann group has established an elegant solid-phase synthesis approach for K-Ras4B 
peptides which employs the highly acid sensitive (chloro)-trityl linker.40,65 For the synthesis of 
a biotinylated K-Ras4B peptide an orthogonally protected lysine building block was Boc-
deprotected and coupled to the solid support via the ɛ-amino group. The immobilized building 
block was C-terminally deprotected using Pd(PPh3)4 and phenylsilane (Scheme 1)65 and the free 
acid was coupled to farnesylated cysteine methyl ester (PyBop, NMM). The N-terminus was 
elongated using cycles of Fmoc-deprotections and coupling to suitably protected amino acids. 
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Scheme 1 Synthesis of a biotinylated and farnesylated K-Ras4B peptide by solid phase synthesis.  
After introduction of an eight-carbon linker, the free amino group on the N-terminus was reacted 
with Biotin-NHS-ester. Subsequent deprotection and cleavage from the solid support with 1% 
TFA in dichloromethane yielded the final peptide. For the synthesis of the biotinylated peptide 
two different lysine protecting group regimes were evaluated. Initially, the lysines were side 
chain-protected with the Alloc group as previously described.40,65 In an attempt to simplify the 
synthesis and increase the yield, the Alloc protecting group was replaced by the highly acid 
sensitive 4-methyltrityl (Mtt) group (Scheme 1). This change in the protecting group regime 
not only reduced the number of synthetic steps but also significantly improved the yield from 
7 % to 20%.  
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4.1.2. Expression of His6-PDEδ in E.Coli 
His6-PDEδ was expressed in E.-coli-Rosetta cells following a slightly modified expression 
protocol from the group of Prof. Wittinghofer. After purification by affinity- and size exclusion 
chromatography, His6-PDEδ was obtained in a high yield of 20 mg protein per liter expression 
culture (Figure 14) 
a b 
 
 
 
 
 
Figure 14 Expression and purification of His6-PDEδ a) UV trace of preparative gelfiltration chromatography; b) 
SDS-PAGE of pooled fractions (165-190 mL elution buffer) from gel filtration chromatography. 
4.1.3 Implementation of an Alpha screen with His6-PDEδ and biotinylated K-Ras4B 
peptide 
The interaction between His6-PDEδ and the biotinylated K-Ras4B peptide was initially 
evaluated using a serial dilution of the two components in a 1:1 ratio. Different additives were 
screened for their ability to suppress unspecific binding and thus to increase the signal to 
background ratio. Polyether based detergents (Tween 20, Triton-100), however decreased the 
signal, presumably by binding into the farnesyl binding cavity. Bovine serum albumin (BSA) 
completely abrogated the PDEδ/K-Ras4B interaction even when used at concentrations as low 
as 0.1%. This observation can be attributed to the binding of the farnesyl group to the fatty acid 
binding patches on the surface of BSA. The addition of the zwitterionic, steroid based detergent 
Chaps on the other hand was tolerated. After optimization of the incubation time the assay 
performed with a signal to background ratio of more than 500:1 and a z´ of 0.8, where z´ is a 
statistical quality assessment parameter for assays.66 The apparent KD of the interaction proved 
to be 600 nM, which is consistent with previous fluorescence polarization (FP) measurements 
(Figure 15).40  
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Figure 15 Representative serial dilutions of a 1:1 complex of His6-PDEδ with a C-terminal, biotinylated K-Ras4B 
peptide measured by assay employing Alpha technology 
For the displacement titrations with small molecules, Sildenafil and Atorvastatin were used as 
controls. Both compounds were able to break the PDEδ-K-Ras4B interaction (Figure 16). 
Atorvastatin proved to be the stronger binder, with an apparent KD,app below 3 µM, whereas 
Sildenafil displayed an affinity KD, app of 4.3 µM. 
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Figure 16 Displacement titrations of PDEδ/K-Ras4B complex with different concentrations of small molecule 
Atorvastatin (Fit: red), Sildenafil (Fit: blue) (concentration PDEδ 3 µM, K-Ras4B 3 µM) observed by 
chemiluminescent Alpha assay. Data were fit by an empirical dose response model and are derived from two 
independent sets of experiments. 
With a working assay system in hand, a library of 40000 molecules was initially screened in a 
semi automatic fashion (PDEδ 600 nM, K-Ras4B 900 nM, 0.005% Chaps). Clustered hits of 
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this screening campaign were analysed in terms of their binding energy per atom (ligand 
efficiency),67 and a series of N-substituted benzimidazoles emerged as the compounds with the 
highest per atom binding efficiency. These compounds were therefore further analysed by 
crystallography and orthogonal biophysical techniques. 
4.2. Thermodynamic and structural analysis of small molecule-PDEδ interaction  
In order to get insight into the binding mode of the highly ligand efficient benzimidazole 
fragments, compound 10 was cocrystallized with PDEδ by Dr. Shehab Ismail and it was found 
that two benzimidazole moieties are located within the prenyl binding pocket of PDEδ (Figure 
17). The cocrystal structure of benzimidazole 10 with PDEδ revealed a virtually complete 
overlap of the two benzimidazole units with the farnesylated C-terminus in the Rheb-PDEδ 
crystal structure (Figure 17, a). Merely the position of Trp90 is slightly different in the cocrystal 
structure of 10 with PDEδ when compared to the Rheb-PDEδ structure (Figure 17, b). The 
movement of Trp90 can be attributed to the larger size and the rigidity of the two benzimidazole 
units compared to the farnesyl moiety.  
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Figure 17 Crystal structure of farnesylated Rheb peptide (Farnesyl : red) with PDEδ in comparison with crystal 
structure of benzimidazole 10 (green) with PDEδ. In the chemical structure key hydrogen bond acceptors are 
highlighted in red. a) overlay of the two crystal structures; b) flip of Trp90 to accomodate the more bulky inhibitor. 
c) Key hydrogen bonding interactions (yellow) between Rheb-PDEδ and benzimidazole 10-PDEδ. The crystal 
structure was solved by Dr. Shehab Ismail.  
Hydrogen bonds to Tyr149 could be identified in both structures. In the Rheb-PDEδ complex 
Tyr149 interacts with the backbone carbonyl of Ser180, whereas in the benzimidazole 10-PDEδ 
structure a key hydrogen bond to the benzimidazole unit is formed (Figure 17, c). Importantly, 
the 10-PDEδ structure features an additional hydrogen bond between Arg61 and the other 
benzimidazole unit (Figure 17, c).  
In order to validate the binding of two benzimidazole units to the prenyl binding cavity of PDEδ, 
cocrystallization with other benzimidazole fragements was attempted. The 1.4 Ả crystal 
structure of benzimidazol fragment 12 confirmed that indeed two benzimidazole units can bind 
to PDEδ (Figure 18, a). An overlay with the cocrystal structure of benzimidazole 10 revealed  
a b 
c 
Trp90 
Tyr149 
Arg61 
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hydrogen bonds to the same amino acids, although the position of the individual benzimidazole 
units is slightly altered (Figure 18, b)).  
 
Figure 18 Cocrystal structure of benzimidazole 12 (green sticks) with PDEδ. a) Key hydrogen bonds are 
highlighted in yellow. b) Overlay with cocrystal structure of benzimidazole 10 (cyan sticks), key hydrogen bonds 
to Arg61 and Tyr149 are highlighted. The crystal structure was solved by Dr. Shehab Ismail.  
With the structural data in hand, isothermal titration calorimetry (ITC) was performed to show 
that at physiologically relevant, low micromolar concentrations two benzimidazole fragments 
are bound to PDEδ. In ITC the change in heat upon interaction of two binding partners is 
measured. In a single experiment the stoichiometry, the equilibrium constant KD and the 
thermodynamic profile of the interaction can be determined.68-72  
 
 
a b 
Arg61 
Tyr149 
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Figure 19 Raw injection trace (left) and total heat per injection (right) derived from a representative ITC 
experiment of compound 10. P=power, V= volume, q=heat. 
From the raw injection trace of the protein to ligand titration (Figure 19, left), it is apparent that 
binding of benzimidazole 10 is highly exothermic. The binding isotherm derived from the area 
under the curves (Figure 19, right) yielded a KD value of 217 ± 12 nM and a stoichiometry of 
1:2 PDEδ:benzimidazole. The stoichiometry is thus consistent with the X-ray data, underlining 
that even at low micromolar concentrations two molecules bind into the farnesyl binding 
pocket. The affinity constant KD of the interaction can be translated into the overall free binding 
energy ΔG°. ΔG° consists of an entropical -TΔS°  and an enthalpic contribution ΔH°, with a 
strongly negative value of ΔG° corresponding to a low KD and high affinity.  
The molecular driving force of the interaction between 10 and PDEδ is the strongly favourably 
change in enthalpy ΔH° upon interaction (-11.5 kcal/mole), which is mainly due to the 
formation of two hydrogen bonds to the two benzimidazole units. The more rigid benzimidazole 
12 displays a similarly exothermic thermodynamic binding profile (ΔH° -11.0 kcal/mole), 
however the entropical contribution -TΔS° to the free energy ΔG° is much less pronounced, 
which results in a lower affinity of 1400 nM. The strongly enthalpy driven binding of the 
benzimidazole fragments 10 and 12 makes them bona fide starting points for the design of 
highly efficient and selective binders of PDEδ.69,73  
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In parallel the previously identified PDEδ inhibitor Atorvastatin was docked into the farnesyl 
binding site. According to the best scoring docking poses, the amide of Atorvastatin functions 
as a hydrogen bond acceptor and interacts with the deeply buried Arg61 (Figure 20). 
 
Figure 20 Best scoring docking pose for the Atorvastatin-PDEδ interaction. a) Overall structure of Atorvastatin 
(colored sticks)-PDEδ model, hydrogen bond of amide to Arg61 is highlighted; b) Surface representation of  
PDEδ cavity (PDB 4JV6) with docked Atorvastatin, highlighting the good fit of Atorvastatin into the binding 
pocket according to best scoring docking pose;c) Overlay with benzimidazole fragments; d) Surface charge 
representation of protein around Atorvastatin, showing a potentially unfavourable interaction of the carboxylate 
with the negatively charged protein surface. 
Closer inspection of the docking pose revealed that the substituted pyrrole core efficiently fills 
the binding pocket (Figure 20, b). The flexible acid side chain of Atorvastatin on the other hand 
does not show any key interactions. Therefore Atorvastatin-derivatives were synthesized in 
which the acid side chain was replaced by a simple aliphatic alcohol of similar length (Scheme 
2). Notably, Tyr149 is not targeted by Atorvastatin. Consequently the acid was converted into a 
strong hydrogen bond acceptor by formation of an amide bond. It was also reasoned that the 
negative charge of Atorvastatin might lead to unfavourable electrostatic interactions with the 
 Arg61 
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negatively charged protein surface ((Figure 20, d). Consequently, a tertiary amine was 
incorporated into novel Atorvastatin-derivatives.  
 
Scheme 2 Synthesis of Atorvastatin derivatives. a) by Paal-Knorr-synthesis or b) by amide bond formation. 
The highest yields were obtained when a large exess of the amine component was used which 
suppressed the competing intramolecular lactonization. With the synthesized Atorvastatin 
derivatives in hand, the potency of this compound class was evaluated using ITC experiments 
(Table 1). 
  
 RESULTS AND DISCUSSION 
31 
 
 
Table 1 Thermodynamic profiles derived from isothermal titration calorimetry for different compounds. For 
compounds marked with an asterisk the error is based on the fit. 
 
Similar to the benzimidazole fragments 10 and 12 (Table 1, entries 1 and 2), binding of 
Atorvastatin derivatives 15 and 17 is strongly enthalpy driven (Table 1, entries 3 and 4). The 
binding affinity of Atorvastatin derivative 14 is similar to benzimidazole 10, however 14 
features only one strong hydrogen bond acceptor (amide), as a result the binding is much less 
enthalpy driven (Table 1, entry 5). Surprisingly, the flexible lipid chain of Atorvastatin 
derivative 10 does not result in an observable entropic penalty upon interaction with the protein. 
These data may suggest a high residual mobility of 14 in the protein bound state, since PDEδ 
is a very flexible protein. 
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4.3. Development of a fluorescence polarization assay to evaluate small molecule-
PDEδ interactions  
ITC is a highly reliable, label-free technique for the determination of KD values. However, 
protein consumption is high, throughput is low and compounds have to be soluble at least to 
double digit micromolar concentrations.74 Therefore, alternative assays for the determination 
of compound affinities were needed. Fluorescence polarization had been previously used to 
determine the affinities of lipidated peptides for PDEδ.40,75-77 Due to the low affinity of the 
peptides large protein concentrations would be needed to perform displacement assays with 
small molecules, since only at high nanomolar protein concentrations a significant amount of 
peptide would be protein-bound. High protein concentrations additionally also lead to 
difficulties in the determination of the affinity of very potent binders. 
In biophysical assays, low affinity, labeled Ras peptides can be readily replaced with high 
affinity small molecules like Fluorescein-Atorvastatin 16 since both target the prenyl binding 
cavity of PDEδ. Atorvastatin derivatives proved to be strong binders to PDEδ in ITC 
experiments. In particular the biotinylated Atorvastatin derivative 15 showed the highest 
binding affinity of all compounds tested in ITC. These data suggest that the structurally similar 
Fluorescein-Atorvastatin 16 would bind with a similarly low KD which would allow the use of 
16 in displacement titrations at low nanomolar protein concentrations. Therefore Fluorescein-
Atorvastatin 16 was used as a starting point for the development of fluorescence polarization 
assays.  
The rationale behind this fluorescence polarization assay is that Fluorescein-Atorvastatin can 
rotate freely in bulk solution, whereas rotation in the protein-bound state is restricted. If linear 
polarized light is used to excite Fluorescein-Atorvastatin, the polarization of the emitted light 
is dependent on the rotational movement of the fluorophore within the fluorescence lifetime. If 
the molecule rotates quickly within the fluorescence lifetime, the emitted light will be 
depolarized. As a result the unbound Fluorescein-Atorvastatin exhibits a low fluorescence 
polarization, whereas protein-bound Fluorescein-Atorvastatin shows a high polarization. If 
unlabeled small molecules are used to displace Fluorescein-Atorvastatin from the prenyl 
binding cavity of PDEδ, the unbound Fluorescein-Atorvastatin will then also exhibit a low 
fluorescence polarization (Figure 21,a).  
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Figure 21 Displacement assay employing Fluorescein-Atorvastatin and unlabeled small molecules (e.g. 
Atorvastatin (1). Displacement of Fluorescein-Atorvastatin is detected via the change in fluorescence polarization. 
Fluorescein-Atorvastatin can rotate freely in bulk solution, whereas rotation in the protein-bound state is restricted. 
If linear polarized light is used to excite Fluorescein-Atorvastatin, the polarization of the emitted light is dependent 
on the rotational movement of the fluorophore within the fluorescence lifetime. If the molecule rotates quickly 
within the fluorescence lifetime, the emitted light will be depolarized. Therefore, unbound Fluorescein-
Atorvastatin exhibits a low fluorescence polarization, whereas protein-bound Fluorescein Atorvastatin shows a 
high polarization. If unlabeled small molecules are used to displace Fluorescein-Atorvastatin from the prenyl 
binding cavity of PDEδ, the unbound Fluorescein-Atorvastatin will then also exhibit a low fluorescence 
polarization. 
As expected Fluorescein-Atorvastatin 16 bound tightly in a direct titration with PDEδ (KD 
7.1 ± 4.0 nM, Figure 22, a). Therefore, low nanomolar concentrations of fluorophore and 
protein could be used for the competition assay which simplified the measurement of small 
molecules with very high affinity (Figure 21, b). 
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Figure 22 Fluorescence polarization assays employing Fluorescein-Atorvastatin and PDEδ; a) Direct titration of 
Fluorescein-Atorvastatin 16 (50 nM) with PDEδ, on the y-axis the fraction of Fluorescein-Atorvastatin that is 
bound to PDEδ is shown; b) Displacement titrations using unlabeled small molecules and 16 as probe (conditions: 
Fluorescein Atorvastatin 24 nM, PDEδ 40 nM). 
Displacement titrations with unlabeled small molecules were performed to obtain the KD values 
of their interaction with PDEδ.78 Atorvastatin (KD, 1250 nM, Table 2, entry 1) proved to be a 
stronger binder than Sildenafil (KD > 5 µM), therefore the Atorvastatin amide compound 
collection was further enlarged (in collaboration with LDC, Dortmund).  
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Table 2 Affinities of Atorvastatin derivatives measured by means of fluorescence polarization (using 16 as probe). 
Compounds marked with an asterisk were synthesized by LDC/Taros. 
 
Conversion of the carboxylic acid of Atorvastatin to an amide increased the affinity of the 
resulting pyrroles compared to Atorvastatin itself by more than one of order of magnitude. We 
reasoned that this striking increase in affinity could be explained by the formation of a second 
strong hydrogen bond to the amide. These Atorvastatin derivatives could potentially form two 
hydrogen bonds to Arg61 and Tyr149 instead of only one, which is to be expected for 
Atorvastatin itself.  
In parallel, the highly ligand efficient benzimidazole fragments were investigated. 
Benzimidazole 10 displayed an affinity of 165 ± 23 nM in the Fluorescein-Atorvastatin 
displacement assay (Table 3), whereas the closely related 1-benzyl 2-phenylindole showed no 
measurable binding. A number of simple benzimidazoles like 10 are found in the MPI 
Dortmund compound library and it was therefore decided to test whether the existing 
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benzimidazole library contained more potent compounds than 10. The library of simple 
N-substituted benzimidazoles was tested at a concentration of 1 µM in the fluorescence 
polarization assay employing Fluorescein-Atorvastatin and the best compounds were retested 
in a dose-response binding assay. From these experiments a simple benzimidazole containing 
an azepane moiety emerged as the most potent compound (Table 3, entry 2). The high affinity 
can be explained by the very high hydrophobicity of this saturated heterocycle, which 
apparently fills the hydrophobic cavity of PDEδ with high efficiency. The introduction of a 
tertiary amine and thus presumably a positive charge is tolerated by the protein. Consistent with 
the fluorescence polarization data, the compound shows a high affinity (KD.app of 110 nM, see 
appendix) in the Alpha screen assay employing a C-terminal K-Ras peptide. 
Table 3 Averaged affinities of simple benzimidazoles determined by means of fluorescence polarization employing 
Fluorescein- Atorvastatin. 
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4.4 Design, synthesis and biophysical evaluation of a bis-benzimidazole library  
Comparison of the KD values determined in different investigations suggested that the 
fragment-sized benzimidazole 10 binds to PDEδ with a higher binding affinity than the 
farnesylated K-Ras4B protein (165 vs 302 nM).40,79 Very high affinity compounds are often 
required to obtain high target occupancy and specificity in a biological environment. Therefore, 
it was decided to link the two benzimidazole fragments identified in the cocrystal structure of 
10 in order to improve potency. Molecular modelling (Schrödinger, Maestro suite) enabled the 
in silico analysis of different linker moieties. The best scoring poses were analysed and 
compared to the cocrystal structure of 10 (Figure 23, a,b). Phenyl rings A and B (Figure 23, a) 
of the two different benzimidazole fragments 10 were well aligned for a T-stacking interaction 
in the cocrystal structure and thus these two rings were left unaltered. Phenyl ring C on the 
other hand was found to be in close proximity to the benzylic position (4.3 Å) of benzimidazole 
fragment 10. Consequently a short linker was used for connecting the two fragments at the 
indicated positions (Figure 23, b, c). 
 
Figure 23 Design of linked benzimidazoles; a) Surface representation of PDEδ cavity (PDB 4JV6). The distance 
between linked atoms is highlighted; b) Best scoring docking pose obtained by docking an allyl substituted (R2) 
bis-benzimidazole into crystal structure of benzimidazole fragment 10 (PDB 4JV6); c) Design of linked bis-
benzimidazole ethers 25. 
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Retrosynthetically, the bis-benzimidazoles were disconnected to phenols 26 and alcohols 27 
(Scheme 3).  
 
Scheme 3 Disconnection of bis-benzimidazoles into fragments 26 und 27.  
The synthesis of benzimidazole fragments 26 started with commercially available 
phenylenediamine, which was reacted with 4-allyloxy benzaldehyde in the presence of sodium 
metabisulfite to yield the desired benzimidazole 30. N-benzylation of the benzimidazole 
followed by allyl deprotection of the phenol furnished the desired products 32-36 in good yields 
(80-84%). 
Scheme 4 Synthesis of benzimidazole fragments  26. 
Benzimidazole fragments 27 were synthesized either by an alkylation/reduction route or by a 
strategy based on a Ugi multi component reaction. Initially, bis-benzimidazoles containing 
small, flexible substituents like an allyl group at position R2 were synthesized to avoid clashes 
with the surface of the protein and to validate that fragment linking leads to higher affinity. 
Such benzimidazole fragments  27 were synthesized by alkylation of commercially available 
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2-phenyl benzimidazole with methyl bromoacetate (Scheme 5). The intermediate ester 39 was 
either directly reduced to the alcohol 40 or further alkylated with allyl bromide and then reduced 
with sodium borohydride. 
 
Scheme 5 Synthesis of benzimidazole fragments 40 and 42 by alkylation/reduction sequence. 
Benzimidazole fragments 27 containing more bulky substituents were synthesized by a strategy 
that is based on a Ugi-four-component reaction.80 Commercially available Boc-protected 
o-phenylenediamine, benzoic acid, benzyl isocyanate and the appropriate aldehyde were stirred 
for 36 h in MeOH to obtain the initial Ugi-product, which was then Boc-deprotected and 
cyclized using HCl/dioxane to yield the intermediate branched amides 48 and 49 respectively 
in one pot and good yields (72-89%, Scheme 6). Activation of the amide by reaction with di-
tert-butyl dicarbonate, followed by reductive cleavage of the amide led to the desired free 
alcohols 52 and 53 in good overall yields.  
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Scheme 6 Synthesis of benzimidazole fragments 27 by a Ugi-4-component strategy. 
Benzimidazole fragments 26 and 27 were subsequently connected via a modified Mitsunobu 
reaction with n-tributylphosphine and tetramethyl azadicarboxamide (TMAD).81 When fresh 
PBu3 and TMAD were used the reaction proceeded well with yields ranging from 59% to 72% 
(Scheme 7).  
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Scheme 7 Fragment linking of benzimidazoles via Mitsunobu reaction employing PBu3, TMAD. 
Boc-protected piperdines were linked in an analogous fashion (Scheme 8). Mitsunobu reaction 
of alcohol 53 with benzimidazoles 32-36 yielded the intermediate Boc-protected piperidines 
(61-70%). Deprotection of the piperdines and purification by reverse phase chromatography 
afforded the final inhibitors (69-74%).  
 
Scheme 8 Synthesis of piperidine containing bis-benzimidazoles via Mitsunobu reaction. 
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In order to obtain a suitable probe for pull down experiments in cell lysates the 
bis-benzimidazole 55 was equipped with a biotin moiety. For this purpose the allyl-substituted 
bis-benzimidazole 55 was oxidatively cleaved and coupled to a biotinylated linker to yield 68 ( 
Scheme 9). 
 
 Scheme 9 Synthesis of acid 67 and subsuequent biotinylation to yield 68. 
4.4.1 Evaluation of bis-benzimidazole affinities for PDEδ by means of fluorescence 
polarization assays and Tm shift measurements 
Due to the large hydrophobic surface area and the high abundance of aromatic rings, linked bis-
benzimidazoles were generally sparingly soluble. Compound 56 for example shows a solubility 
below 1 µM (Solrank, LDC Dortmund). This low solubility in aqueous buffers may result in 
experimental artifacts, which lead to an underestimation of the real affinity for this compound. 
Therefore, in addition to fluorescence polarization assays an orthogonal direct binding assay 
was needed which is not sensitive to compound solubility. Tm shift assays measure changes in 
the protein melting point Tm upon binding of a small molecule to the protein. The experiments 
should be performed by using a stoichiometry of protein to small molecule of approximately 
1:1, which avoids precipitation of the small molecule, since the protein solubilizes the small 
molecule by soaking it into the hydrophobic cavity. Additionally, precipitation is avoided by 
the gradual increase in temperature during the experiment.  
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Different methodologies have been used for the detection of changes in the protein melting 
point upon binding of small molecules. Fluorophores which bind to unfolded patches of the 
protein may be used for the detection of protein melting points. 82,83 CD-spectroscopy has a 
relatively low throughput but it has the advantage of being label free.84,85 To ensure 
orthogonality with the fluorescence polarization assays CD-spectroscopy was employed here 
to determine the melting point of PDEδ in the absence and presence of small molecule (Figure 
24). 
 
Figure 24 Schematic representation of the Tm shift assay. The ellipticity is proportional to the difference in 
absorption of left and right circular polarized light. Upon heating the chiral secondary structure elements of the 
protein (red) start to unfold, resulting in a decrease in the absolute value of ellipticity. In the presence of a small 
molecules (grey) the melting curve of the protein is shifted towards higher temperatures (red curve), leading to a 
higher Tm.  
CD-spectroscopy measures the difference in absorption of left and right circular polarized light. 
The measured so-called ellipticity is proportional to the difference in absorption of left and right 
circular polarized light. Upon heating, the chiral secondary structure elements of the protein 
(Figure 24) start to unfold, resulting in a decrease in ellipticity. In the presence of small 
molecules (grey) the melting curve of the protein is shifted towards higher temperatures, leading 
to a higher Tm. 
Under the assumption that the thermodynamic binding profile within a compound series is 
constant, it has been shown that the Tm shift correlates with the affinity of the compound.83 
PDEδ displays a typical CD-spectrum for a beta-barrel protein, consisting mainly of beta sheets. 
Measurements in DMSO containing buffer solutions (due to compound storage in DMSO) have 
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to be carried out at relatively long wavelengths, because of the strong absorption of DMSO at 
wavelengths below 230 nm. Consequently a wavelength of 232 nm was chosen. The absolute 
value of ellipticity at that wavelength decreased clearly when the protein unfolds at elevated 
temperatures (Figure 25). Strikingly, all benzimidazoles shift the melting curve to substantially 
higher temperatures.  
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Figure 25 Determination of melting point (Tm) with CD-spectroscopy in the absence or presence of benzimidazole 
compounds. 
Bis-benzimidazole 56 even shifts the melting point of the protein close to the detection limit of 
the instrument, since for technical reasons the ellipcity could not be reliably measured above 
90°C. Thus, linkage of the benzimidazole fragments indeed leads to higher affinities. 
The very large increase in the melting point T
m
 for all compounds can be explained by a 
decrease of the protein flexibility upon ligand binding.86,87 Unliganded PDEδ does not 
crystallize suggesting a high intrinsic flexibility of the protein. Addition of a ligand causes the 
protein to rigidify. This interpretation is substantiated by recent ultrasound velocimetry data 
which show that the complex of a simple farnesyl derivative with PDEδ is much less dynamic 
than free PDEδ.87  
Subsequently cocrystallization of the validated bis-benzimidazole-based PDEδ inhibitors was 
attempted by Dr. Shehab Ismail. Gratifyingly, the 55-PDEδ complex gave well-diffracting 
crystals with a resolution down to 1.75 Ả. The x-ray structure revealed an almost complete 
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overlap of the bis-benzimidazole with the guiding benzimidazole fragment 10 and a very good 
overlay with the highest scoring docking pose (Figure 26). Inspection of the 55-PDEδ structure 
revealed a hydrophobic cavity around the allyl group, which could also be filled by larger 
substituents. 
 
Figure 26 Cocrystal structure of bis-benzimidazole 55 with PDEδ; left) Overlay of the bis-benzimidazole 
(coloured sticks) with the guiding benzimidazole fragments (faint grey sticks); right) view of cavity surrounding 
the bis-benzimidazole. 
Binding of linked benzimidazole 55 was also analysed by means of fluorescence polarization. 
Consistent with the Tm shift, PDEδ bound to 55 with a 4-5 fold higher affinity compared to 
fragment 10. A library with varying subtituents at position R2 (Table 4) was designed and 
evaluated with the Tm shift – and the fluorescence polarization assay. Increasing the size of the 
substituent R1 with the use of a isopropyl and a cyclohexyl group increased both the affinity 
and the protein melting point (Table 4, entries 2+3), whereas introduction of a negative charge 
and omission of the substituent R1 led to no improvement (Table 4, entry 4). Coupling of the 
bis-benzimidazole core to a PEG-linker and biotinylation resulted in decreased affinity (Table 
4, entry 5). Due to a presumed steric clash with the surface of the binding pocket, a Boc-
protected piperidine showed only weak interaction with PDEδ (Table 4, entry 6). Owing to the 
proximity of the allyl group to the backbone carbonyl of Cys56 in the cocrystal of 55 with 
PDEδ, an additional hydrogen bond was envisaged. Therefore, piperidines were used to replace 
the allyl group. Amongst the tested piperidines, piperidine 62 proved to be the most potent 
(entry 10). Unexpectedly the affinity of piperidine 62 was slightly lower compared to the allyl 
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and cyclohexyl substituted bis-benzimidazoles. However, introduction of the piperidine groups 
substantially increased the solubility of the small molecules in aqueous solutions, and the idea 
of installing a piperidine functionality as a hydrogen bonding donor was investigated further. 
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Table 4 Library of bis-benzimidazoles with varying substituents at the position R2. Compounds marked with an 
asterisk were synthesized by LDC/Taros. 
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Further structural variations were conducted with the piperidine moiety in place, and focused 
on the variation of the benzyl moiety. The distance between the benzyl group of benzimidazole 
55 and Trp32 is below 4 Angstrom such that it can undergo a T-stacking interaction with the 
electron rich indole moiety (Figure 27). T-stacking interactions are usually strongly dependent 
on the electronic nature of the interacting aromatic moieties.88,89 Therefore, electron-donating 
and electron withdrawing groups were introduced at position R1 (Table 2).  
 
Figure 27 T-stacking interaction between benzimidazole 55 and PDE 
Unexpectedly neither the synthesis of electron-poor aromatic systems (4-fluorbenzene, 
pyridine; Table 5, entries 2-3) nor electron-rich toluene derivatives (Table 5, entries 4-5) 
resulted in more potent compounds. Owing to these disappointing results the benzyl moiety 
was retained in further studies. 
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Table 5 Variation of the substituent R1 which undergoes a T-stacking with Trp32. 
 
4.4.2 Synthesis and biophysical evaluation of ester linked bis-benzimidazoles 
The results in Table 4 suggest that the rigid ether linker might make the backbone carbonyl of 
Cys56 unavailable for interaction with the piperidine group. Consequently the length of the 
linker moiety was increased and the ether replaced by a more flexible ester. In analogy to the 
disconnection of the ether compounds, ester linked bis-benzimidazoles were divided into two 
benzimidazole fragments: 74 and 27 (Scheme 10).  
 
Scheme 10 Disconnection of linked bis-benzimidazoles esters. 
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Benzimidazole fragments  74 were synthesized starting from 2-chloro benzimidazole (75). 
Nucleophilic aromatic substitution with ethyl piperidine-4-carboxylate (76) afforded compound 
77 in 81 % yield. The free benzimidazole was subsequently either benzylated with 
caesiumcarbonate and benzyl bromides in acetonitrile (78-79) or underwent a Mitsunobu 
reaction with 3-hydroxymethyl thiophene (61%) using tributyl phosphine and TMAD (80). 
Cleavage of the ester under basic or strongly acidic, aqueous conditions furnished the free 
carboxylic acids 81-83.  
 
Figure 28 Synthesis of benzimidazole fragments  74.  
Benzimidazole fragments  74 were then reacted with fragments 27 under Mitsunobu reaction 
conditions (PS-PPh3, DtBAD) and deprotected, if necessary, to yield the linked 
bis-benzimidazoles (Figure 29). 
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Figure 29 Synthesis of ester-linked bis-benzimidazoles from fragments 81-83 and 27 containing a) a cyclohexyl 
group or b) a piperidine moiety. 
The ester compound collection was evaluated subsequently in fluorescence polarization assays 
and the data in Table 6 show that replacement of the phenyl ether with a piperidyl ester in this 
compound class leads generally to higher affinities. Gratifyingly, ester 90 bound to PDEδ with 
an affinity of 10 nM. The increased affinity of ester 90 compared to the related ether compound 
series might be explained by the formation of an additional H-bond to Cys56 as it was envisaged 
by docking experiments.  
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Indeed, a cocrystal structure of 90 with PDEδ confirmed the presence of a third hydrogen bond 
between the backbone carbonyl of Cys56 and the piperidine moiety (Figure 30).  
 
Figure 30 Cocrystal structure of 90 with PDEδ confirms third hydrogen bond of the bis-benzimidazole with the 
backbone carbonyl of Cys56 (PDB 4JVF).79 
Compared to the guiding piperidine containing ester 90, cyclohexyl and isopropyl substituted 
esters (R1) displayed lower affinity (Table 6, entries 2 and 3). Consistent with the data shown 
in Table 1 additional electron withdrawing substituents on the benzyl ring reduce the binding 
affinity and thus yield higher KD values (Table 6, entries 4 and 5). The replacement of the benzyl 
moiety at R1 with a 3-methyl thiophene however resulted in similar affinities (Table 6, entries 
6 and 7). In general, the cyclohexyl substituted benzimidazoles which cannot form a third 
H-bond to Cys56 bind with lower affinities to the protein than the piperidines (Table 6, entries 
1,4,6 vs 2,5,7). 
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Table 6 Affinities of ester linked bis-benzimidazoles measured by means of competitive titrations employing 
Fluorescein-Atorvastatin. 
 
Since the cocrystal structure of 90 with PDEδ revealed a third hydrogen to Cys56 it was 
envisaged to further explore how strongly the additional hydrogen bond affects affinity.  
Replacement of the 4-piperidyl moiety at R2 by a 3-piperidyl substituent (Table 7, entries 2 and 
3), a pyrrolidine (entries 4 and 5) and a 4-methylene piperidine (entry 6) resulted in compounds 
with slightly reduced or similar affinity compared to ester 90. Notably, all ester-linked 
benzimidazoles bind with higher affinities than the related ethers. 
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Table 7 Affinities of ester linked bis-benzimidazoles measured by means of competitive titrations employing 
Fluorescein-Atorvastatin. Compounds other than 90 were synthesized by Taros/LDC. 
 
4.4.3 Synthesis and biophysical evaluation of amide and carbamate linked bis-
benzimidazoles 
The higher potency of the ester linked bis-benzimidazoles was attributed to the increased 
flexibility and length of the linker moiety. Due to a possible susceptibility of the ester 
compounds towards cleavage by hydrolases in prospective cellular investigations, the ester 
moiety was replaced by more stable linkers. Therefore, similarly long linkers like amides and 
carbamates were investigated. Amide linked bis-benzimidazoles were synthesized from alcohol 
53 (Scheme 11). The alcohol was transformed into the phthalimide by means of a Mitsunobu 
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reaction. Deprotection with hydrazine afforded the free amine 100, which was coupled with the 
free acid 83 using PyBop/DIPEA. Boc-protected benzimidazole 101 was deprotected with HCl 
in dioxane to afford the free piperidine. 
Scheme 11 Synthesis of amide linked bis-benzimidazoles starting from alcohol 53. 
Amide 102 was evaluated in fluorescence polarization assays and it was found that the rigid 
amide 102 binds to PDEδ with lower affinity than the related ester (Table 8). This can be 
attributed to the planarity/rigidity of the amide bond, the different hydrogen bonding properties 
and/or a different conformation. In another effort it was attempted to replace the ester by a 
similarly flexible carbamate. For the synthesis of the carbamate, alcohol 53 was reacted 4-
nitrophenyl chloroformate (103). The intermediate carbonate was in situ activated with HOBt 
and then reacted with piperazine 104 to afford the Boc-protected carbamate 105. Boc-
deprotection furnished to desired carbamate 106. 
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Scheme 12 Synthesis of carbamate linked bis-benzimidazoles. 
Carbamate 106 showed much stronger binding compared to the rigid amide 102, yet it was not 
as good as the best ester compounds (Table 8). 
Table 8 Affinities of ester, carbamate and amide linked bis-benzimidazoles. 
 
4.4.4 Separation of racemic bis-benzimidazoles and biophysical evaluation  
With the aim of investigating if the different enantiomers of the bis-benzimidazole compounds 
bound with strongly different affinities, the enantiomers of the Boc-protected bis-
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benzimidazoles 57 and 89 were separated by preparative chiral HPLC. Deprotection using 
HCl/dioxane and subsequent biophysical experiments revealed a 4-6 fold difference in potency 
for each pair of enantiomer with affinities of 38 ± 16 nM vs  190 ± 55 nM for compounds 62, 
and KD values of 7 ± 3 nM and 39 ± 18 nM for compound 92. Although the absolute 
configuration of these compounds could in principle be obtained by cocrystallization with 
PDEδ, a very high resolution would be needed. Since such highly diffracting crystals were not 
available, it was decided to assign the absolute configuration by analogy to well established 
enantioselective syntheses. 
4.4.5 Enantioselective synthesis of bis-benzimidazoles 
The racemic ester and ether linked benzimidazoles displayed low nanomolar KD values, it was 
however at this stage unclear which enantiomer bound with higher affinity. It was realized that 
the chiral benzimidazole fragments 27 can be retrosynthetically traced back to amino alcohols 
(Scheme 13). 
 
Scheme 13 Disconnection of chiral benzimidazole into amino alcohol. 
Since the chiral synthesis of amino acids and alcohols is well established, it was planned to 
assign the absolute sterochemistry according to literature precedent. In addition, the 
enantioselective synthesis should provide gram quantities of chiral building blocks for the 
synthesis of 62 and 92. Two well-established routes for the enantioselective synthesis of chiral 
amino alcohols were investigated in parallel; asymmetric hydrogenation and Evans azidation 
methodology. Both asymmetric hydrogenation and azidation have been succesfully applied to 
the synthesis of chiral amino acid and alcohol building blocks including (R)-piperidinyl 
glycine.90,91 Both approaches were used to synthesize gram quantities of the two different 
enantiomers of key intermediate 107 (Scheme 14). The asymmetric hydrogenation approach 
started with N-boc 4-piperidone which was reacted with N-Cbz-phosphonoglycine trimethyl 
ester (110) in a Horner-Woodsworth-Emmons reaction.91 The resulting Cbz-protected enamine 
was then subjected to asymmetric hydrogenation using [(R,R)Me-BPE_Rh-COD]OTf (112) as 
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a catalyst (4% mol) at 3-5 bar hydrogen pressure. The ester was Cbz deprotected by 
hydrogenolysis employing H2 on Pd/C and the ester functionality reduced with sodium 
borohydride. Nucleophlic aromatic substitution with 1-fluoro 2-nitrobenzene provided the key 
alcohol 107, which was used to evaluate enantiomeric purity since it is a common intermediate 
in both enantioselective approaches.  
 
Scheme 14 Enantioselective synthesis of chiral alcohol 107 by asymmetric hydrogenation with [(R,R)Me-
BPE_Rh-COD]OTf or by Evans azidation. Reaction conditions. a) 1. NaBH4, MeOH 2. H2, Pd/C, EtOH 3. 1-
Fluoro-2-nitrobenzene, DIPEA, NMP, 100°C, 6h.; 21% over three steps b) 1. H2, Pd/C, EtOH; 2. NaBH4, MeOH 
3. 1-Fluoro-2-nitrobenzene, DIPEA, NMP, 100°C, 6h, 45% over three steps. 
The alternative synthesis based on Evans azidation started from the commercially available N-
Boc-protected acid 114, which was activated with PivCl and in situ coupled to deprotonated 
(S)-4-phenyl-2-oxazolidinone . On gram scale an alternate synthesis of oxazolidinone 115 was 
preferred: To avoid the use of butyl lithium, LiCl was employed to mediate the coupling of 
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N-Boc-protected acid 114 with (S)-4-phenyl-2-oxazolidinone.92 The resulting oxazolidinone 
115 was obtained in high purity after recrystallization and was thus directly subjected to 
azidation with trisyl azide in a mixture of toluene/THF at -60°C. As precedented in literature, 
quenching the intermediate sulfonyl triazene intermediate with buffered acid acid, avoids diazo 
transfer and provides the azide 116 in good yields.93 Reduction with sodium borohydride in 
methanol, followed by hydrogenation with palladium over carbon and nucleophilic aromatic 
substitution provided the intermediate alcohol 107.  
Analysis of the chiral HPLC traces of intermediate 107 revealed that asymmetric hydrogenation 
gave an ee of only 88%. Evans azidation on the other hand led to the completely enantiopure 
intermediate alcohol 107. Therefore, the Evans methodology was used for all further syntheses 
of enantiopure compounds. Key chiral alcohol 107 was reacted with phenol 32 using Mitsunobu 
conditions to yield ether (S)-117 (Scheme 15). The intermediate was cyclized under reductive 
conditions and Boc-deprotected to yield (S)-62. This compound was termed Deltarasin due its 
ability to break the Ras-PDEδ interaction in cellulo (see below).  
 
Scheme 15  Enantioselective synthesis of the bis-benzimidazole Deltarasin. 
Boc-protected Deltarasin was evaluated in terms of chiral purity by analytical, chiral HPLC. As 
references the racemic compound mixture and the separated enantiomers (prep. HPLC) were 
used. 
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Figure 31 Chiral HPLC trace for racemic benzimidazoles 57 (Boc-Deltarasin) and for the (S)-enantiomers (red) 
obtained by both preparative chiral HPLC and enantioselective synthesis.  
Analysis of the chiral HPLC traces allowed for the assignment of the two peaks to the respective 
enantiomers, with the faster eluting compound being the (S)-enantiomer. In an analogous 
approach for the assignment of the absolute configuration of ester compound 92, Boc protected 
alcohol (S)-107 was reacted with acid 83 using Mitsonubu conditions to yield nitro aniline (S)-
118, which was cyclized with benzaldehyde (Scheme 16). Coinjection of the racemate, the 
separated enantiomers (prep. HPLC) and the (S)-enantiomer allowed for the assignment of the 
enantiomers (Figure 32). For both ether 62 and ester 92, the (S)-enantiomers proved to be more 
potent than the (R) enantiomers.  
 
Scheme 16 Enantioselective synthesis of ester (S)-118 by Mitsunobu reation, followed by cyclization of a nitro 
aniline intermediate. 
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Figure 32 Chiral HPLC traces for racemic benzimidazole 89 (black) and for the (S)-enantiomers (red) obtained 
by both preparative chiral HPLC and enantioselective synthesis. Stereochemistry was assigned according to 
literature precedents. 
Despite the good results obtained with the described enantioselective approaches, the whole 
synthetic sequence was rather long. Therefore, shorter enantioselective routes towards 
bis-benzimidazoles were investigated. It was planned to synthesize alcohol (S)-53 via a 
sequence of enantio- and regioselective iridium catalysed alkylation followed by ozonolysis 
and reduction. 
 
Figure 33 Alternative retrosynthetic analysis of alcohol (S)-53 
Hartwig and coworkers describe an iridium catalyzed enantio- and regioselective alkylation of 
benzimidazoles in very high yields.94 Substrates tested include a cyclohexyl group at position 
R1 and a phenyl group at R2 (but not both together, Scheme 17). However, the catalyst of the 
reactions was synthesized in a glove box, due to its instability. Only one example is presented 
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where the iridium catalyst is formed in situ, although the whole reaction is still carried out in 
the glove box.  
 
Scheme 17 Enantioselective asymmetric allylation of benzimidazoles using iridium catalyst.94 
Nevertheless the reaction was investigated as an an alternative to synthesize the desired 
enantiomers. Intial attempts under normal Schlenk conditions and in situ formation of the 
catalyst did not lead to the desired product in acceptable yields. The attempted reaction (R1=Ph, 
R2=Ph, Scheme 17) resulted in a complex reaction mixture which includes two regioisomeric 
products with the expected mass along with the dialkylation product in a 1:1.5:2.2 ratio 
(Coronona detector, LC-MS). Due to these discouraging results no further optimization was 
attempted. 
4.4.6. Biophysical evaluation of enatiomerically pure ester and ether linked compounds 
While highly potent molecules were identified among the bis-benzimidazoles, ligand efficiency, 
solubility and drug likeness of the compounds still left room for improvement.67 It was therefore 
envisaged to reduce the number of aromatic rings and the size of the benzimidazoles while 
trying to maintain potency. With the enantioselective route towards the bis-benzimidazoles in 
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hand, initial attempts focused on replacing the 2-phenyl substituent in the ester compound series 
by alkyl residues (Scheme 18, Table 9).  
 
Scheme 18 Enantioselective synthesis of esters (S)-127-130 by cyclization of a common nitro aniline intermediate. 
Indeed, replacement of the phenyl group in the guiding benzimidazole (S)-92 with an isopropyl, 
an ethyl or a cyclopropyl group yielded similarly potent compounds (Table 9, entries 2-4) 
However, the introduction of a methyl group resulted in reduced affinity. 
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Table 9: Affinities of ester-linked benzimidazoles as measured by fluorescence polarization  
 
4.4.7 Structural simplification of bis-benzimidazoles 
In a further effort to decrease the size of the compounds the stereocenter was eliminated in both 
the ester and the ether series. Surprisingly high affinity compounds were identified which bind 
with improved ligand efficiency (Table 10, entries 1-5). These data suggest that a third hydrogen 
bond to Cys56 might not necessary for the development of highly potent compounds targeting 
the K-Ras-PDEδ interaction. Additionally the dataset suggests that large hydrophobic 
substituents like cyclohexyl and isopropyl are also not essential for high affinity. Analysis of 
the existing crystal structures and docking experiments do not provide any simple explanation 
for this finding.  
A possible explanation might be revealed by an analysis of protein dynamics. Biophysical 
experiments showed that in the farnesyl bound state PDEδ is conformationally constrained 
compared to the free state, which results in an entropic penalty upon binding of ligands into the 
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farnesyl cavity.86 In addition, PDEδ does not crystallize in the absence of bound ligands, 
highlighting the high intrinisic flexibility of the protein. Therefore, the unexpectedly high 
affinity of the bis-benzimidazoles in Table 10 might be due to the less pronounced restriction 
of proteins dynamics, resulting in a lower entropic penalty upon binding of a small molecule.86 
Table 10: Affinities of smaller benzimidazoles measured by means of fluorescence polarization. Compounds were 
synthesized by LDC/Taros. 
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4.4.8 Synthesis of TAMRA-labeled bis-benzimidazoles and evaluation of specificity 
As shown above, bis-benzimidazoles bind strongly to PDEδ in biophysical displacement 
titrations employing Fluorescein-Atorvastatin. In order to validate the strong interaction, the 
bis-benzimidazoles (S)-62 Deltarasin and ester (S)-92 were labeled with the rhodamine-based 
dye TAMRA (Scheme 19) and their interaction with PDEδ was further investigated.  
Scheme 19 Synthesis of TAMRA-labeled (S)-92. TAMRA-Deltarasin was synthesized by analogy. 
Both labeled compounds display very high affinities for PDEδ with KD values in the single digit 
nanomolar range (Figure 34). In direct titrations employing labeled compounds these values 
can be regarded as upper limits, since picomolar affinities cannot be measured under these 
experimental conditions. For fluorophores like TAMRA low signal to background ratios 
(fluorescence intensity) are commonly observed at low nanomolar fluorophore concentrations 
which introduce artifacts into binding isotherms. For the differentiation of high affinity, labeled 
compounds two solutions exist: a) competitive titrations using unlabeled compounds of known 
affinity or b) kinetic experiments which allow for the determination of the KD from the ratio of 
association and dissociation rate constants (see below). For competitive titrations the two 
TAMRA-labeled compounds were subjected to titrations with PDEδ in the presence of an 
excess of unlabeled Atorvastatin.  
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Figure 34 Direct Titration of TAMRA-(S)-92 (100 nM, left) and TAMRA-Deltarasin (175 nM, right) with PDEδ. 
Fit to a one-site binding model derived from the law of mass action yields the the corresponding KD values 
(TAMRA-(S)-92 KD 5.3 ± 1.5 nM and TAMRA-Deltarasin 7.6 ± 1.3 nM). The titrations for TAMRA-Deltarasin 
were also repeated at lower concentrations (35 nM) resulting in similar KD values. 
The data can be approximately fit by a single site model, however no standard binding model 
is available for this experimental setup (Figure 35).95 Even in the presence of competitor the 
binding isotherms for TAMRA-(S)-92 still display a stepwise shape suggesting a higher affinity 
than the fit suggests. Under these conditions the TAMRA-labeled compounds, however, can be 
differentiated in terms of their relative affinities, and the data suggest that the ester TAMRA-
(S)-92 binds more strongly than TAMRA-Deltarasin. 
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Figure 35 Titrations of TAMRA-(S)-92 (60 nM) and TAMRA-Deltarasin (100 nM) with PDEδ in the presence of 
1000 nM unlabeled Atorvastatin.  
Although both TAMRA-labeled compounds bind with high affinity to PDEδ it was unclear how 
specific the interaction between PDEδ and these bis-benzimidazoles is. Therefore, binding to 
the related solubilizing factors UNC119a/HRG4 and UNC119b was investigated, which feature 
a high degree of structural similarity to PDEδ. 32 Both contain a beta barrel structure which can 
accommodate a lipid moiety. In contrast to PDEδ, UNC119a/b bind myristoylated peptides with 
low nanomolar affinity. Additionally specificity was tested against the presumed Ras specific 
lipid binding proteins Galectins1/3.25,96,97 
To test the specificity both TAMRA-labeled compounds were titrated with the mentioned lipid 
binding proteins (Figure 36). Only PDEδ led to an increase in fluorescence polarization upon 
addition of protein to the labeled probes TAMRA-(S)-92 and TAMRA-Deltarasin. The 
TAMRA-labeled bis-benzimidazoles did not bind to any other lipid binding proteins and are 
therefore selective probes for exploring the interaction of small molecules with PDEδ.  
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Figure 36 Titration of TAMRA-(S)-92 (100 nM, left) and TAMRA-Deltarasin (175 nM, right) with PDEδ, 
UNC119A/HRG4, UNC119B, Galectin-1 and Galectin-3 in PBS buffer (containing 0.05% Chaps). Solely addition 
of PDEδ led to a change in fluorescence anisotropy of the TAMRA-labeled probes.  
4.5 Displacement titrations of TAMRA-Deltarasin with benzimidazoles 
TAMRA-(S)-92 and TAMRA-Deltarasin were also investigated for their suitability in 
displacement titrations. Initial qualitative experiments suggested that TAMRA-Deltarasin 
unlike Fluorescein-Atorvastatin and TAMRA-(S)-92 displays a relatively fast dissociation rate 
from the protein (half lifes on the minute scale, see also kinetic analysis below). The advantage 
of using probes with relatively fast dissociation rates is that precipitation effects can be avoided, 
because equilibration times with unlabeled small molecules are shorter. This is of particular 
interest for sparingly soluble small molecules like bis-benzimidazoles (see discussion Tm shift). 
Therefore, displacement titrations of TAMRA-Deltarasin with the benzimidazole fragment 10 
and the bis-benzimidazole Deltarasin were also investigated (Figure 37). Both compounds 
showed a dose dependent decrease of fluorescence anisotropy and thus the fraction of protein-
bound fluorophore (KD values: Benzimidazoles fragment 10: 21 nM, Deltarasin 4 nM). The 
affinities for the unlabeled compounds are markedly higher compared to the dataset obtained 
with Atorvastatin-Fluoresein.  
 RESULTS AND DISCUSSION 
70 
 
1E-3 0,01 0,1 1 10
0,0
0,2
0,4
0,6
Deltarasin
fr
a
c
ti
o
n
 b
o
u
n
d
 10
concentration of small molecule / µM
 
Figure 37 Representative displacement titrations of TAMRA-Deltarasin with benzimidazole fragment 10 (fit in 
blue) and Deltarasin (fit in red). Conditions: TAMRA-Deltarasin 33 nM, PDEδ 40 nM. Data were fit to an exact 
competition model based on the law of mass action. 
4.6 Displacement Alpha screen with biotinylated Atorvastatin 
Although fluorescence polarization and Tm shift assays were successfully used to evaluate 
compound libraries, other assay formats were investigated. Alpha technology was successfully 
used with a biotinylated K-Ras peptide as described above. However, due to the low affinity of 
K-Ras4B peptides for PDEδ high protein concentrations were needed and thus the affinity of 
highly potent inhibitors remained elusive. Biotin-Atorvastatin 15 on the other hand showed a 
very high affinity in the Tm shift assay (22.8°C), and ITC (67 nM). Therefore, in analogy to the 
direct titration of biotinylated K-Ras4B with PDEδ (Figure 13, Figure 15) Atorvastatin was 
titrated with PDEδ and an apparent KD,app of around 7 nM was obtained (Figure 38).  
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Figure 38 Dilution series of Biotin-Atorvastatin 15 with PDEδ using Alpha screen readout. 
Notably, the binding curve for Biotin-Atorvastatin 15 displays a bell-like shape which can be 
explained by the so-called hooking effect.98 The Biotin-Atorvastatin 15 / PDEδ/ donor bead / 
acceptor bead system can be regarded as a four body binding equilibrium. Some ternary and 
higher-order equilibria exhibit a bell-shaped dose response curve in which increasing the total 
concentration of the central species can actually cause reduction in ternary or higher-order 
complex concentration, and thus lead to a decreased signal (for a three body illustration see 
Figure 39). 
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Figure 39 Illustration of the hooking effect, a general property of three body binding equilibria, applied to Alpha 
technology.99  
In the case of a three body system using Alpha technology with just one analyte (e.g. a 
biotinylated, His-tagged protein, Figure 39), it means that excess analyte concentrations lead to 
decreased ternary complex formation because all binding sites on the donor and the acceptor 
beads are already occupied. In this situation excess analyte will not bring the two beads 
together, rather a situation results where the bridging species, which causes the signal, will 
compete with excess analyte that binds only to one bead and not to the other.     
In the case of a four body system as observed with Biotin-Atorvastatin 15 / PDEδ / donor bead 
/ acceptor bead, the system can be reduced to a three body problem as in Figure 39 at high 
concentrations of compound and protein. If compound and protein are used at a 1:1 
stoichiometry, at concentrations above the KD virtually all of the compound will be bound to 
protein. Under these conditions neither free compound nor free protein exist, therefore the 
system can be reduced to a three body binding equilibrium containing the Biotin-Atorvastatin-
Protein-complex, the donor bead and the acceptor bead. Therefore, the illustration in Figure 39 
can also be applied to the discussed four body equilibrium. 
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Displacement titrations employing Atorvastatin derivative 17 and bis-benzimidazole 55 lead to 
apparent affinities of 45 ± 20 and 55 ± 10 nM (Figure 40). The affinity for bis-benzimidazole 
55 is therefore in the same range as measured by fluorescence polarization (39 nM).  
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Figure 40 Representative displacement titrations of Biotin-Atorvastatin 15 with Atorvastatin derivative 17 (blue) 
and bis-benzimidazole 55 (black). Data were fit to an empirical dose response model. KD,app values of 45 ± 20 
(17) and 55 ± 10 nM (55) can be derived from two independent sets of experiments employing different orders 
of compound addition . (Atorvastatin 6 nM, PDEδ 24 nM). 
The displacement assay with Biotin-Atorvastatin is thus a viable alternative to the other 
assays (ITC, fluorescence polarization, Tm shift). 
4.7 Kinetic analysis of small molecule-PDEδ interactions 
For medicinal chemistry the rate constant koff is of particular interest, because arguably koff is 
more predictive of cellular activity than the equilibrium constant KD.100 Various methods have 
been described to measure the kinetic rate constants, kon and koff, for a protein/ligand 
interaction.101-103 Very fast association and dissociation kinetics for example are readily 
obtainable by stopped flow measurements employing for example fluorescence anisotropy as 
readout.44 Slow dissociation rates of labeled small molecules can be determined by means of 
time resolved fluorescence anisotropy measurements in standard 96 well plates. In a standard 
assay setup with PDEδ, the TAMRA labeled small molecules were preincubated with PDEδ and 
 RESULTS AND DISCUSSION 
74 
 
then a large excess of unlabeled competitor was added to determine the displacement of labeled 
compound in real time. 
 
Figure 41 Displacement assay for measuring koff of labeled compounds using an excess of the unlabeled molecule. 
The addition of an excess of small molecule ensures that no rebinding of the labeled compound to the proteins 
occurs. 
When TAMRA-(S)-92 and TAMRA-Deltarasin were used, the high initial fluorescence 
anisotropy decreased over time after addition of unlabeled Deltarasin (Figure 42). Strikingly, 
the rate constants for TAMRA-Deltarasin koff ((6 ± 1) x 10-4 s-1) and for TAMRA-(S)-92 ((9 ± 
5) x 10-5 s-1) are several orders of magnitude lower than the previously determined koff of 3 s-1 
for a farnesylated peptide mimicking the Ras-family protein Rheb (Table 11, entries 1-3).44  
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Figure 42 Representative competition experiment of TAMRA-Deltarasin with an excess of unlabeled Deltarasin, 
observed by a fluorescence anisotropy time course. 
Table 11 Rate constant koff for labeled small molecules and peptides. & KD values derived from direct titration 
measured by fluorescence polarization. Adopted from references.40,44 
 
While fluorescence polarization experiments allow for the determination of rate constants for 
labeled molecules like TAMRA-Deltarasin, these experiments necessitate a label, which may 
influence the interaction. Therefore, label-free experimental techniques were investigated. 
Surface plasmon resonance (SPR) allows for the determination of affinities and kinetic 
parameters in a single experiment.102,103 In SPR experiments with unlabeled small molecules, 
the protein is immobilized via its affinity tag. The small molecule is added to a flow cell and 
the adsorption of the small molecule onto the solid phase is monitored over time and in a 
concentration dependent manner. In collaboration with the company Biaffin, Kassel an assay 
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system employing immobilized GST-PDEδ was established. To this end, GST-PDEδ was 
reversibly immobilized on an anti GST capturing surface. In these binding experiments simple 
benzimidazole 10 showed a fast association and a fast dissociation from immobilized PDEδ 
(Figure 43, left).  
 
 
Figure 43. Representative SPR experiments carried out at 35°C on a Biacore T100. For benzimidazole 10  
compound concentrations were varied from  63 to 8000 nM (left)), for the bis-benzimidazole Deltarasin a 
concentration range of 2-64 nM was used (right). Experiments were carried out by Biaffin GmbH, Kassel. 
The bis-benzimidazoles (S)-90 and Deltarasin displayed a similarly fast association, whereas 
the dissociation rate was strongly reduced (Table 12, entries 2 and 3). The dissociation rates koff 
derived from SPR experiments agree well with fluorescence polarization data (see above). The 
equilibrium constants KD derived from kinetic experiments are higher for the benzimidazole 
fragment 10, whereas they are much lower for the bis-benzimidazole Deltarasin and (S)-90. 
According to the SPR experiments ester (S)-90 displays very tight binding with an affinity of 
77 pM (Table 12, entry 3). 
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Table 12 Surface plasmon resonance data for the interaction of benzimidazoles with PDEδ. KD values marked 
with an asterisk are derived from the ratio of rate constants. Value in parenthesis is derived from steady state 
analysis. 
  
       
4.8 Effect of GppNHp-loaded Arl2/3 on the small molecule-PDEδ interaction 
It was previously shown that the Arl2/3 GTPases actively released farnesylated cargo proteins 
from PDEδ and that farnesylated Rheb and K-Ras display KD-values for binding to PDEδ in the 
higher nanomolar range (Rheb KD = 394 nM, K-Ras KD = 302 nM).40 Therefore, it was explored 
whether Arl2/3 can also displace cargo with much lower KD-values, as for instance TAMRA-
labeled Deltarasin and ester (S)-92.  
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Figure 44 Active displacement of TAMRA-(S)-92 (50 nM) with an excess of Arl3 observed by fluorescence 
anisotropy. 
Interestingly, the TAMRA-labeled ester (S)-92 was readily displaced by GppNHp-loaded Arl3 
(Figure 44). Therefore, it was tested whether Arl2/3 release high-affinity ligands in a 
concentration dependent manner: Preformed PDE/ TAMRA-Deltarasin or ester (S)-92 
complex were treated either with Arl2 or Arl3. The PDE-TAMRA-Deltarasin complex was 
disrupted by both Arl2 and Arl3 as seen by the rapid and concentration-dependent release of the 
inhibitor from the prenyl-binding protein (Figure 45, left). Arl3 released the labeled small 
molecule more efficiently from the farnesyl binding site than Arl2. Using a simplified 
competition model KD values of 24 nM for Arl2 and 1 nM for Arl3 are obtained from this 
dataset. Surprisingly, Arl2 was not able to readily displace the labeled ester TAMRA-(S)-92 
from the farnesyl binding site (Figure 45, right).  
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Figure 45 Representative displacement titrations showing the release of high-affinity ligands from PDEδ by 
Arl2/3. Displacement titrations of TAMRA-Deltarasin (left) or TAMRA-(S)-92 (right) bound to PDEδ (both 100 
nM) with different concentrations of GppNHp-loaded Arl2/3 measured by fluorescence anisotropy. 
These experiments suggest that very high-affinity compounds like TAMRA-(S)-92 can only be 
efficiently released by Arl3, whereas Arl2 does not efficiently displace these tight binding 
ligands from the farnesyl binding site.  
Similar to the TAMRA-(S)-92-PDEδ complex, the Fluorescein-Atorvastatin-PDEδ complex 
displays dissociation half lives on the hour scale, suggesting very high affinity. Therefore, this 
different chemotype was also investigated in qualitative experiments employing labeled 
Atorvastatin and Arl2/3 (Figure 46). Like TAMRA-(S)-92, Fluorescein-Atorvastatin is stable 
towards displacement by Arl2, but readily released by Arl3. 
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Figure 46 Qualitative release experiments of Fluorescein-Atorvastatin with GppNHp-loaded Arl2/3. A complex 
of Fluorescein-Atorvastatin and PDEδ was treated with equal amounts of Arl2 and Arl3. Only Arl3 can efficiently 
release Fluorscein-Atorvastatin. 
High to medium affinity cargo like TAMRA-Deltarasin and farnesylated peptides on the other 
hand are susceptible to displacement by both Arl2 and Arl3. In a direct titration with PDEδ 
TAMRA-Deltarasin shows a similar KD compared to Fluorescein-Atorvastatin and TAMRA-
(S)-92 (5-7 nM), but even at the lowest technically possible protein concentrations these 
compounds cannot be differentiated in terms of affinity in a direct titration. The dissociation 
rates of the three compounds however are clearly different (see above), suggesting that 
Fluorescein-Atorvastatin and TAMRA-(S)-92 both indeed bind with higher affinity than 
TAMRA-Deltarasin.  
Notably, Arl3 but not Arl2 displaces the farnesylated ciliary phosphatase INPP5E from PDEδ 
in cell lysates (Figure 47).56 suggesting a higher affinity complex of INPP5E-PDEδ compared 
to Ras-PDEδ. 
Consistent preliminary direct titrations performed with a C-terminal TAMRA-labeled INPP5E 
peptide show higher affinities compared to Ras peptides, with a labeled peptide INPP5E peptide 
displaying an affinity of 48 nM. 
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Figure 47 Differential release of farnesylated phosphatase INPP5E by Arl2 and Arl3, measured by Thomas et al.56 
LAP6-PDE and myc-INPP5E in RPE cells were incubated with increasing amount of either GDP (TN)- or GTP 
(QL)-mimicking mutant GST-ARL2 or GST-ARL3 as indicated. Immunoprecipitation of PDE with anti-GFP 
antibodies and detection of co-immunoprecipitated INPP5E by anti-Myc immunoblotting reveal specific ARL3 
QL-dose dependent interaction between INPP5E and PDE. 56 
These findings have important consequences for the cellular effect of small molecules targeting 
PDE. Since Arl2/3 and PDE are present in cells in comparable concentrations (low 
micromolar),104, the cargo-releasing ability of Arl2/3 would necessitate higher compound 
concentrations to observe a cellular effect than to be expected based on the affinity constant KD. 
The displacement titration data suggest that Arl2 and Arl3 have different binding affinities for 
PDEδ, with Arl3 being the more potent interactor. Preliminary SPR experiments and 
fluorescence polarization data support this notion.105 The binding data also hints at different 
roles for Arl2 and Arl3 in the cell. Arl2/3 are both expressed in the cytoplasm, where they may 
unload low-affinity, prenylated cargo like Ras from PDEδ. Therefore their roles may be 
interchangeable in that part of the cell. Arl3 on the other hand is also strongly expressed in cilia, 
where it may release high affinity cargo like INPP5E from PDEδ. Interestingly, for UNC119a/b 
high affinity myristoylated peptides can also be only released by Arl3 and not by Arl2.106 Here, 
the Arl3 N-terminal helix has been described as a pocket opener. The interaction of Arl3 with 
PDEδ must be structurally different since the lipid binding site of UNC119 is on the other side 
of the protein compared to PDEδ.106 Since Arl3 regulates targeting of both farnesylated and 
myristoylated cargo to the primary cilium,106,107 it can be reasoned that it is the central release 
factor for transport of lipidated cargo to the cilium.  
The high affinity cargo identified for UNC119a/b and PDEδ are all of ciliary origin,106,107 
suggesting two differential roles for the lipid binding proteins. Apparently this class of lipid 
binding proteins controls the localization of low affinity cargo like Src kinases for UNC119a 
and Ras GTPases for PDEδ in the cell body, whereas high affinity cargo is transported to the 
primary cilium and released by Arl3.  
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4.9 Effect of GppNHp-Arl2 on the displacement kinetics of cargo from PDEδ 
In addition to equilibrium titrations, the influence of GppNHp-Arl2 on the kinetics of cargo 
release was investigated. Since Arl2 forms a low affinity ternary complex with farnesylated 
Rheb and PDEδ, which rapidly dissociates, the addition of Arl2 to PDEδ should increase the 
dissociation rate of bound cargo. Consequently the impact of Arl2 on the dissociation rate of 
TAMRA labeled small molecules was investigated. 
  
 RESULTS AND DISCUSSION 
83 
 
 
 
 
 
 
 
Figure 48 Principle of kinetic experiments involving TAMRA-labeled compounds (Cpd), Arl2 and PDEδ. When 
Arl2 is added to a complex of TAMRA-labeled small molecule and PDEδ, formation of a ternary complex is 
complex is observed. The amount of ternary complex formed is dependent on the relative concentration of Arl2 
compared to PDEδ and the equilibrium constant KD3. The exchange reaction between TAMRA-labeled and 
unlabeled small molecule is then initiated by adding an excess of the free small molecule, which allows for the 
calculation of apparent dissociation rate constants koff,obs. The maximum value of koff,obs corresponds to koff,Arl2 of 
the TAMRA-labeled small molecule from the ternary Arl2-PDEδ-TAMRA-Cpd complex. 
When a preformed PDEδ-TAMRA-Deltarasin complex (both 33 nM) was treated with a 20-fold 
excess of unlabeled compound a slow dissociation with a half life around 20 min was observed 
(Figure 49). If the competitor was added after preincubation with different concentrations of 
GppNHp-Arl2 the dissociation rate was readily increased, with two equivalents already 
showing a significant effect (4 fold increase). Further excess of GppNHp-Arl2 led to the release 
of the labeled small molecule from the binding site with a half-life in the second range (lower 
detection limit). 
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Figure 49 Time-resolved fluorescence anisotropy measurement of premixed TAMRA-Deltarasin (lower panel) 
and PDEδ (33 nM) after initializing the dissociation  with a 20-fold excess of unlabeled ester (green dots). The 
experiments were also carried out in the presence of different concentrations of GppNHp loaded Arl2 protein (blue, 
red and black dots). 
It was also tested if GppNHp-Arl2 could affect the kinetics of cargo release when the very high 
affinity TAMRA-(S)-92 was used as probe. TAMRA-(S)-92 cannot be efficiently displaced by 
Arl2, however it was reasoned that the binding kinetics of TAMRA-(S)-92 to PDEδ might be 
altered (Figure 50).  
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Figure 50 Time-resolved fluorescence anisotropy measurement of premixed TAMRA-(S)-92 (33nM) after 
initializing the dissociation with a 20-fold excess of unlabeled ester (green dots). The experiments were also carried 
out in the presence of different concentrations of GppNHp loaded Arl2 protein (blue, red and black dots).  
When a preformed PDEδ-TAMRA-(S)-92 complex (both 33 nM) was treated with an excess of 
unlabeled compound in the presence of Arl2 a similar dissociation rate enhancement was 
observed compared to TAMRA-Deltarasin. Two equivalents of Arl2 increased the measured 
dissociation rate by a factor 5, a 20:1 ratio of Arl2:PDEδ resulted in a 63-fold dissociation rate 
enhancement (Figure 51). This suggests that the apparent dissociation rate constant koff,obs for 
TAMRA-(S)-92-PDEδ correlates linearly with the intial Arl2 concentration.  
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Figure 51 Dependance of apparent dissociation rate constant koff,obs on the initial Arl2 concentration for the 
dissociation of the TAMRA-(S)-92-PDEδ complex.  
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Since koff,obs has to correlate with the amount of the ternary TAMRA-Cpd-PDEδ-Arl2 complex 
it has to level off when the TAMRA-Cpd-PDEδ complex is fully saturated with Arl2. The 
observed rate koff,obs is actually indicative of the fraction bound of TAMRA-small molecule-
PDEδ to Arl2 and the data can be fitted according to the law of mass action to obtain the 
equilibrium constant KD3. A simulation of the experimental conditions using a KD3 in the low 
micromolar range reveals good agreement between theory and experiments (Figure 52). At the 
experimentally used nanomolar concentrations, a micromolar affinity constant KD3 would result 
in a low fraction bound of TAMRA-Cpd-PDEδ to Arl2. At low Arl2 concentrations relative to 
the KD3 a linear increase of koff,obs with the concentration of Arl2 is expected. Since the observed 
experimental data is in agreement with this analysis it can be concluded that KD3 must be in the 
micromolar range.  
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Figure 52 Simulated values for koff,obs (normalized) in dependence of Arl2 concentrations reveal a hyperbolic 
relationship. A region of linear increase of kobs with increased Arl2 concentrations (red) is observed for a KD3 5 µM. 
(cPDEδ-TAMRA-(S)-92 33 nM).   
These data have also important implications for the release of small molecules from the PDEδ 
binding site in the living cell. Since ternary Arl2-Cpd-PDEδ complexes display relatively low 
affinity and rapidly dissociate, high Arl2 concentrations may locally lower the affinity of the 
Cpd-PDEδ complex so that even low affinity, locally enriched farnesylated proteins can 
displace the small molecule. 
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Small molecule screen for finding Arl2/3 like allosteric inhibitors of the Ras- PDEδ 
interaction 
Arl2/3 and small molecule inhibitors can both antagonize the Ras-PDEδ interaction. In contrast 
to small molecules, which bind to the hydrophobic cavity of PDEδ, Arl2/3 increase the 
dissociation rate of bound cargo by forming ternary complexes. Kinetic experiments allow for 
the differentiation of small molecules which bind to the hydrophobic cavity of PDEδ and 
allosteric binders. In order to identify small molecules which bind allosterically, displacement 
experiments of TAMRA-(S)-92 with small molecules were carried out. The tested small 
molecule library consisted of 300 selected high-affinity binders which were identified by the 
Ras-PDEδ Alpha screen.  The library was tested at a concentration of 20 µM and Arl3 was used 
as a control since it rapidly displaces cargo from the prenyl-binding cavity of PDEδ. 
Unfortunately no allosteric inhibitor could be identified by this screen. Due to the large, flat and 
flexible interaction surface area this finding is not surprising. Screening of a larger set of 
compounds however might reveal starting points for the design of potent allosteric binders of 
PDEδ. 
4.10 Synthesis of benzimidazole-pyrrole hybrid inhibitors 
The results obtained for the bis-benzimidazoles and the Atorvastatin derivatives demonstrate 
that the farnesyl-binding site of PDEδ is amenable to structure guided improvement of 
compound affinity. Since both compound classes display high affinities it was decided to 
combine structural elements from both compound classes into hybrid inhibitors, with the goal 
of achieving high ligand efficiency. 
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Figure 53 Design of  hybrid Atorvastatin-benzimidazole inhibitors. Top panel: Key hydrogen bond acceptors are 
highlighted. Lower panel: Overlay of bis-benzimidazole (cyan) and Atorvastatin (pink) from best scoring docking 
pose. In a hybrid approach it was envisaged to keep the isopropyl substituted pyrrole moiety of Atorvastatin which 
according to docking extends into a hydrophobic pocket that was not targeted by the bis-benzimidazole 
compounds. 
The reduced number of non-H atoms could lead to a decrease in logD, an increase in ligand 
efficiency and possibly improved solubility.  
 
Figure 54 Retrosynthetic analysis of benzimidazole-pyrrole hybrid molecules. 
Initially it was envisaged to install the pyrrole moiety by a Paal-Knorr synthesis (Figure 54, 
upper panel). Coupling of the acid 143 to phenylendiamine, followed by cyclization would then 
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furnish the benzimidazole. This route, however, allowed for little diversity and low step 
efficiency. Consequently, it was decided to start with commercially available benzimidazole 2-
carboxaldehyde and install the pyrrole at a later stage of the synthesis (Figure 54, lower panel). 
The aldehyde was therefore subjected to aldol condensation with acetophenone resulting in an 
-unsaturated ketone (Figure 55). Stetter reaction with aliphatic aldehydes, followed by Paar-
Knorr synthesis furnished the benzimidazole pyrrole core structure and alkylation as previously 
described led to the N-substituted benzimidazoles. 
 
Figure 55 Synthesis of benzimidazole-pyrrole hybrid inhibitors. 
Unfortunately, the resulting hybrid benzimidazole-pyrrole compound series did not show strong 
binding to PDEδ (Table 13). Consistent with other benzimdiazole binding data, the free, non-
alkylated benzimidazole did not display notable binding to PDEδ (Table 13, entry 4). 
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Table 13: Affinities of benzimidazole-pyrrole- hybrid compounds measured by fluorescence polarization 
and Tm shift assays. 
 
4.11 Evaluation of bis-sulfonamides as PDEδ inhibitors 
By means of the biophysical Alpha Screen assay employing a K-Ras4B peptide and PDEδ 
(described above, conducted by COMAS, Dortmund), alternative chemotypes were idientified 
by high-throughput screening. Among these, commercially available bis-sulfonamides were 
identified as potent PDEδ binders. High inhibitory potency in the Alpha screen assay was 
independently confirmed by the competitive FP assay with labeled Atorvastatin (Table 14). 
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Table 14 Hit cluster derived from screening of 56 commercially available bis-sulfonamides. R1 and R2 are 
carbocycles and heterocycles. 
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From Table 14 it is apparent that all clusters contain highly potent molecules. For the 
understanding of structure activity relationships, representative bis-sulfonamides were docked 
into the cocrystal structure of ester (S)-90 with PDEδ (Figure 56, a). As expected the bis-
sulfonamides are able to interact with both Tyr149 and Arg61. Gratifiyingly, Shehab Ismail was 
able to obtain a cocrystal structure of compound 165 with the protein which confirmed the 
representative docking pose (Figure 56, b). In addition to the expected hydrogen bonds with 
Tyr149 and Arg61 a clear H-bond with a glutamine (Gln78) is observed. 
 
 
Figure 56 Structural models for binding of bis-sulfonamides to PDEδ a) Docking pose of a representative bis-
sulfonamide, hydrogen bonds to Arg61 and Tyr149 are highlighted; b) Snapshot from cocrystal structure of 165 
with PDEδ (solved by Dr. Shehab Ismail). 
In contrast to the Atorvastatin derivatives and the bis-benzimidazoles, the bis-sulfonamides 
contain a short linker (phenyl ring), whereas the other compound classes use longer linking 
moieties to bridge the distance between Tyr149 and Arg61. In the bis-sulfonamides series the 
pharmacophore is therefore concentrated on a much smaller scaffold and features an additional 
hydrogen bond. With the structural data in hand, the hit clusters were analysed, and structure 
activity relationships were derived. Generally, the analysis of the 56 compound dataset proved 
to be very difficult, which can be attributed to the symmetry of the molecules. Here the analysis 
will be limited to the hit cluster containing the cocrystallized bis-sulfonamide. The combination 
of a saturated carbocyle and phenyl derivatives revealed highly potent compounds (Table 15, 
entries 1 and 2). Exchanging the cyclopentyl substituent with a methyl furfuryl group decreased 
Arg61 
Tyr149 
Arg61 
a b 
Gln78 
Tyr149 
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the affinity by one order of magnitude (Table 15, entries 1 vs 3). Replacement of the para-
chlorobenzyl group (Table 15, entry 3) with an ortho-fluoro substituent increased the KD 
strongly (Table 15, entry 4), while very bulky secondary sulfonamides (Table 15, entry 5) were 
also unfavorable suggesting clashes with the protein surface.  
Table 15 Stucture activity relationships for representative hit cluster members. Averaged affinities of triplicate 
measuremetns are shown. 
 
Based on the cocrystal structure of 164 with PDEδ it is apparent that this bis-sulfonamide does 
not extend into the pocket close to Cys56, therefore improvement in analogy to the bis-
benzimidazoles seems readily possible. Indeed, the results shown in Table 14 revealed that the 
most potent hit cluster features two secondary sulfonamides (also compare the docking Figure 
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56, a,), which presumably extend into that pocket. Secondary sulfonamides incorporating a 
piperidine for targeting Cys56 are currently being synthesized by Pablo Martin-Gago. 
4.12   Cellular Experiments with PDEδ inhibitors 
4.12.1 “Pull down” experiments in cell lysates with biotinylated probes 
With a library of very potent bis-benzimidazoles in hand, it was decided to test whether these 
compounds also bind to PDEδ in cell lysates. Therefore, bis-benzimidazole (S)-169 was 
hydrogenated employing Raney-Ni, and the resulting amine coupled to a biotin unit to yield 
Biotin-Deltarasin (170). Biotin is commonly used for immobilization of compounds on 
Streptavidin-coated beads which allows for the enrichment of interacting proteins by affinity 
isolation. 
 
Figure 57: Synthesis of Biotin-Deltarasin (170). 
An excess of Biotin-Deltarasin (170) and Biotin-Atorvastatin (15) were treated with 
Streptavidin-coated magnetic beads, washed and then subjected to “pull down” experiments 
with MDCK cell lysates (For principle see Figure 58) 
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Figure 58 Principle of direct binding assay with immobilized compounds (upper panel, 1) or competition 
experiment (lower panel, 2) of immobilized compound with free compound. (modified from reference108). 
The fraction of PDEδ in the cell lysate that bound to the immobilized compounds was analysed 
by Western blotting using an anti-PDEδ antibody (Santa Cruz). In Figure 59 a) it is apparent 
that compared to control, both immobilized compounds can enrich PDEδ at the solid phase, and 
thus bind to PDEδ in cell lysates.   
 
Figure 59 Representative pull-down experiments using immobilized Biotin-Deltarasin and Biotin-Atorvastatin in 
MDCK cell lysates. Western Blots were stained with anti-PDEδ antibody. a) qualitative “pull down” experiments 
employing biotinylated compounds; b) competition experiments employing Biotin-Deltarasin and free Deltarasin. 
Additionally, independent competition experiments with varying concentrations of free 
compound (Figure 59, b) validated the interaction of both biotinylated and free Deltarasin with 
PDEδ in MDCK cell lysates. The binding data generated with the immobilized and the free 
a      b 
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benzimidazole in cell lysates show that the structure guided approach towards the development 
of small molecule inhibitors of PDEδ was successful. 
4.12.2 In cell measurements of the effect of Deltarasin on the interaction of Ras with 
PDEδ and resulting delocalization of K-Ras 
To address whether the synthesized compounds also break the interaction of Ras family proteins 
with PDEδ in the cell, FRET-FLIM experiments were conducted by Björn Papke, Anchal 
Chandra und Nachiket Vartak from the group of Prof. Bastiaens. Since K-Ras4B localizes 
predominantly to the plasma membrane, it is difficult to monitor its interaction with cytosolic 
PDEδ in the living cell. The Rheb-PDEδ interaction was therefore used as a model system, 
because Rheb as well as PDEδ are enriched in the cytosol (Figure 60). The fraction of 
interacting Rheb with PDEδ is relatively high, and a change in fluorescence lifetime upon 
inhibition with a small molecule can be easily monitored.   
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Figure 60 Live-cell imaging using mCherry-PDEδ and mCitrine-Rheb. a) Principle of assay: If mCherry-PDEδ 
and mCitrine-Rheb interact, the two fluorophores come close to each other and upon excitation of mCitrine-Rheb, 
energy may be transfered to mCherry-PDEδ. The resulting Förster-Resonance-Energy-Transfer (FRET) decreases 
the lifetime of the excited state of Citrine Rheb. Therefore, Fluorescence-Lifetime-Imaging (FLIM) can be used to 
quantify the fraction of interacting Rheb and PDEδ; b) FRET-FLIM time series on MDCK cells treated with 
Deltarasin. Treatment with Deltarasin resulted in an increase in fluorescence lifetime av and decrease in fraction 
bound of Rheb. The normalized quantification is shown in the lower panel.79 
Treatment of MDCK cells with Deltarasin led to a loss of interaction between mCherry-PDEδ 
and mCitrine-Rheb, resulting in an increase in fluoresence lifetime av and decrease in fraction  
of interacting Rheb ( (Figure 60, b, upper panel). The loss of interaction between Rheb and 
PDEδ was visible within 2 minutes. This observation is similar to in vitro data showing a rapid 
displacement of farnesylated Rheb from PDEδ. A dose-response study of the effect of 
Deltarasin on the Rheb-PDE interaction revealed that the compound breaks the interaction 
efficiently at concentrations as low as double digit nanomolar (Figure 61) in the living cell. 
  
Rheb 
PDE 
Citrine 
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Figure 61 Effect of different concentrations of Deltarasin on the Rheb-PDEδ interaction. a) Concentration 
dependent FRET-FLIM measurements using the mCitrine-Rheb-mCherry-PDEδ interaction; b) Quantification of 
FRET-FLIM data using a simple dose response model and the Cheng-Prusoff equation.79 
It was also of interest to confirm that the small molecules directly interact with PDEin the 
living cell. Therefore, cells were treated with TAMRA-Deltarasin which resulted in a reduction 
of the donor lifetime of mTFP-PDEhis experiment confirmed the binding of the small 
molecule to PDEin the living cell (Figure 62). 
 
Figure 62 a) Effect of TAMRA-Deltarasin on the donor lifetime of mTFP-PDEδ in MDCK cells transfected with 
mTFP-PDEδ; b) Quantification of the observed impact on donor lifetime; c) Relocalization of Ras in PANC-TU-
I cells upon treatment of different concentrations of Deltarasin. 
a b 
c 
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In addition, immunofluorescence staining of fixed and permeabilized human pancreatic ductal 
adenocarcinoma cells (hPDAC) with a pan-antibody against Ras showed a relocalisation of 
endogenous Ras in PANC-TU-I cells after 2 h (Figure 62, c). In summary, it has been shown that 
Deltarasin binds to endogenous PDEin cells, thereby breaks the interaction of Ras family 
proteins with PDEand alters the localization of Ras proteins in the cell. 
4.12.3 Evaluation of PDEinhibitors in Ras signaling 
The effect of Ras-PDEδ inhibitors on oncogenic K-Ras signaling was subsequently studied in 
hPDAC cells by the Bastiaens group.79 Singh et al. had previously shown that shRNA can be 
used to deplete K-Ras in pancreatic cancer cell lines harboring K-Ras mutations in order to 
classify these cell lines whether they require K-Ras for survival.109 Thus, the effect of Deltarasin 
on cell survival of K-Ras dependent (CAPAN-1 and PANC-TUI) and K-Ras independent 
pancreatic cancer cell lines (PANC-1 and BxPC3) was compared by real time cell analysis 
(RTCA).109 In parallel it was tested whether survival of these four cell lines is dependent on 
PDEδ expression levels by transfecting the cells with a lentiviral construct for doxycycline 
inducible shRNA expression against PDEδ. Treatment of cells with 5 µM Deltarasin or 
doxycycline induced knock-down of PDEδ resulted in reduced cell proliferation of the K-Ras 
dependent PANC-TUI and CAPAN1 hPDAC cell lines and had only a slight effect on the 
growth of K-Ras independent PANC-1 and BcPX3 hPDAC cells. This experiment clearly 
showed that survival signaling from oncogenic K-Ras is attenuated by the inhibition of the K-
Ras-PDEδ interaction by Deltarasin that leads to relocalization of K-Ras to endomembranes. In 
addition, only K-Ras dependent pancreatic tumor cells showed a clear effect of PDEδ inhibition 
on their overall proliferation. In order to assess whether the Deltarasin induced proliferation 
inhibition of K-Ras dependent hPDAC cells was caused by programmed cell death, a 
fluorescence assisted cell sorting (FACS) cell death assay was performed. Both oncogenic K-
Ras dependent mPDAC cell lines (PANC-TUI and CAPAN1) displayed a strong increase in 
programmed cell death after 24h incubation with Deltarasin, whereas the K-Ras independent 
hPDAC cells (Panc1 and BxPC3) showed little effect.  
To address if inhibition of the PDEδ-K-Ras interaction by Deltarasin has an effect on oncogenic 
K-Ras signal transduction, the epidermal growth factor (EGF) mediated Erk1/2 response was 
studied by the Bastiaens group. Quantitative Western blot analysis of phosphorylated Erk1/2 
revealed that the K-Ras dependent PANC-TUI had a high basal Erk activity that was reduced 
upon inhibition of PDEδ by Deltarasin. Importantly, the two oncogenic K-Ras dependent 
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hPDAC cell lines (PANC-TUI and CAPAN-1) showed a reduction in the EGF mediated 
transient Erk signal response as compared to the K-Ras independent hPDAC cells (PANC-1 
and BcPX3). The loss of the spatial organization of oncogenic K-Ras after inhibition of the 
PDEδ-K-Ras interaction thus impaired survival and proliferative signaling that specifically 
causes cell death in K-Ras dependent hPDAC cells. 
In further experiments the effect of Deltarasin on human cancer cells xenografted into mice was 
evaluated by Prof. Hahn and coworkers, Uni Bochum. Deltarasin was administered to nude 
mice bearing subcutaneous human PANC-TUI tumour cell xenografts. Deltarasin was delivered 
to the mice bearing human tumour cells by intra-peritoneal injection once (QD) or twice (BID) 
a day (Figure 63, a). Treatment of mice with Deltarasin resulted in a dose-dependent reduction 
in PANC-TUI tumour growth rate compared to controls. Mice that were treated with Deltarasin 
(10 mg kg−1 twice a day), displayed virtually no tumour growth within the first nine days. 
Administration of the compound also resulted in a reduced variance of tumour size compared 
to control at the end of day nine (Figure 63, b).  
 
Figure 63 Deltarasin impairs dose-dependent in vivo growth of xenografted pancreatic carcinoma in nude mice.79 
a) Tumour volume measurements: Deltarasin was administered by the group of Prof. Hahn by intra-peritoneal 
injection once (QD) or twice (BID) per day at 10 mg kg−1 QD, 15 mg kg−1 QD and 10 mg kg−1 BID. Changes in 
mean tumour volumes are given relative to the volumes at treatment initiation; b) Tumour volume at day 9 of Panc-
Tu-I xenograft experiments. P values derived from t-test. **P ≤ 0.01, *P ≤ 0.05 indicate statistical significance.79 
4.12.4 Evaluation of PDEinhibitors in Hedgehog signaling 
Due to the involvement of PDEin ciliopathies and the crosstalk between oncogenic K-Ras 
and Hedgehog signaling, the benzimidazole library was evaluated for its impact on signal 
a  b 
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transduction in mouse embryonic mesoderm fibroblasts by COMAS, Dortmund. Multipotent 
mesenchymal cells (C3H10T1/2) are able to differentiate into osteoblasts after treatment with 
the Smoothened (SMO) agonist Purmorphamine. The differentiation process is coupled to the 
expression of osteoblast specific genes such as alkaline phosphatase. Upon addition of a 
chemoluminescent substrate (e.g. CDP-star), alkaline phosphatase induces luminescence by a 
hydrolysis reaction. In the presence of a Hedgehog pathway inhibitor a reduced signal is 
expected, since less alkaline phosphatase is expressed. Pleasingly, the benzimidazole library 
contained various inhibitors of the Hedgehog pathway (Table 16). The best compounds showed 
activities in the low micromolar range. Piperidine-containing compounds, however, displayed 
undesired toxicity in the control viability experiments (Table 16, entries 4-7). 
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Table 16 Inhibition of Hedgehog signaling by benzimidazole compounds.  
 
 
C3H10T1/2 cells have been described as an ideal screening system for monitoring cilia 
function,110 which is linked strongly to Hedgehog signal transduction. Joubert syndrome is a 
developmental disease, which may be caused by a mislocalization of the farnesylated 
phosphatase INPP5E in the cell. INPP5E exclusively localizes to the primary cilium if 
functional PDEδ is present. A homozygous mutation of PDEδ completely abrogates binding of 
prenylated proteins to PDEδ and leads to impaired transport of farnesylated INPP5E to the 
cilium. PDEδ-mutated patients display eye defects due to mislocalization of the rhodopsin 
kinases GRK1 and 7, but additionally show limb, renal, and cerebral anomalies.56 These 
anomalies are typical developmental disorders which might be accounted for by impaired 
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Hedgehog signaling from the primary cilium. Due to the developmental anomalies of PDEδ-
mutated patients, it is not surprising that PDEδ inhibitors are active in Hedgehog signaling. 
Most likely the effect of the small molecules on Hedgehog signaling is caused by a 
mislocalization of INPP5E or another prenylated ciliary protein (e.g. RAB28), which functional 
PDEδ normally transports to the primary cilium. In addition, the crosstalk between Ras and 
Hedgehog signaling may account for the observed effect.58 Oncogenic K-Ras activates 
Hedgehog signaling in pancreatic adenocarcinoma cells through activation of a downstream 
effector pathway involving RAF/MEK/ERK. Whether this crosstalk also exists in embryonic 
fibroblasts is currently unclear. 
Since INPP5E plays an essential role in the primary cilium by controlling ciliary growth factor 
and PI3K signaling,111 small molecule inhibitors of PDE should affect PI3K signaling in 
ciliated cells. Testing of these inhibitors in ciliated cells might provide novels insight into the 
function of cilia as signaling hubs in developmental cells. 
4.13 Evalution of the prenyl-speficity of PDEδ in vitro  
To date conflicting data has been reported on the prenyl specifity of PDE.30,31,40,46,112 While 
some reports indicate a significantly higher affinity of farnesylated vs geranylgeranylated 
peptides for PDEthis selectivity could not be confirmed in more elaborate model systems. 
Pull down experiments identified similar amounts of farnesylated and geranygeranylated 
proteins.54,56 Proteomics experiments by Philipp Küchler, MPI Dortmund show also no clear 
preference of PDEfor farnesylated proteins. Biophysical investigations thus far have not 
explored the same peptide sequence with either a geranylgeranyl or a farnesyl modification. 
Therefore, fluorescein labeled peptides derived from the C-terminus of G-were tested in  
fluorescence polarization measurements for their binding to PDE  (Figure 64). 
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Figure 64 Represenatative titrations of G derived peptides differing only in the lipid modification 
(geranylgeranyl vs farnesyl). Fitting of the data yields KD values of 200 nM for the farnesylated and 499 nM for 
the geranylgeranylated peptide. 
The titrations indicated a slight preference of PDEfor farnesylated peptides over 
geranylgeranylated peptides (KD values 200 vs 499 nM), but the difference in affinity was not 
as strong as previously measured using peptides with different amino acid sequences. 40 These 
data clearly suggest that due to the flexibility and size of the prenyl binding pocket both lipids 
can be accommodated by PDEwith high affinityIn vivo distinct differences between the 
shuttling of geranylgeranylated vs farnesylated proteins exist. RhoGDI has been shown to bind 
the geranylgeranylated RhoA GTPase with an affinity in the low picomolar range, suggesting 
that at least for RhoGTPases proteins other than PDEregulate membrane trafficking.113 The 
extremely high affinity of RhoA for RhoGDI is due to lipid protein interactions and additional 
protein-protein backbone interactions. For PDEsuch protein-protein backbone contacts have 
not been identified thus far. It is generally expected that solubilizing factors for 
geranylgeranylated proteins display a higher affinity for their cargo since these proteins show a 
40-60 fold higher affinity for membranes compared to farnesylated proteins.114 Future cellular 
experiments using a set of geranylgeranylated proteins should clarify whether PDEalso 
maintains the spatial organization of these lipidated proteins. 
4.14 Rational design of UNC119a/b inhibitors 
Similar to PDEδ, UNC119a/HRG4 and UNC119b are lipid binding proteins.32,115 However 
unlike PDEδ they recognize N-myristoylated proteins. UNC119a/HRG4 has been shown to 
shuttle Src kinases and to participate in targeting transducin-to the outer segment of 
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photoreceptors via interaction with its acylated N-terminus.34,116-118 UNC119b shuttles 
nephrocystin-3 (NPHP3) and targets it to the primary cilium.107 Therefore, UNC119a/b are 
interesting targets for tool compound development and potentially also for drug development. 
The paralogs UNC119a/b share a very high sequence identity, and feature very similar lipid 
binding sites (Figure 65). So far, only crystal structures with UNC119a have been obtained. 
Interestingly, the hydrophobic lipid binding pocket in UNC119a/b is located on the other side 
of the protein compared to PDEand RhoGDI. 
     
Figure 65 Structural analysis of UNC119a in complex with a lauroylated peptide a) Overall structure of UNC119a 
in complex with a lauroylated peptide (green sticks) derived from the N-terminus of the transducin- subunit; b) 
Hydrophobic binding pocket of UNC119a (PDB 3RBQ), key H-bonds are highlighted in black dashes.
Binding of a lauroylated peptide mimicking the N-terminus of transducinto UNC119a is 
mediated by hydrophobic interactions as well as hydrogen bonding. The cocrystal structure 
reveals that although the fatty acid chain and six N-terminal amino acids are deeply buried, the 
hydrophobic cavity is still far from being completely filled (Figure 65, b). Notably, the 
relatively short lauroyl C-12 chain leaves unexplored hydrophobic space deep in the binding 
site. Consistent with this finding the longer myristoyl group shows stronger binding. Key H-
bonds are observed mainly with the N-terminal amide bond, highlighting its significance for 
inhibitor development (Figure 65). Tyr149 donates an H-bond to the carbonyl of the amide, 
whereas Ser218 and Glu163 interact with the NH of the amide. Ser218 points directly towards 
the amide NH forming an H-bond suggesting that Ser218 may at least partially be depronated. 
H165 
E163 
Y131 
S218 
a b 
 RESULTS AND DISCUSSION 
106 
 
The long lipid group seemed central to activity and was used as a starting point for the rational 
design of small molecule inhibitors. The previously identified APT1/2 inhibitor Palmostatin B 
features a long lipid chain and incorporates a lactone, which may act as a hydrogen bond 
acceptor for Tyr131. In addition it can covalently modify nucleophilic serins.19,119,120 
For an investigation of the binding of Palmostatin B to UNC119a, a fluorescent probe was 
needed for competition experiments. Therefore, an N-terminal, myristoylated peptide of Src 
family kinase Lyn was synthesized by standard solid phase peptide synthesis (Scheme 20). 
 
Scheme 20 Solid phase peptide synthesis of a mono and double lipidated Lyn peptide starting from an orthogonally 
protected lysine building block (see above). 
 
Subsequently the binding of Palmostatin B to UNC119a was investigated by means of a 
competitive assay using fluorescence polarization as readout. The fluorescence polarization 
decreases in a dose dependent manner upon addition of Palmostatin B (Figure 66). Although 
the binding curve does not level off at low micromolar concentrations, concentrations as low as 
100 nM already affected the binding of the fluorescently labeled Lyn peptide. To additionally 
validate the binding TAMRA-Palmostatin B was employed and yielded a KD value of 2.5 ± 1 
µM for UNC119a and 3.5 ± 1.1 µM for UNC119b. It is of note that TAMRA-Palmostatin bound 
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to UNC-119a/b although the compound is labeled on the lipid tail.  Although the affinity of 
Palmostatin B for UNC119a/b is only in the low micromolar range these results suggest that 
lipidated beta-lactones might be valuable starting points for the synthesis of high affinity 
UNC119a/b inhibitors. Screening of a larger set of strained lactones might reveal much better 
inhibitors, which could potentially also form a covalent bond to a serine residue (like the buried 
Ser218) of the protein. 
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Figure 66 Binding of Palmostatin B to UNC119b measured by means of a competitive fluorescence polarization 
assay employing labeled N-terminal Lyn kinase peptide (left); direct binding of TAMRA-labeled Palmostatin B to 
UNC119b (right). 
In an additional approach towards the rational design of UNC119a inhibitors the helical 
conformation of the N-terminal transducin- peptide in the complex with UNC119a was 
exploited. Generally conformational preorganization of peptides in their protein bound 
conformation can lead to increased affinities. Hydrocarbon–peptide stapling has emerged as a 
powerful tool for conformational preorganization.121 Stapling requires the introduction of two 
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methylated and alkenylated amino acids into the peptide sequence of interest and macrocycle 
formation by ring closing metathesis to generate a bridging moiety connecting two turns of an 
-helix. Commonly two modified amino acids are incorporated at positions i and i+4 to form 
an eight-carbon bridge because these residues usually display an NHi-COi+4-hydrogen bond 
within a helix.  On the other hand i and i+3 staples are also frequently used to generate peptide 
macrocyles. Bridging positions i and i+3 of the peptide does not strongly stabilize helical 
peptide conformation, but it rigidifies the peptide backbone and potentially reduces the entropic 
penalty of binding by conformational preorganization. 
  
Figure 67 Hydrocarbon stapling of transducin-a peptides for lead generation of UNC119a/b binders. Left) helical 
conformation of transducin-a peptide bound to UNC, right) sequences of two stapled peptides incorporating an 
hydrocarbon bridge. Numbers are KD values in nM.  
 
An initial screen of four stapled, unlabeled peptides in a competitive fluorescence polarization 
assay revealed two promising binders featuring an i and i+3 hydrocarbon bridge. In order to 
validate the binding the corresponding fluorescein-labeled peptides were resynthesized by 
Philipp Cromm and evaluated in direct fluorescence polarization assays. Gratifyingly, the 
stapled peptides showed affinities down to double digit nanomolar (Figure 67), and at least one 
peptide showed a 9-fold selectivity between UNC119a and b (Figure 67). Due to the lipid 
modification and their overall hydrophobicity these peptides are expected to be membrane 
permeable and at least partially protease resistant due to the potentail binding to lipid transport 
proteins. Further structure guided design and library synthesis by Philipp Cromm might enable 
finding peptides with higher affinities than wild type transducin-nM to UNC119a).106 In 
this context it seems particularly promising to replace the myristoyl group with hydrophobic 
small molecules and create hybrid small molecule-stapled peptide inhibitors.  
 
Myr-GAYASXEEKH (183) 
Myr-GYGAXAEEKH (184) 
KD 25 ± 3 nM 12 ± 1 nM 
KD 17 ± 2 nM 155 ± 33 nM 
  UNC119a           UNC119b 
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5 SUMMARY 
Ras proteins are molecular switches, which regulate cellular growth and differentiation. 
Mutations in the Ras encoding genes lock Ras proteins in a permanent “on” state which may 
result in sustained cellular growth and ultimately carcinogenesis. Due to the high abundance of 
Ras mutations in tumors, these proteins have been at the focus of anti-cancer treatment for 
decades. Of particular interest has been the medicinally most relevant isoform K-Ras. The 
localization of K-Ras in the cell is strongly linked to its function as a biological switch, since 
K-Ras enrichment at the plasma membrane is required for proper Ras signaling. The shuttling 
protein PDEδ regulates the cellular localization of K-Ras and thus oncogenic K-Ras signaling. 
PDEδ features a large hydrophobic binding pocket, which accommodates the prenyl group of 
proteins like K-Ras in the cell. In contrast to K-Ras, PDEδ turned out to be readily druggable 
and inhibitors of the K-Ras-PDEδ interaction should impair oncogenic K-Ras signaling. 
Identification and optimization of benzimidazole based K-Ras-PDEδ inhibitors 
For the identification of small molecules targeting the K-Ras-PDEδ interaction, a high 
throughput assay based on the Alpha technology was employed and the highly ligand-efficient 
benzimidazole fragment 10 was identified. ITC experiments as well as cocrystallization of the 
benzimdazoles with PDE revealed that two benzimidazoles moieties may bind to the farnesyl-
binding cavity (Figure 68, a and b). Binding of the fragment 10 was clearly enthalpy driven, 
consistent with the formation of two hydrogen bonds to the protein (Arg61, Tyr149). In order 
to increase affinity and specificity, the two benzimidazole moieties of fragment 10 were linked. 
The best ether-linked bis-benzimidazoles showed significantly improved affinities down to 
16 nM and an increase of the protein melting temperature of more than 25°C. The cocrystal 
structure of bis-benzimidazole 55 with PDErevealed that the allyl group points to the 
backbone carbonyl of Cys56 (Figure 68, c). Further structure based optimization focused on 
targeting this carbonyl group by an additional H-bond. Therefore, the allyl group was replaced 
by a piperdine moiety and the bridging phenyl ether was substituted by a more flexible piperidyl 
ester. Gratifiyingly the resulting ester-linked bis-benzimidazoles showed higher affinities. A 
cocrystal structure of (S)-92 with PDEconfirmed the additional hydrogen bond to Cys56 
(Figure 68, d). 
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Figure 68 a) Structure and binding affinities of benzimidazole compounds as determined by displacement titrations 
employing Fluorescein-Atorvastatin and fluorescence polarization as readout; b) Ribbon diagram of PDEδ 
structure in complex with 10 (yellow), and overlay with the previously obtained crystal structure of farnesylated 
Rheb peptide with PDEδ (cyan). Benzimidazole fragment 10 (green) and farnesyl group (red) are shown as ball 
and sticks. Hydrogen bonding interactions between two molecules of 10 and Tyr149 and Arg61 in the cocrystal 
structure are highlighted; c) Structure of (rac)-55 (orange sticks) in complex with PDEδ. Overlaid is the structure 
of two molecules of 10 (faint grey sticks) in complex with PDEδ; d) Cocrystal structure of (S)-90 with PDEδ 
confirms the presence of a hydrogen bond between the piperidine and the backbone carbonyl of Cys56. Cocrystal 
structures were obtained by Dr. Shehab Ismail. 
Direct titrations of TAMRA-labeled compounds (S)-62 Deltarasin and (S)-92 revealed affinities 
for PDE in the single digit nanomolar range, close to the detection limit assays employing 
fluorescence polarizationhese compounds were therefore employed in direct titrations with 
other lipid binding proteins, showing no interaction with UNC119a/b and Galectin 1/3. 
Consistent with the high affinity time resolved fluorescence anisotropy measurements revealed 
very slow dissociation rates with half lifes in the range of hours for TAMRA-labeled (S)-92. 
 
b   
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SPR experiments confirmed the very high affinity of ester-linked bis-benzimidazoles also for 
unlabeled benzimidazoles with affinities down to 77 pM for ester (S)-90. 
Small molecule inhibition of the K-Ras-PDEinteraction impairs oncogenic K-Ras 
signaling 
Due to the potential instability of ester containing bis-benzimidazoles in the cell, the biological 
evaluation of this compound class was carried out with the well-soluble, ether-linked (S)-62 
Deltarasin. Pull down experiments with biotinylated Deltarasin revealed very strong binding to 
PDEin cell lysates. Competition experiments with biotinylated and free compound 
highlighted the high affinity of the benzimidazole compounds for PDEin cell lysates. In 
collaboration with the group of Prof. Bastiaens FRET-FLIM experiments were carried out in 
the living cell which showed that Deltarasin can break the Ras-PDEinteraction and induce 
relocalization of Ras family proteins, particularly of the clinically relevant K-Ras protein. The 
inhibition of the K-Ras-PDEinteraction by Deltarasin also impaired oncogenic K-Ras 
signaling, as judged by the decrease in ERK phosphorylation and selective growth inhibition of 
K-Ras dependent cells. The group of Prof. Hahn showed that Deltarasin also inhibits the growth 
of xenografted pancreatic carcinoma cells in nude mice. 
Further structure-based optimization of small molecules targeting the prenyl binding 
cavity of PDE  
Further structure-based optimization and synthesis of bis-benzimidazoles led to a decrease in 
molecular weight of the inhibitors, a decrease in hydrophobicity and an increase in ligand 
efficiency. In a further attempt to find other compound classes, which target PDEthe known 
inhibitor Atorvastatin was modified and binding affinity was increased by almost two orders of 
magnitude. Additionally high-throughput screening enabled the identification of bis-
sulfonamides as very potent binders to PDEAltogether 56 sulfonamides were tested and 
revealed very high affinities down to the low nanomolar range. 
Allosteric release of PDEinhibitors by Arl2/3 
Although the most potent bis-benzimidazoles display KD values for PDEin the low nanomolar 
range, no inhibitor with nanomolar potency in cells could be identified. Previously it was shown 
that Arl2/3 actively release low affinity, farnesylated cargo proteins from PDEby an allosteric 
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displacement mechanism. Therefore, it was tested whether the Arl2/3 GTPases could also 
impair the binding of small molecules to PDEand whether these allsosteric release factors 
may reverse the biological effect of small molecules targeting PDEin the cell. To investigate 
the effect of Arl2/3 on the high-affinity complexes between TAMRA-labeled small molecules 
and PDEthe preformed complexes were titrated with increasing concentrations of Arl2/3, 
making use of time-resolved fluorescence polarization measurements. In the case of TAMRA-
Deltarasin both Arl2 and Arl3 were able to release the small molecule from the farnesyl binding 
cavity, whereas the very high-affinity TAMRA-(S)-92-PDEcomplex could only be disrupted 
by Arl3 in analogous experiments. These displacement titrations showed that Arl3 has a much 
higher binding affinity for PDE than Arl2 and suggested two differential roles for Arl2 and 
Arl3. While Arl2 regulates the localization of low-affinity Ras GTPases in the cytoplasm, Arl3 
is essential for the release of high-affinity prenylated cargo like the inositol phosphatase 
INPP5E, which is transported to the primary cilium. 
Prenyl specificity of the interaction between lipidated proteins and PDE 
PDEfunctions as a shuttling protein for farnesylated proteins like K-Ras in the cell. The 
interaction with geranylgeranylated proteins however remains controversial. Within this thesis 
binding of prenylated peptides to PDE was explored and fluorescence polarization 
experiments revealed a slight preference (factor 2.5) of PDEfor farnesylated over 
geranylgeranylated peptides. These data suggest that the selectivity is much less pronounced 
than previously thought. 
Effect of PDEinhibitors on Hedgehog signaling 
In a further study together with COMAS, Dortmund it was shown that PDEinhibition affects 
the differentiation of mouse embryonic mesoderm fibroblasts, and therefore down regulates 
Hedgehog signaling. It was reasoned that this effect may be due to the impaired transport of 
prenylated proteins like INPP5E to the primary cilium, since the primary cilium is a signaling 
hub required for correct Hedgehog signal transduction. 
Rational design of high potency binders of UNC119a and UNC119b 
Similar to PDEthe related lipid binding proteins UNC119a and UNC119b feature a large 
hydrophobic cavity which can be addressed be with small molecules. The previously identified 
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APT1 inhibitor Palmostatin B was shown to bind to UNC119a/b with affinities in the low 
micromolar range, whereas rationally designed stapled peptides displayed affinities in the low 
nanomolar range. Cellular studies with these high-affinity peptides should clarify the role of 
UNC119a/b in the transport of lipidated protein cargo in the cytoplasm and to the primary 
cilium. 
 
In summary, a novel approach for targeting oncogenic K-Ras signaling has been presented 
within this thesis. Rational, structure guided design resulted in the generation of highly potent 
inhibitors which target the prenyl binding cavity of PDEThe optimized inhibitors break the 
K-Ras-PDE-interaction in vitro and in cellulo and impair oncogenic K-Ras signaling. The 
results presented within this thesis show that Ras could potentially be druggable and that drug 
discovery programs aimed at oncogenic K-Ras may be successful in the long run.  
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6 EXPERIMENTAL SECTION 
Biochemical Experiments and experiments with cell lysates 
General Buffers: 
5x SDS-PAGE loading buffer (0.225 M Tris-HCl pH = 6.8, 50% glycerol, 5% SDS-b. 0.05% 
Bromophenol Blue, 0.25 M DTT),1x Running buffer (1 M Tris-HCl, 0.9 M HEPES, 35 mM 
SDS-b), 10x PBS (phosphate buffered saline, 1.37 M NaCl, 27 mM KCl, 0.1 M NaH2PO4,20 
mM KH2PO4, pH= 7.4), 10x TBS (0.2 M Tris-HCl, 1.5 M NaCl, pH = 7.4), TBST (TBS + 0.1% 
Tween 20), Transfer or blotting buffer (25 mM Tris-HCl, 0.2 M Glycine, MeOH / H2O = 1/4) 
Protein Expression of His6-PDEδ 
His6-PDEδ was expressed in E.Coli Rossetta cells (pet28a). A 10 L expression liquid culture 
was cultivated from 15 LB agar plates and the expression was carried out at a temperature of 
28°C until the cells reached an OD of 0.5. Kanamycin and chloramphenicol were used as 
selection markers. The expression temperature was lowered then to 16°C and overexpression 
of His6-PDEδ was induced with IPTG. After 16 hours the cells were centrifuged and the pellet 
was resuspended in 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM mercaptoethanol. Cells were 
lysed by sonication, centrifuged and to the supernatant was added PMSF to a final concentration 
of 1 mM. The lysate was applied to a Ni-NTA column and washed with 5 column volumes of 
buffer containing 20 mM imidazole. The protein was eluted with a gradient of imidazole. 
Precipitation of some eluted fractions containing imidazole was observed, therefore protein 
solutions were diluted with imidazole-free buffer and incubated at 4°C over night. Eluted 
protein was concentrated and applied in 4 runs to a gelfiltration column. Eluted fractions were 
pooled and concentrated yielding 210 mg of protein. 
Alpha-Screen with biotinylated K-Ras4B 
Screening for inhibitors of the His6-PDEδ-K-Ras4B interaction was conducted in white, non-
binding 384-well plates (Corning) in a final volume of 20 µL. For the screen a mixture of His6-
PDEδ, and biotinylated K-Ras-peptide (final concentrations 600 nM and 900 nM  in HEPES 20 
mM, 100 mM NaCl, 0,005% Chaps pH 7.5) were added to the 1536-well plates. Compound 
solutions were directly added from 10 mM DMSO stock solutions to a final concentration of 
10 µM and the resulting mixture was incubated for 30 min (For Dose response curves, 
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compounds were tested at concentrations betwen 10 µM and 5 nM). Premixed Nickel Chelate 
Acceptor Beads and Streptavidin Donor Beads were added to a final concentration of 10 µg/mL. 
The resulting mixture was incubated at 4°C overnight. Plates were read on a Paradigm reader 
(Molecular devices, Alphascreen 1536 HTS detection cartridge, temperature 29°C-33°C).   
Screening (COMAS) based on Alpha-technology was conducted in white, non-binding 1536-
well plates (Corning) in a final volume of 6 µL. For the screen a mixture of His6-PDEδ, and 
biotinylated K-Ras-peptide (final concentrations 100 nM and 250 nM in HEPES 20 mM, 100 
mM NaCl, 0,005% Chaps pH 7.5) were added to the 1536-well plates. Compound solutions 
were directly added from 10 mM DMSO stock solutions to a final concentration of 10 µM and 
the resulting mixture was incubated for 30 min (For Dose response curves, compounds were 
tested at concentrations betwen 10 µM and 5 nM). Premixed Nickel Chelate Acceptor Beads 
and Streptavidin Donor Beads were added to a final concentration of 10 µg/mL. The resulting 
mixture was incubated at 4°C overnight. Plates were read on a Paradigm reader (Molecular 
devices, Alphascreen 1536 HTS detection cartridge, temperature 29°C-33°C).  
Dose response curves using Alpha technology with biotinylated Atorvastatin: 
Assays were conducted in white, non-binding 384-well plates (Corning) in a final volume of 
20 µL. Biotin-Atorvastatin and His6-PDEδ (final concentrations 6 nM and 24 nM  in HEPES 
20 mM, 100 mM NaCl, 0.005% Chaps, 0.1 % BSA pH 7.5) were added to 384-well plates. 
Compound solutions were added and the mixture incubated for 5 h at room temperature. The 
same assay was also conducted by adding unlabeled small molecule first to His6-PDEδ, 
followed by addition of Biotin-Atorvastatin. Premixed Nickel Chelate Acceptor Beads and 
Streptavidin Donor Beads were added to a final concentration of 10 µg/mL. The resulting 
mixture was incubated at 4°C overnight. Plates were read then on a Paradigm reader (Molecular 
devices, Alphascreen 384 HTS detection cartridge, 
Fluorescence polarization measurements for the determination of the binding constant KD 
of fluorophore-labeled compounds 
PDEδ was serially diluted in a solution containing 100 nM of TAMRA-labeled small molecules 
in 200 µL PBS-buffer (containing 0.05% Chaps, 0.5% DMSO). The 96-well plates were 
incubated at room temperature for 3 h. The fluorescence polarization values (Ex: 530 nM, 
Em: 580) were read on a Safire II plate reader (Tecan, temperature ~30°C).  
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Data was corrected for changes in fluorescence intensity and the fraction bound was fit to a one 
site binding model derived from the law of mass action using KD as the only fiiting parameter.75 
Non-linear regression was performed in OriginPro 8.6. 
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LTot: total concentration of fluorophore, P: protein concentration 
Data for Fluorescein-Atorvastatin were fit analogously. 
 
All fluorescence polarization experiments were run in at least two different sets of experiments 
using triplicate determinations unless indicated otherwise. 
 
Displacement titrations of labeled Atorvastatin-probe for the determination of KD values: 
To fluorescein-labeled Atorvastatin 15 (24 nM) and His6-tagged PDEδ (40 nM) in 200 µL PBS-
buffer (containing 0.05% Chaps, 1% DMSO) in a black, non-binding 96-well plate (Greiner) 
the small molecule was added from a DMSO stock solution. The resulting solution was serially 
diluted, holding the concentrations of 15, PDEδ and DMSO constant. The sealed plates were 
shaken overnight at room temperature and centrifuged at the beginning of the next day. The 
fluorescence polarization values (Ex: 470 nm, Em: 525 nm) were read on a Safire II plate reader 
(Tecan, temperature 28-32°C).  
For the fitting of the data to a competition model the exakt mathematical solution derived from 
the law of mass action was used as described by Roehrl et al.122 Fraction bound data was fit 
using KD2 as the only fitting parameter and total ligand concentration as independent variable 
(OriginPro8.6, function codec from origin).  
FSB=(2*(sqrt((KD1+KD2+LST+LT-RT)^2-3*((LT-RT)*KD1+(LST-
RT)*KD2+KD1*KD2)))*cos((acos((-2*(KD1+KD2+LST+LT-
RT)^3+9*(KD1+KD2+LST+LT-RT)*((LT-RT)*KD1+(LST-RT)*KD2+KD1*KD2)-27*(-
KD1*KD2*RT))/(2*sqrt(((KD1+KD2+LST+LT-RT)^2-3*((LT-RT)*KD1+(LST-
RT)*KD2+KD1*KD2))^3))))/3)-(KD1+KD2+LST+LT-
RT))/(3*KD1+2*sqrt((KD1+KD2+LST+LT-RT)^2-3*((LT-RT)*KD1+(LST-
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RT)*KD2+KD1*KD2))*cos((acos((-2*(KD1+KD2+LST+LT-
RT)^3+9*(KD1+KD2+LST+LT-RT)*((LT-RT)*KD1+(LST-RT)*KD2+KD1*KD2)-27*(-
KD1*KD2*RT))/(2*sqrt(((KD1+KD2+LST+LT-RT)^2-3*((LT-RT)*KD1+(LST-
RT)*KD2+KD1*KD2))^3))))/3)-(KD1+KD2+LST+LT-RT)). 
 
FSB: Fraction bound of fluorescent probe 
KD1: Binding constant of fluorescent probe determined from direct titration 
KD2: Fitting parameter (Binding constant of unlabeld competitor) 
LST: Total concentration of unlabeled small molecule competitor 
RT: Total protein concentration 
 
For the fitting of data to a competition model with cooperative binding of two benzimidazole 
fragments the program Scientist 3.0 was used. An experimental system was defined as a series 
of partial equations including the equilibrium relationships between the various species. 
Anisotropy data was converted to fraction bound and fitting was carried out  in anlogy to a 
previously described set of equilibrium relationships by Goody and coworkers.123  
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A: equilibrium conentration of free fluorophore 
L: equilibrium concentration of free ligand 
APDED: equilibrium concentration of bound fluorescent probe 
LPDED: equilibrium conentration of bound small molecule 
PDEDf: equlibrium conentration of free protein 
This model was used (together with equations describing the mass balance) to numerically 
simulate the FSB of fluorophore and compared with the experimental data. 
 
Scientist input file: 
// Micromath Scientist Model File 
IndVars: LST 
DepVars: A,L,APDED,LPDED,PDEDf,FSB 
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Params: ATOT,PDED,KD1,KD2 
LPDED= L^2*PDEDf/KD2 
APDED=A*PDEDf/KD1 
ATOT=A+APDED 
LST=L+LPDED 
PDED=PDEDf+APDED+LPDED 
0<A<ATOT 
0<L<LST 
0<PDEDf<PDED 
FSB=1-A/ATOT 
LST=0 
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Kinetic experiments using TAMRA-labeled benzimidazoles 
To labeled small molecule (33 nM) and His6-tagged PDEδ (33 nM) in 300 µL PBS-buffer  in a 
black, non-binding 96-well plate (Greiner) was added a 20 fold excess of unlabeled small 
molecule from a DMSO stock solution (final DMSO concentration 0.3%). DMSO was used as 
control. The fluorescence polarization values (Ex: 530 nm, Em: 580 nm) were read on a Safire 
II plate reader (Tecan, temperature 28-32°C). Plates were shaken in between measurements and 
polarization values were read at appropriate time intervals. 
 
Displacement titrations of TAMRA-labeled-probes with GppNHp-loaded Arl2/3 
To labeled small molecule (33 nM) and His6-tagged PDEδ (33 nM) in 250 µL Tris-Buffer (20 
mM Tris (pH 7.5), 150 mM NaCl, 5 mM MgCl2) in a black, non-binding 96-well plate (Greiner) 
was added GppNHp-loaded Arl2/3 from a concentrated stock solution (200 µM). The mixture 
was serially diluted with respect to Arl2/3 holding the concentration of labeled small molecule 
and PDEδ constant. The proteins Arl2/3 were provided by Dr Shehab Ismail.  
  
Kinetic experiments using TAMRA-labeled benzimidazoles in the presence of Arl2 
To labeled small molecule (33 nM), His6-tagged PDEδ (33 nM) and Arl2 in 300 µL Tris-Buffer 
(20 mM Tris (pH 7.5), 150 mM NaCl, 5 mM MgCl2) in a black, non-binding 96-well plate 
(Greiner) was added a 20 fold excess of unlabeled small molecule from a DMSO stock solution 
(final DMSO concentration 0.3%). The fluorescence polarization values (Ex: 530 nm, 
Em: 580 nm) were read on a Safire II plate reader (Tecan, temperature 28-32°C). Plates were 
shaken in between measurements and polarization values were read at appropriate time 
intervals. 
 
Isothermal titration calorimetry 
Titrations were carried out on an iTC200 calorimeter (MicroCal Inc). PDEδ protein (280 µM) 
was titrated to small molecule (30 µM) in 50 mM Tris, pH 7.5, 150 mM NaCl containing a final 
amount of 5% DMSO. Titrations were carried out at 25°C and data were fit by using a single 
site binding model as implemented in the software of the instrument supplier. 
 
SPR experiments: 
SPR experiments were carried out by Biaffin GmbH, Kassel. GST-PDEδ was used for site-
directed affinity capture of the GST fusion construct. A second anti-GST capture surface was 
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used as reference. For reversible immobilization of GST-PDEδ running buffer (see below) 
containing 500 mM NaCl and 0.05% Tween 20 was used to minimize/prevent aggregation on 
the chip surface. Experiments were carried out at 35°C using 20 mM Tris (pH 7.4), 150 mM 
NaCl, 20 µM EDTA, 0.005% Tween 20, 5% DMSO as running buffer on a Biacore T100 
instrument. 
 
Tm-Shift assays 
Protein melting points in the presence of small molecules were detected by CD-
spectroscopy (Jasco J-815, 0.1 cm path length cell). Melting curves were run in PBS-buffer 
(1% DMSO) containing 30 µM of small molecule and 25 µM PDEδ. Due to absorption of 
DMSO unfolding of PDEδ was detected at 232 nm (heating rate 1°C per minute, starting from 
30°C).  
 
Pull-down experiments with cell lysates 
MDCK cells were provided by Philipp Küchler. The cells were washed 3x with cold PBS puffer 
and then treated with lysis buffer (25 mM sodium hydrogenphosphate, 150 mM NaCl, 5 mM 
MgCl, 300 mM sucrose, 1 mM EDTA, protease inhibitor cocktail) for 15 min, transfered into 
eppendorf cups, sonicated for 10 min and repeatedly pressed through a syringe needle. The 
heterogeneous mixture was centrifuged for 30 min at 13000 rpm and the supernatant collected. 
The protein concentration was measured to be between 0.5-1.5 mg/mL. Lysates were frozen at 
-80°C and used within a month.  
For pull down experiments 500 µL Streptavidin beads (Pierce) were washed with PBS buffer, 
incubated with 500 µL 10 µM Biotin-Deltarasin in PBS buffer for 2 h at room temperature and 
then washed 4 x with PBS buffer containing 0.05% Chaps. The beads were incubated with 
500 µL cell lysate for 2h. For competition experiments the cell lysate was preincubated with an 
appropriate concentration of the soluble inhibitor (up to 10 µM) for 10 min and treated with the 
beads containing the immobilized compound. The beads were washed 5x with PBS buffer 
containing 0.05% Chaps. 
The immobilized proteins were eluted using boiling SDS sample buffer and separated by SDS-
PAGE. Proteins were transfered to PVDF membranes by electroblotting. Membranes were 
blocked with 5% milk in Tris buffered saline/ Tween (TBST) buffer for 15 min, washed with 
TBST buffer and treated with PDEδ antibody for 1.5 h at room temperature (Santa Cruz, N15, 
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1:500 in 5% milk). After washing with TBST the membrane was incubated with HRP coupled 
secondary anti-goat antibody for 1 h at room temperature. Chemiluminescence was observed 
with a licor odyssey machine employing Super Signal West Pico solution. 
Molecular modelling: 
Molecular modelling experiments were carried out with the Maestro 9.1 suite (Schrӧdinger). 
Both ligand and receptor flexibility were taken into account by using receptor docking (Glide) 
in combination with the protein structure prediction embedded in the program Prime. For 
protein preparation, the program Protein Preparation Wizard embedded in the Schrödinger 
Maestro suite was used to prepare the PDEδ cocrystal structuresure before carrying any out 
docking experiments. Water molecules were removed from the protein crystal structure, 
hydrogen atoms were added and resulting structure was refined by OPLS2005 force-field. The 
minimization was ended when the RMSD reached 0.18 Å. Then, the Receptor Grid Preparation 
option present in Glide was used to generate the protein grid that was subsequent utilized in 
docking experiments. The Van der Waals radius scaling factor was set to 0.5 with a partial 
charge cutoff of 0.25. In the Constraints options, tyrosine (Y149) and arginine (R61) were 
selected as sites for hydrogen bonding. Ligand preparation for docking was carried out with 
LigPrep in Maestro 9.1 and the OPLS_2005 force-field. Epika was used to generate possible 
states at target pH 7.0 ± 4.0. Desalt, Generate tautomers and Retain specified chiralities were 
selected. In case of rings, 20 low energy ring conformations were generated per ligand. Ligand 
docking options in Glide were used for the first round of docking experiments. Under Setting, 
XP (extra precision), Dock flexibly, Sample nitrogen inversions, Sample ring conformation and 
Epik state penalties to docking score were selected, amide bonds were penalized for nonplanar 
conformation. Under the Ligands section, the Van der Wals radius scaling factor was set to 0.5 
and the docking was set to match at least 1 out of two constraints. Several poses were generated 
and cocrystallized compounds were redocked and analysed in terms of overlay with the X-ray 
structure. Then, all poses with a GScore of more than two orders of magnitude lower than that 
of the cocrystallized compound were discarded. Furthermore, the remaining poses were visually 
inspected and those with significant clashes were not considered any further. If the clash was 
found in a region where the protein was expected to be flexible the pose was however taken 
account.  
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Chemical Synthesis 
General considerations. NMR spectroscopic data were recorded on a 400 MHz or 600 MHz 
instrument at room temperature. NMR spectra were calibrated to the solvent signals of 
deuterated DMSO-d6 or CDCl3. The following abbreviations are used to indicate the signal 
multiplicity: s (singlet), d (doublet), t (triplet), q (quartet), br (broad), m (multiplet). Analytical 
HPLC-MS data were recorded on a HPLC system with a C18 reverse column coupled to an ESI 
spectrometer, flow rate: 1.0 mL/min; time: 15 min; solvent A: 0.1% HCOOH in water, Solvent 
B: 0.1% HCOOH in Acetonitrile; 1 min 10% B, in 10 min to 100% B. High resolution mass 
spectra (HR-MS) were measured using electrospray ionization (ESI). Chiral HPLC analysis 
was performed on a Chiralpak IC Column 250 mm x 4.6 mm, flow rate: 0.5 mL/min; ethanol 
in iso-hexane. Preparative HPLC separations were carried out using a reversed-phase C18 
column (RP C18, flow 20.0 mL/min, solvent A: 0.1% TFA in water, solvent B: 0.1% TFA in 
Acetonitrile, from 10 % B to 100 % B.  In addition to analytical HPLC, U-HPLC was employed 
using the following methods indicated for each compound: Column: Acquity UPLC® BEH 18, 
1.7um, 2.1 x 50mm, 5min_A:flow 0.5mL/min,0.0min: 95% (water+0.05%TFA) + 5% (ACN + 
0.05% TFA),0.5min: 95% (water+0.05%TFA) + 5% (ACN + 0.05% TFA),2.5min: 0% 
(water+0.05%TFA) + 100% (ACN + 0.05% TFA), 5.0min: 0% (water+0.05%TFA) + 100% 
(ACN + 0.05% TFA);5min_B:flow 0.5mL/min,0.0min: 100% (water+0.05%TFA) + 0% (ACN 
+ 0.05% TFA),0.1min: 100% (water+0.05%TFA) + 0% (ACN + 0.05% TFA), 5.0min: 0% 
(water+0.05%TFA) + 100% (ACN + 0.05% TFA;10min_C:flow 0.5mL/min,0.0min: 95% 
(water+0.05%TFA) + 5% (ACN + 0.05% TFA), 0.5min: 95% (water+0.05%TFA) + 5% (ACN 
+ 0.05% TFA), 8.0min: 0% (water+0.05%TFA) + 100% (ACN + 0.05% TFA), 10.0min: 0% 
(water+0.05%TFA) + 100% (ACN + 0.05% TFA);10min_D:flow 0.5mL/min,0.0min: 100% 
(water+0.05%TFA) + 0% (ACN + 0.05% TFA) 0.1min: 100% (water+0.05%TFA) + 0% (ACN 
+ 0.05% TFA)10.0min: 0% (water+0.05%TFA) + 100% (ACN + 0.05% TFA. Atorvastatin was 
purchased from Sequoia Reseach Products. Biotin-PEG-COOH and Biotin-PEG-NH2 were 
purchased from PolyPeptide Group. The library of simple benzimidazoles and the bis-
sulfonamides shown in the supporting information were purchased from Enamine and Chemdiv. 
All other commercially available chemicals were purchased from Alfa Aesar, Aldrich, Acros, 
ABCR, TCI, Chess, MerckMillipore, Strem. Peptides 171a/b were synthesized by Sasikala 
Thavam. TAMRA-Palmostatin and Palmostatin were synthesized by Dr. Marion Rusch, Stapled 
peptides 184 and 185 were synthesized by Philipp Cromm. Compounds synthesized by LDC 
and Taros are marked with asterisks in the corresponding tables. All biochemically tested 
 EXPERIMENTAL SECTION 
123 
 
compounds, whether synthesized or purchased, possess a purity of at least 95%, as measured 
by LC-MS. 
Synthesis of biotinylated, C-terminal K-Ras4B peptide 
 
Biotinylated K-Ras4B peptide 9 The C-terminal K-Ras4B peptide was synthesized by means 
of solid-phase peptide synthesis (scale: 0.1 mmol, loading 0.5 mmol/g trityl resin) similar to a 
previously described procedure employing immobilized Fmoc-Lys-Cys-Far-OMe. 40 Fmoc 
cleavage was achieved using 5 mL of 20% piperidine, 2% DBU in DMF twice for 10 minutes. 
Subsequently the resin was washed 5 times with DMF. All amino acids were coupled twice 
employing 4 eq of amino acid, 4 eq of HCTU and 8 eq of DIPEA in 5 ml DMF. Double 
couplings were carried out at 60°C for 30 minutes each cycle. The resulting N-terminal amino 
acid was coupled with 5eq Biotin-NHS ester at room temperature in DMF. Cleavage from the 
solid support was performed by treating the resin with 10 mL of 1 % TFA in dry DCM 
containing 2 % TES for for 1 hour, then with 1.5 % TFA for 1 h and with 2% TFA in DCM for 
an additional hour. After each treatment the resin was washed DCM/MeOH 1:1 and MeOH. 
Finally toluene was added to the mixture and the solvent was evaporated under reduced 
pressure. The resulting crude product was dissolved in a minimal amount of MeOH, filtered 
through a syringe filter and slowly added to an ice-cold solution of Et2O. The precipitate was 
dissolved in DMSO and after purification by preparative HPLC using a C18 column the peptide 
was obtained (40 mg, 20%). 1H NMR (600 MHz, DMSO-d6) δ 8.51 – 7.68 (m, 31H), 6.42 (s, 
1H), 6.38 (s, 1H), 5.19 – 5.01 (m, 3H), 4.52 – 4.10 (m, 11H), 4.01 – 3.94 (m, 1H), 3.66 – 3.53 
(m, 5H), 3.22 – 2.94 (m, 4H), 2.90 – 2.59 (m, 18H), 2.19 – 1.85 (m, 8H), 1.77 – 1.14 (m, 64H), 
1.02 (d, J = 6.2 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ 173.45, 172.74, 172.59, 172.23, 
172.20, 172.15, 171.64, 170.70, 170.20, 163.44, 159.59, 159.39, 159.18, 158.97, 139.40, 
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135.27, 131.33, 124.76, 124.31, 120.73, 120.68, 118.75, 116.77, 67.33, 62.50, 61.75, 59.91, 
58.49, 56.10, 55.59, 53.29, 53.22, 52.97, 52.68, 35.89, 35.81, 32.18, 32.05, 31.95, 31.81, 31.65, 
29.84, 29.46, 29.33, 29.16, 28.88, 28.72, 27.29, 27.25, 27.01, 26.85, 26.54, 26.14, 26.04, 25.87, 
23.11, 22.90, 22.70, 19.99, 19.91, 18.20, 16.46, 16.41. LC-MS (ESI): calcd for 
C92H170N22O17S2: 960.63506 [M+2H]
2+, found 960.97 [M+2H]2+, Rt = 4.80 min; HR-MS found 
960.63545 [M+2H]2+. [∝]𝐷
20 : -66.5° (c=0.72, H2O). 
General Procedure A for the N-Alkylation of benzimidazoles 
To a suspension of the benzimidazole in acetonitrile (1 mL/ 0.1 mM benzimidazole) was added 
caesium carbonate (1.5 eq) and the corresponding alkyl bromide (1.05 eq). The reaction mixture 
was stirred at room temperature for 1-3 hours and after this time it was concentrated in vacuo. 
The residue was suspended in a mixture of DCM and sat. NaHCO3 (vol % 50:50, 10 mL/0.1 
mmol benzimidazole). The aqueous layer was extracted with DCM (2 x, 10 mL/0.1 mmol 
benzimidazole). The combined organic layers were dried over Na2SO4, filtered and the solvent 
was removed under reduced pressure. The crude product was purified by flash chromatography 
as described below. 
  
 
 
1-Benzyl-2-phenyl-1H-benzo[d]imidazole (10) The N-benzylation of 2-phenyl benzimidazole 
(185 mg, 0.92 mmol) was performed following the general procedure described above. The 
crude product was purified by flash column chromatography (gradient of 
cyclohexane:ethylacetate 10:1 to 1:1) to yield the desired compound 
(212 mg, 0.74 mmol, 86%). 1H NMR (400 MHz, DMSO-d6) δ 7.76 – 7.67 (m, 3H), 7.57 – 7.47 
(m, 3H), 7.47 – 7.42 (m, 1H), 7.31 – 7.16 (m, 5H), 6.98 (d, J = 7.3 Hz, 2H), 5.57 (s, 2H). 13C 
NMR (101 MHz, DMSO-d6) δ 153.94, 143.37, 137.60, 136.57, 130.84, 130.50, 129.72, 129.45, 
128.15, 126.77, 123.37, 122.89, 119.95, 111.78, 48.15. LC-MS (ESI): calcd for C20H16N2 : 
285.13863 [M+H]+, found 285.01 [M+H]+, Rt = 5.90 min; HR-MS found 285.13883  [M+H]
+. 
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6-Pyiridyl-5,6-dihydrobenzo[4-5]imidazo[1,2-c]quinazoline (12) A mixture of 2-
pyridinecarboxaldehyde (99 mg, 0.93 mmol) and 2-(2-aminophenyl)-1H-benzimid-
azole (200 mg, 0.93 mmol) was dissolved in acetic acid (2 mL). The reaction mixture was 
stirred at 65°C for 16 h. After cooling to room temperature the reaction mixture was diluted 
with DCM (15 mL) and a sat. NaHCO3 – solution was slowly added until a basic pH was 
reached. The aqueous layer was extracted with DCM (2 x 15 mL). The combined organic phases 
were dried over Na2SO4, filtered and the solvent was removed under reduced pressure. The 
crude product was purified by flash column chromatography (gradient of DCM: MeOH 50:1 to 
5:1) to yield the desired compound (196 mg, 0.66 mmol, 71%). 1H NMR (400 MHz, DMSO-
d6) δ 8.51 – 8.35 (m, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.73 (td, J = 6.1, 3.0 Hz, 1H), 7.69 (d, J = 
2.0 Hz, 1H), 7.65 – 7.59 (m, 1H), 7.35 – 7.30 (m, 1H), 7.30 – 7.24 (m, 1H), 7.24 – 7.06 (m, 
5H), 6.84 (d, J = 8.2 Hz, 1H), 6.81 – 6.70 (m, 1H). 13C NMR (101 MHz, DMSO-d6) δ 159.05, 
150.14, 147.51, 144.46, 143.64, 138.10, 133.69, 132.20, 125.25, 124.61, 122.85, 122.70, 
120.87, 119.25, 118.70, 115.36, 112.70, 111.07, 69.04. LC-MS (ESI): calcd for C19H14N4: 
299.12912 [M+H]+, found 299.01 [M+H]+, Rt = 2.70 min; HR-MS found 299.12929 [M+H]
+. 
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Synthesis of Atorvastatin derivatives 
 
5-(4-fluorophenyl)-1-(6-hydroxyhexyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-
carboxamide 14 To a suspension of commercially avalailable 2-[2-(4-Fluorophenyl)-2-oxo-1-
phenylethyl]-4-methyl-3-oxopentanoic acid phenylamide (Atorvastatin derivative M, 13, 
100 mg, 0.24 mmol) in a mixture of toluene: heptane: THF 6:5:1 (5 mL) was added 6-
aminohexan-1-ol (168 mg, 1.4 mmol) and acetic acid (0.2 mL). The resulting reaction mixture 
was heated under reflux conditions for 16 h. The reaction mixture was allowed to cool to room 
temperature. The reaction mixture was concentrated under reduced pressure, diluted with 
saturated sodium hydrogen carbonate solution and extracted with DCM (3x 20 mL). The 
combined organic phases were dried (Na2SO4), filtered and concentrated to dryness. 
Purification by automated flash chromatography (gradient cyclohexane : ethyl acetate 10:1 to 
1:1) afforded the desired product (60 mg, 58%). 1H NMR (400 MHz, cdcl3) δ 7.16 – 7.02 (m, 
9H), 7.02 – 6.88 (m, 5H), 6.79 (s, 1H), 3.77 – 3.70 (m, 2H), 3.52 – 3.39 (m, 3H), 1.50 – 0.75 
(m, 15H).13C NMR (101 MHz, CDCl3) δ 164.91, 163.62, 161.17, 141.51, 138.57, 134.83, 
133.37, 133.29, 130.67, 128.96, 128.80, 128.60, 128.57, 128.47, 126.69, 123.61, 121.84, 
119.70, 115.57, 115.36, 62.80, 44.74, 32.56, 31.68, 26.66, 26.41, 25.29, 21.87. LC-MS (ESI): 
calcd for C32H35N2O2F 499.27553, found 499.27540 [M+H]+.  
 
1-((23R,25R)-23,25-Dihydroxy-5,21-dioxo-1-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno-
[3,4-d]imidazol-4-yl)-10,13,16-trioxa-6,20-diazaheptacosan-27-yl)-5-(4-fluorophenyl)-2-
isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (15) To Atorvastatin Calcium (25 mg, 
0.043 mmol) in DMF (1 mL) was added PyBob (39 mg, 0.08 mmol), DIPEA (72 µL, 0,4 mmol) 
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and Biotin-PEG3-NH2*TFA (126 mg, 0.23 mmol). The reaction mixture was stirred at room 
temperature for 18 h and then directly applied to reverse phase chromatography to yield the 
desired product as a TFA salt (20 mg, 41%).1H NMR (600 MHz, DMSO-d6) δ 9.75 (s, 1H), 7.79 
– 7.66 (m, 2H), 7.48 (d, J = 7.9 Hz, 2H), 7.25 – 7.13 (m, 6H), 7.08 – 7.03 (m, 4H), 7.00 – 6.94 
(m, 2H), 4.28 (dd, J = 7.6, 4.7 Hz, 1H), 4.10 (dd, J = 7.7, 4.4 Hz, 1H), 3.53 – 3.47 (m, 5H), 3.46 
– 3.41 (m, 4H), 3.39 – 3.33 (m, 4H), 3.24 – 3.18 (m, 1H), 3.10 – 3.01 (m, 5H), 2.82 – 2.77 (m, 
1H), 2.13 – 2.08 (m, 2H), 2.02 (t, J = 7.4 Hz, 2H), 1.65 – 1.54 (m, 6H), 1.53 – 1.37 (m, 5H), 
1.37 – 1.33 (m, 6H), 1.31 – 1.23 (m, 3H). 13C NMR (151 MHz, dmso) δ 172.59, 171.25, 166.82, 
163.37, 161.56, 159.12, 158.95, 140.11, 136.61, 135.58, 134.05, 129.82, 129.10, 128.29, 
127.96, 126.11, 123.33, 121.26, 120.06, 116.10, 70.43, 70.20, 68.78, 68.75, 66.67, 66.47, 61.73, 
59.88, 56.09, 44.46, 44.26, 36.40, 35.89, 30.08, 30.02, 28.89, 28.71, 26.33, 25.97, 22.98. LC-
MS (ESI): calcd for  C53H71N6O9FS: 987.50600 [M+H]+,HR-MS found: 987.50543. 
1-
((19R,21R)-1-(3',6'-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-ylamino)-
19,21-dihydroxy-17-oxo-1-thioxo-6,9,12-trioxa-2,16-diazatricosan-23-yl)-5-(4-
fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (16) To Atorvastatin 
(20 mg, 35 µmol) in DMF (200 µL) was added DIPEA (24 µL, 140 µmol), FITC-PEG3-NH2
124 
(90 mg, 148 µmol) and PyBOP (27 mg, 50 µmol). The reaction mixture was stirred for 36 hours 
and then directly applied to a reverse phase C-18 column (gradient water: acetontrile 9:1 to 1:5 
containing 0.1% TFA) to yield fluorescein-labeled atorvastatin (17 mg, 15 µmol, 41%). 1H 
NMR (600 MHz, DMSO-d6) δ 9.89 (s, 1H), 9.77 (s, 1H), 8.19 (s, 1H), 8.05 (s, 1H), 7.75 (t, J = 
5.6 Hz, 1H), 7.69 (s, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.24 – 7.13 (m, 8H), 7.07 – 7.01 (m, 4H), 
6.99 – 6.92 (m, 2H), 6.66 – 6.63 (m, 2H), 6.59 – 6.52 (m, 4H), 3.94 – 3.87 (m, 1H), 3.79 (dd, J 
= 11.9, 7.1 Hz, 1H), 3.75 – 3.68 (m, 2H), 3.24 – 3.15 (m, 2H), 3.10 – 2.98 (m, 3H), 2.09 (d, J 
= 6.3 Hz, 2H), 1.78 (p, J = 6.5 Hz, 2H), 1.64 – 1.53 (m, 4H), 1.53 – 1.43 (m, 1H), 1.41 – 1.30 
(m, 8H), 1.28 – 1.17 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 171.26, 169.20, 166.81, 
161.35, 160.14, 152.53, 136.57, 135.55, 129.79, 129.68, 129.32, 129.11, 128.30, 127.93, 
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126.03, 123.65, 121.22, 120.04, 118.06, 116.11, 115.96, 113.25, 110.37, 102.88, 70.42, 70.39, 
70.23, 70.19, 68.73, 66.63, 66.46, 44.45, 44.26, 41.48, 39.38, 36.36, 29.94, 29.19, 22.98; LC-
MS (ESI): calcd for C64H68FN5O12S: 1150.46420 [M+H]
+, found: 1150.21 [M+H]+, Rt = 8.81 
min; HR-MS found 1151.46229 [M+H]+. 
 
1-((3R,5R)-7-(3-(Dimethylamino)propylamino)-3,5-dihydroxy-7-oxoheptyl)-5-(4-
fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (17) To Atorvastatin 
Calcium (10 mg, 0.017 mmol) in DMF (0.3 mL) was added N1,N1-dimethylpropane-1,3-
diamine (67 µL, 0.54 mmol) and PyBob (10 mg, 0.019 mmol). The reaction mixture was stirred 
at room temperature for 18 h and then directly applied to reverse phase chromatography to yield 
the product (7 mg, 61%) as a TFA salt. 1H NMR (600 MHz, DMSO-d6) δ 9.76 (s, 1H), 9.35 (s, 
1H), 7.93 (t, J = 5.8 Hz, 1H), 7.48 (d, J = 7.8 Hz, 2H), 7.24 – 7.14 (m, 5H), 7.08 – 7.02 (m, 
4H), 7.00 – 6.94 (m, 2H), 4.70 (s, 1H), 4.62 (s, 1H), 3.96 – 3.88 (m, 1H), 3.86 – 3.80 (m, 1H), 
3.77 – 3.69 (m, 1H), 3.54 – 3.48 (m, 1H), 3.24 – 3.16 (m, 1H), 3.14 – 3.01 (m, 2H), 2.98 (t, J = 
7.3 Hz, 2H), 2.73 (s, 6H), 2.16 – 2.05 (m, 2H), 1.76 – 1.65 (m, 2H), 1.64 – 1.56 (m, 1H), 1.53 
– 1.45 (m, 1H), 1.43 – 1.37 (m, 1H), 1.35 (d, J = 7.0 Hz, 6H), 1.29 – 1.23 (m, 1H). 13C NMR 
(151 MHz, DMSO-d6) δ 171.92, 166.81, 161.43, 140.09, 136.58, 135.54, 134.06, 134.00, 
129.79, 129.39, 129.11, 128.32, 127.94, 126.05, 123.66, 121.24, 120.05, 118.19, 116.12, 
115.98, 66.59, 66.38, 55.59, 55.27, 44.56, 44.31, 42.92, 41.50, 40.72, 39.51, 35.99, 26.32, 
25.11, 23.01, 22.99. LC-MS (ESI): calcd for C38H47N4O4F: 643.36596 [M+H]+, found: 643.31 
[M+H]+, Rt = 6.4 min, HR-MS : 643.36593. 
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1-((3R,5R)-7-((2-(Dimethylamino)ethyl)amino)-3,5-dihydroxy-7-oxoheptyl)-5-(4-
fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (18) The compound 
was synthesized by Carsten Schultz-Fademrecht, LDC Dortmund. 1H NMR (400 MHz, DMSO-
d6) δ 9.71 (s, 1H), 7.69 (t, J = 5.6 Hz, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.24 - 7.12 (m, 6H), 7.04 
(m, 4H), 6.95 (m, 2H), 4.66 (br.s, 1H), 3.88 (m,1H), 3.82 - 3.61 (m, 5H), 3.20 (quin, J = 6.9 Hz, 
1H), 3.10 (q, J = 6.3 Hz, 2H), 2.25 (t, J = 6.7 Hz, 2H), 2.11 (m, 1H), 2.10 (s, 6H), 1.59 (m, 1H), 
1.50 (m, 1H), 1.38 (m, 1H), 1.34 (d, J = 7.0 Hz, 6H), 1.27 (m, 1H). LC-MS:5min_A: Rt 
=1.92min, 10min_C: Rt =4.23min. LC-MS (ESI): calcd for C37H45N4O4F: 629.35031 [M+H], 
HR-MS found: 629.35127. 
 
1-((3R,5R)-3,5-Dihydroxy-7-morpholino-7-oxoheptyl)-5-(4-fluorophenyl)-2-isopropyl-
N,4-diphenyl-1H-pyrrole-3-carboxamide (19) The compound was synthesized by Carsten 
Schultz-Fademrecht, LDC Dortmund.1H NMR (400 MHz, CDCl3)δ 7.21 - 7.13 (m, 9H), 7.06 
(d, J = 8.0 Hz, 2H), 6.99 (m, 3H), 6.86 (s, 1H), 4.59 (br.s, 1H), 4.23 - 4.07 (m, 2H), 3.94 (m, 
1H), 3.77 (m, 1H), 3.66 (m, 4H), 3.64 - 3.54 (m, 4H), 3.40 (t, J = 4.9 Hz, 2H), 2.31 (m, 2H), 
1.65 (m, 2H), 1.54 (d, J = 7.1 Hz, 6H), 1.47 (m, 1H), 1.18 (dt, J = 14.2 Hz, J = 2.1 Hz, 1H). LC-
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MS: 5min_A: Rt=2.22min, 10min_C: Rt=5.02min.LC-MS (ESI): calcd for C37H42N3O5F: 
628.31867 [M+H], HR-MS found: 628.31974. 
 
1-((15R,17R)-15,17-Dihydroxy-13-oxo-2,5,8-trioxa-12-azanonadecan-19-yl)-5-(4-
fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (20) The compound 
was synthesized by Carsten Schultz-Fademrecht, LDC Dortmund. 1H NMR (400 MHz, CDCl3) 
δ 7.20 - 7.10 (m, 9H), 7.06 (d, J = 7.9 Hz, 2H), 7.02 - 6.95 (m, 3H), 6.90 (s, 1H), 6.77 (t, J = 
5.3 Hz, 1H), 4.83 (br.s, 1H), 4.11 (m, 2H), 3.92 (m, 1H), 3.73 (m, 1H), 3.65 - 3.51 (m, 12H), 
3.36 (q, J = 5.9 Hz, 2H), 3.54 (s, 3H), 2.24 (m, 2H), 1.75 (quin, J = 6.0 Hz, 2H), 1.70 - 1.57 (m, 
2H), 1.53 (d, J = 7.1 Hz, 6H), 1.45 (m, 1H), 1.25 (d, J = 14.2 Hz, 1H). LC-MS:5min_A: 
tR=2.21min, 10min_C: tR=5.02min. LC-MS: 5min_A: Rt =2.21min, 10min_C: Rt =5.02min. 
LC-MS (ESI) C41H52FN3O7 calcd: 717, found: 718 [M+H]+.LC-MS (ESI): calcd for 
C41H52N3O7F: 718.38621 [M+H]+, HR-MS found: 718.38856.  
Procedures for synthesis of benzimidazole fragments  
 
2-(4-(Allyloxy)phenyl)-1H-benzo[d]imidazole (30) To a mixture of 4-allyloxybenzaldehyde 
(4.00 g, 23.9 mmol) and phenylendiamine (2.72 g, 25.1 mmol) in DMF (50 mL) at room 
temperature was added Na2S2O5 (4.50 g, 23.9 mmol). The reaction mixture was heated at 70 °C 
for 3 h. To the reaction mixture was added ice water (150 mL) and the resulting suspension was 
stirred for 2 h at 0°C. The slightly brown precipitate was filtered, washed with cold water (100 
mL), ethyl acetate (3x 20 mL) and dried in vacuo to afford the product. (4.85 g, 19.8 mmol, 81 
%).  1H NMR (400 MHz, DMSO-d6) δ 8.11 (d, J = 8.7 Hz, 2H), 7.56 (dd, J = 5.9, 3.1 Hz, 2H), 
7.23 – 7.06 (m, 4H), 6.11-5.99 (m, 1H), 5.41 (d, J = 16.8 Hz, 1H), 5.27 (d, J = 10.6 Hz, 1H), 
4.64 (d, J = 4.7 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 160.3, 151.9, 139.7, 134.1, 128.8, 
123.1, 122.6, 118.3, 115.8, 115.4, 69.02; LC-MS (ESI): calcd for C16H14N2O:  251.11789 
[M+H]+, found 251.13 [M+H]+, Rt = 5.84 min; HR-MS found 251.11800  [M+H]
+. 
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2-(4-(Allyloxy)phenyl)-1-benzyl-1H-benzo[d]imidazole (32a) Compound 32a was 
synthesized according to Procedure (A) for the synthesis of N-alkylated benzimidazoles starting 
from 30 (262 mg, 1.04 mmol). The crude product was purified by automated flash 
chromatography using a gradient of cyclohexane : ethyl acetate  10:1 to 1:2 to yield the 
benzimidazole (325 mg, 0.95 mmol, 91%). 1H NMR (400 MHz, DMSO-d6) δ 7.70 – 7.60 (m, 
3H), 7.43 – 7.37 (m, 1H), 7.30 – 7.14 (m, 5H), 7.07 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 7.4 Hz, 
2H), 6.11 – 5.93 (m, 1H), 5.55 (s, 2H), 5.40 (dd, J = 17.3, 1.7 Hz, 1H), 5.26 (dd, J = 10.5, 1.7 
Hz, 1H), 4.62 (d, J = 5.2 Hz, 2H).13C NMR (101 MHz, DMSO-d6) δ 160.00, 153.89, 143.40, 
137.68, 136.61, 134.08, 131.13, 129.47, 128.12, 126.72, 123.14, 123.07, 122.75, 119.72, 
118.40, 115.60, 111.59, 68.99, 48.14. LC-MS (ESI): calcd for C23H20N2O: 341.16484 [M+H]
+, 
found: 341.25 [M+H]+, Rt = 7.43 min; HR-MS found 341.16508 [M+H]
+. 
 
2-(4-(Allyloxy)phenyl)-1-(2-methylbenzyl)-1H-benzo[d]imidazole (33a) The product was 
synthesized according to Procedure A for the N-alkylation of benzimidazoles starting from 
30 (291 mg, 1.27 mmol). The crude product was purified by automated flash chromatography 
(gradient cylohexane : ethyl acetate 10:1 to 1:2) to yield the product (387 mg, 
1.09 mmol, 86%). 1H NMR (400 MHz, DMSO-d6) δ 7.71 (dd, J = 7.9, 0.6 Hz, 1H), 7.61 – 7.54 
(m, 2H), 7.30 (dd, J = 7.9, 0.7 Hz, 1H), 7.27 – 7.08 (m, 4H), 7.07 – 6.97 (m, 3H), 6.37 (d, J = 
7.7 Hz, 1H), 6.03 (ddt, J = 17.3, 10.5, 5.3 Hz, 1H), 5.49 (s, 2H), 5.46 – 5.31 (m, 1H), 5.25 (dd, 
J = 10.5, 1.7 Hz, 1H), 4.63 – 4.54 (m, 2H), 2.29 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 
160.01, 153.97, 143.37, 136.75, 135.62, 135.55, 134.06, 131.05, 130.84, 127.88, 126.93, 
125.11, 123.07, 123.04, 122.79, 119.73, 118.41, 115.59, 111.53, 68.97, 46.56, 19.34; LC-MS 
(ESI): calcd for C24H22N2O: 355.18049  [M+H]
+, found:  355.19 [M+H]+, Rt = 7.75 min; HR-
MS found 355.18092 [M+H]+. 
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2-(4-(Allyloxy)phenyl)-1-(3-methylbenzyl)-1H-benzo[d]imidazole (34a) Compound 34a 
was synthesized according to Procedure A for the N-alkylation of benzimidazoles starting from 
30 (316 mg, 1.26 mmol). The crude product was purified by automated flash chromatography 
(gradient cyclohexane : ethyl acetate  10:1 to 1:2) to yield the product (394 mg, 
1.11 mmol, 88%). 1H NMR (400 MHz, DMSO-d6) δ 7.72 – 7.58 (m, 3H), 7.38 (dt, J = 6.7, 3.7 
Hz, 1H), 7.25 – 7.11 (m, 3H), 7.09-7.03 (m, 3H), 6.85 (s, 1H), 6.74 (d, J = 7.6 Hz, 1H), 6.12 – 
5.94 (m, 1H), 5.50 (s, 2H), 5.40 (dd, J = 17.3, 1.7 Hz, 1H), 5.26 (dd, J = 10.5, 1.7 Hz, 1H), 
4.63-4.60 (m, 2H), 2.19 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 160.00, 153.89, 143.38, 
138.65, 137.63, 136.62, 134.09, 131.13, 129.40, 128.82, 127.31, 123.75, 123.15, 123.06, 
122.74, 119.70, 118.40, 115.61, 111.58, 68.99, 48.13, 21.68. LC-MS (ESI): calcd for 
C24H22N2O: 355.18049 [M+H]
+, found: 355.23 [M+H]+, Rt = 7.67 min; HR-MS found 
355.18107 [M+H]+. 
 
2-(4-(Allyloxy)phenyl)-1-(4-fluorobenzyl)-1H-benzo[d]imidazole (35a) Compound 35a was 
synthesized according to Procedure A for the N-alkylation of benzimidazoles starting from 30 
(243 mg, 0.97 mmol). The crude product was purified by automated flash chromatography 
(gradient cyclohexane : ethylacetate 10:1 to 1:2) to yield the product (301 mg, 
0.84 mmol, 86%). 1H NMR (400 MHz, DMSO-d6) δ 7.72 – 7.58 (m, 3H), 7.46 – 7.37 (m, 1H), 
7.24 – 7.16 (m, 2H), 7.14 – 6.93 (m, 6H), 6.05 (ddt, J = 17.3, 10.5, 5.2 Hz, 1H), 5.54 (s, 2H), 
5.44 – 5.36 (m, 1H), 5.29 – 5.23 (m, 1H), 4.67 – 4.57 (m, 2H). 13C NMR (101 MHz, DMSO-
d6) δ 163.26, 160.84, 160.01, 153.82, 143.40, 136.49, 134.08, 133.86, 131.15, 128.89, 128.81, 
123.13, 123.08, 122.80, 119.75, 118.41, 116.40, 116.19, 115.62, 111.56, 68.99, 47.48. LC-MS 
(ESI): calcd for C23H19FN2O : 359.15542 [M+H]
+, found: 359.19 [M+H]+, Rt = 7.41 min; HR-
MS found 359.15576 [M+H]+. 
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2-(4-(Allyloxy)phenyl)-1-(pyridin-2-ylmethyl)-1H-benzo[d]imidazole (36a) The product 
was synthesized according to Procedure A for the N-alkylation of benzimidazoles starting from 
30. The crude product was purified by automated flash chromatography (gradient DCM:MeOH 
50:1 to 20:1) to yield the product  (83%, 1.27 mmol, 432 mg).1H NMR (400 MHz, DMSO-d6) 
δ 8.45 – 8.39 (m, 1H), 8.29 – 8.24 (m, 1H), 7.71 – 7.62 (m, 3H), 7.53 – 7.46 (m, 1H), 7.31 – 
7.16 (m, 4H), 7.08 (t, J = 5.8 Hz, 2H), 6.10 – 5.98 (m, 1H), 5.61 (s, 2H), 5.41 (dd, J = 17.3, 1.7 
Hz, 1H), 5.27 (dd, J = 10.5, 1.7 Hz, 1H), 4.63 (d, J = 5.2 Hz, 2H). 13C NMR (101 MHz, DMSO-
d6) δ 160.04, 153.86, 149.45, 148.47, 143.40, 136.40, 134.66, 134.08, 133.30, 131.21, 124.47, 
123.22, 123.02, 122.90, 119.81, 118.43, 115.66, 111.54, 69.00, 45.91. LC-MS (ESI): calcd for  
C20H19N3O : 342.16009 [M+H]
+, found: 342.18 [M+H]+, Rt = 5.95 min. 
 
General Procedure B for the deprotection of allyl-protected phenols 
 
The allyl-protected phenol (1eq) was dissolved in degassed methanol (5 mL/mmol protected 
phenol). To this mixture was added K2CO3 (3 eq) and Pd(PPh3)4 (0.2 eq). The reaction mixture 
was stirred at room temperature for 1-3 hours and after this time it was concentrated in vacuo. 
The residue was resuspended in DCM (10 mL/mmol) and a sat. NH4Cl-solution was 
subsequently added. The pH of the aqueous layer was adjusted to 8 and the aqueous layer was 
extracted with DCM (3 x 20 mL/mmol phenol). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified as described below. 
 
 
4-(1-Benzyl-1H-benzo[d]imidazol-2-yl)phenol (32b) Compound 32b was synthesized 
according to Procedure B for the allyl-deprotection of benzimidazoles. The compound was 
purified by automated flash chromatography using a gradient of cyclohexane: ethyl acetate 20:1 
to 1:1 to afford the dersired compound (143 mg, 0.47 mmol, 83%). 1H NMR (400 MHz, DMSO-
d6) δ 9.93 (s, 1H), 7.72 – 7.59 (m, 1H), 7.54 (d, J = 8.6 Hz, 2H), 7.41 – 7.33 (m, 1H), 7.32 – 
7.12 (m, 5H), 6.99 (d, J = 7.4 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 5.53 (s, 2H); 13C NMR (101 
MHz, DMSO-d6) δ = 160.3, 151.9, 139.7, 134.1, 128.8, 123.1, 122.6, 118.3, 115.7, 115.4, 69.0 
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LC-MS (ESI): calcd for C20H16N2O : 301.13354 [M+H]
+, found:  301.18 [M+H]+, Rt = 5.89 
min; HR-MS found 301.13367 [M+H]+.  
 
 
4-(1-(2-Methylbenzyl)-1H-benzo[d]imidazol-2-yl)phenol (33b) Compound 33b was 
synthesized according to Procedure B for the allyl-deprotection of benzimidazoles. The crude 
product was purified by automated flash chromatography using a gradient of cyclohexane: ethyl 
acetate 20:1 to 1:1 to yield compound 33 (160 mg, 0.51 mmol, 81%). 1H NMR (400 MHz, 
DMSO-d6) δ 9.92 (s, 1H), 7.68 (dd, J = 7.9, 0.5 Hz, 1H), 7.65 – 7.57 (m, 1H), 7.57 – 7.50 (m, 
1H), 7.47 (t, J = 5.6 Hz, 2H), 7.32 – 7.10 (m, 5H), 7.01 (t, J = 7.5 Hz, 1H), 6.86 – 6.78 (m, 2H), 
6.37 (d, J = 7.6 Hz, 1H), 5.46 (s, 2H), 2.28 (s, 3H).13C NMR (101 MHz, DMSO-d6) δ 159.56, 
154.42, 143.39, 136.72, 135.67, 135.54, 132.68, 132.20, 132.11, 131.02, 130.94, 129.48, 
129.36, 127.84, 126.89, 125.15, 122.88, 122.68, 121.30, 119.61, 116.21, 111.45, 46.53, 
19.33. LC-MS (ESI): calcd for C21H18N2O : 315.14919  [M+H]
+, found: 315.09 [M+H]+, Rt = 
6.29 min; HR-MS found 315.14919 [M+H]+.   
 
 
4-(1-(3-Methylbenzyl)-1H-benzo[d]imidazol-2-yl)phenol (34b) Compound 34b was 
synthesized according to Procedure B for the allyl-deprotection of benzimidazoles. The crude 
product was purified by automated flash chromatography using a gradient of cyclohexane: ethyl 
acetate 20:1 to 1:1 to yield compound 34 (167 mg, 0.53 mmol, 83%). 1H NMR (400 MHz, 
DMSO-d6) δ 9.98 (s, 1H), 7.70 – 7.64 (m, 1H), 7.57 – 7.48 (m, 2H), 7.39 – 7.33 (m, 1H), 7.23 
– 7.10 (m, 3H), 7.03 (d, J = 7.6 Hz, 1H), 6.92 – 6.83 (m, 3H), 6.75 (d, J = 7.5 Hz, 1H), 5.48 (s, 
2H), 2.18 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 159.59, 154.36, 143.41, 138.63, 137.68, 
136.60, 131.22, 129.36, 128.79, 127.35, 123.78, 122.89, 122.64, 121.40, 119.58, 116.26, 
111.51, 48.13, 21.67. LC-MS (ESI): calcd for C21H18N2O : 315.14919   [M+H]+, found: 315.12 
[M+H]+, Rt = 6.33 min; HR-MS found: 315.14939 [M+H]+.  
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4-(1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl)phenol (35b) Compound 35b was 
synthesized according to Procedure B for the allyl-deprotection of benzimidazoles. The crude 
product was purified by automated flash chromatography using a gradient of cyclohexane: ethyl 
acetate 20:1 to 1:1 to yield compound 10 (156 mg, 0.49 mmol, 84%). 1H NMR (400 MHz, 
DMSO-d6) δ 9.94 (s, 1H), 7.69 – 7.63 (m, 1H), 7.56 – 7.48 (m, 2H), 7.44 – 7.37 (m, 1H), 7.24 
– 7.14 (m, 2H), 7.10 (t, J = 8.8 Hz, 2H), 7.06 – 6.98 (m, 2H), 6.87 (d, J = 8.4 Hz, 2H), 5.52 (s, 
2H). 13C NMR (101 MHz, DMSO-d6) δ 163.24, 160.82, 159.56, 154.27, 143.42, 136.46, 133.93, 
133.90, 131.22, 128.91, 128.83, 122.95, 122.69, 121.31, 119.62, 116.37, 116.25, 116.16, 
111.48, 47.45. LC-MS (ESI): calcd for C20H15FN2O: 319.12412 [M+H]
+, found: 319.11 
[M+H]+, Rt = 6.21 min; HR-MS found 319.12438 [M+H]
+.   
 
4-(1-(Pyridin-2-ylmethyl)-1H-benzo[d]imidazol-2-yl)phenol (36b) Compound 36b was 
synthesized according to Procedure B for the allyl-deprotection of benzimidazoles. The crude 
product was purified by automated flash chromatography using a gradient of DCM: MeOH 
100:1 to 10:1 to yield compound the product (123 mg, 0.41 mmol, 80%).  1H NMR (400 MHz, 
DMSO-d6) δ 9.95 (s, 1H), 8.42 (dd, J = 4.3, 1.8 Hz, 1H), 8.27 (s, 1H), 7.71 – 7.60 (m, 1H), 7.56  
– 7.49 (m, 2H), 7.50 – 7.44 (m, 1H), 7.31 – 7.24 (m, 2H), 7.24 – 7.15 (m, 2H), 6.95 – 6.83 (m, 
2H), 5.60 (s, 2H).13C NMR (101 MHz, DMSO-d6) δ 159.59, 154.30, 149.41, 148.49, 143.42, 
136.37, 134.68, 133.36, 131.27, 124.45, 123.04, 122.80, 121.25, 119.69, 116.30, 111.46, 45.89. 
LC-MS (ESI):calcd for C19H15N3O:302.12933.[M+H]
+.302.13 [M+H]+, Rt = 4.13 min.
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Methyl 2-(2-phenyl-1H-benzo[d]imidazol-1-yl)acetate (39) To a suspension of 2-phenyl 
benzimidazole (37) (0.32 g, 1.6 mmol) in acetonitrile (5 mL) was added caesium carbonate 
(0.80 g, 2.5 mmol) and  methyl bromoacetate (0.16 mL, 1.7 mmol). The reaction mixture was 
stirred at room temperature for 3 hours and concentrated in vacuo. The residue was suspended 
in a mixture of DCM and sat. NaHCO3 (vol % 50:50, 15 mL). The aqueous layer was reextracted 
with DCM (2 x 20 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated in in vacuo to afford the product (0.40 g, 1.5 mmol, 91%). 1H NMR (400 MHz, 
DMSO-d6) δ 7.77 – 7.63 (m, 3H), 7.63 – 7.44 (m, 4H), 7.33 – 7.09 (m, 2H), 5.21 (s, 2H), 3.64 
(s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 169.40, 153.91, 143.08, 136.91, 130.57, 130.51, 
129.62, 129.53, 123.45, 123.00, 119.87, 111.36, 53.17, 46.57. LC-MS (ESI): calcd for 
C16H14N2O2: 267.11280 [M+H]
+, found: 267.18 [M+H]+; HR-MS found 267.11311  [M+H]+. 
 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)ethanol (40) To a solution of benzimidazole 
39 (400 mg, 1.43 mmol) in MeOH (5 mL) was added NaBH4 (376 mg, 10.0 mmol) at room 
temperature. The reaction mixture was stirred at room temperature for 12 h. To the reaction 
mixture was added sat. NH4Cl-solution (15 mL), followed by DCM (30 mL). The pH of the 
aqueous layer was adjusted to 8 by addition of sat. NaHCO3-solution. The aqueous layer was 
reextracted with DCM (2x 20 mL). The combined organic layers were dried (Na2SO4), filtered 
and concentrated in vacuo and the residue was purified by flash chromatography (gradient 
cyclohexane : ethyl acetate 100:1 to 1:1) to afford the product (302 mg, 1.26 mmol, 84%). 1H 
NMR (400 MHz, DMSO-d6) δ 7.97 – 7.84 (m, 2H), 7.76 – 7.60 (m, 2H), 7.60 – 7.45 (m, 3H), 
7.34 – 6.99 (m, 2H), 5.08 (s, 1H), 4.33 (t, J = 5.5 Hz, 2H), 3.89 – 3.56 (m, 2H). 13C NMR (101 
MHz, DMSO-d6) δ 154.25, 143.32, 136.56, 131.27, 130.32, 130.20, 129.21, 122.93, 122.56, 
119.71, 111.89, 59.92, 47.49. LC-MS (ESI): calcd for C15H14N2O: 239.11789 [M+H]
+, found:  
239.19 [M+H]+, Rt = 4.32 min; HR-MS found 239.11806 [M+H]+. 
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Methyl 2-(2-phenyl-1H-benzo[d]imidazol-1-yl)pent-4-enoate (41) To a solution of 
39 (500 mg, 1.88 mmol) in DMF (5 mL) was added at 0°C NaH (83 mg, 60% mineral oil 
suspension). The reaction mixture was stirred for 60 minutes, then a solution of allyl bromide 
(244 µL, 2.90 mmol) in DMF (2 mL) was added. The reaction mixture was allowed to warm to 
room temperature and stirred for 3 h. A saturated solution of NH4Cl (10 mL) was added at 0°C 
to the reaction mixture. The aqueous suspension was extracted with DCM (3 x 20 mL). The 
combined organic phases were dried over Na2SO4, filtered and concentrated to dryness. The 
crude product was purified by automated flash chromatography using a of gradient 
cyclohexane : ethyl acetate 10:1 to 1:3 to yield the product (340 mg, 1.11 mmol, 59%). 1H NMR 
(400 MHz, DMSO-d6) δ 7.71 – 7.66 (m, 1H), 7.65 – 7.59 (m, 2H), 7.60 – 7.53 (m, 3H), 7.51 – 
7.43 (m, 1H), 7.30 – 7.19 (m, 2H), 5.36 (dd, J = 9.5, 6.3 Hz, 1H), 5.32 – 5.16 (m, 1H), 4.76 (d, 
J = 10.2 Hz, 1H), 4.65 (d, J = 17.1 Hz, 1H), 3.68 (s, 3H), 2.99 – 2.77 (m, 2H). 13C NMR (101 
MHz, DMSO-d6) δ 170.08, 154.65, 143.50, 134.57, 133.12, 130.73, 130.61, 130.17, 129.53, 
123.50, 122.94, 120.30, 119.37, 112.40, 58.12, 53.61, 33.85. LC-MS (ESI): calcd for 
C19H18N2O2 : 307.14410 [M+H]
+, found: 307.16 [M+H]+; HR-MS found 307.14440  [M+H]+. 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)pent-4-en-1-ol (42) A solution of benzimidazole 
41 (320 mg, 0.94 mmol) in EtOH:THF (1:5, 5 mL) was added to a suspension of NaBH4 (188 
mg, 5 mmol) in THF (4 mL) at room temperature over 1 h. The reaction mixture was stirred at 
room temperature for 12 h. NaBH4 (94 mg, 2.5 mmol) was added to the reaction mixture and 
stirring was continued for 3 h. To the reaction mixture was added sat. NH4Cl-solution (15 mL), 
followed by DCM (30 mL). The pH of the aqueous layer was adjusted to 9 by addition of sat. 
NaHCO3-solution. The aqueous layer was again extracted with DCM (2x 20 mL). The 
combined organic layers were dried (Na2SO4), filtered, concentrated to dryness and the residue 
was purified by flash chromatography (gradient cyclohexane : ethyl acetate 100:1 to 1:1) to 
afford the product (217 mg, 0.77 mmol, 83%). 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.62 (m, 
1H), 7.63 – 7.56 (m, 2H), 7.47 (d, J = 7.9 Hz, 1H), 7.44 – 7.30 (m, 3H), 7.27 – 7.11 (m, 2H), 
5.41 – 5.19 (m, 1H), 4.88 – 4.65 (m, 2H), 4.65 – 4.45 (m, 1H), 4.35 – 4.10 (m, 1H), 3.94 – 3.76 
(m, 1H), 2.85 – 2.62 (m, 1H), 2.57 – 2.43 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 155.69, 
143.40, 133.48, 133.05, 130.70, 130.37, 129.78, 128.62, 122.64, 122.53, 120.20, 118.56, 
112.31, 62.97, 59.55, 34.09. LC-MS (ESI): calcd for C18H18N2O: 279.14919 [M+H]
+, found: 
279.10 [M+H]+; HR-MS found 279.14941 [M+H]+. 
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N-Benzyl-2-cyclohexyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)acetamide (48) A mixture of 
the aniline 43 (1.80 g, 9.0 mmol) and cyclohexyl carbaldehyde 44 (1.10 g, 9.9 mmol) was stirred 
at room temperature in MeOH (4 mL) for 10 minutes. To the reaction mixture was added 
benzylisocyanide (1.10 mL, 9 mmol) and a solution of benzoic acid (1.10 g 9.0 mmol) in MeOH 
(4 mL). The reaction mixture was stirred at room temperature for 36 h. After this time HCl in 
dioxane (4 M, 2 mL) was added to the reaction mixture. The reaction mixture was stirred for 
36 h at room temperature and then the solvent was removed under reduced pressure. The residue 
was redissolved in DCM (20 mL) and washed with a sat. NaHCO3 solution (30 mL). The 
aqueous layer was extracted with DCM (3x 20 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated to dryness under reduced pressure. The residue was purified 
by flash chromatography using a gradient of  cyclohexane :ethyl acetate 50:1 to 1:2 to afford 
the product (3.42 g, 8.06 mmol, 89 %,).1H NMR (400 MHz, CDCl3) δ 7.97 – 7.86 (m, 1H), 7.81 
– 7.69 (m, 1H), 7.56 – 7.35 (m, 5H), 7.36 – 7.19 (m, 5H), 7.10 (dd, J = 6.8, 2.4 Hz, 2H), 6.13 
(s, 1H), 4.50 – 4.29 (m, 3H), 2.76 – 2.56 (m, 1H), 1.96 (d, J = 12.3 Hz, 1H), 1.71 – 1.41 (m, 
3H), 1.36 – 1.18 (m, 1H), 1.12 – 0.86 (m, 3H), 0.86 – 0.69 (m, 1H), 0.66 – 0.46 (m, 1H). 13C 
NMR (101 MHz, CDCl3) δ 168.50, 154.93, 143.37, 137.77, 134.33, 130.74, 130.24, 129.92, 
129.14, 128.96, 127.91, 123.51, 123.12, 120.18, 113.97, 66.39, 43.97, 37.84, 31.36, 29.18, 
26.13, 25.81. LC-MS (ESI): calcd for C28H29N3O: 424.23834 [M+H]
+, found 424.21 [M+H]+; 
HR-MS found 424.23733 [M+H]+. 
 
N-Benzyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)acetamide (49) A 
mixture of the aniline 43 (1.20 g, 5.7 mmol) and the tert-butyl 4-formylpiperidine-1-carboxylate 
(45) (1.34 g, 6.3 mmol) was stirred at room temperature in MeOH (3 mL) for 10 minutes. To 
the reaction mixture was added benzylisocyanide (0.70 mL, 9.0 mmol) and a solution of benzoic 
acid (0.70 g 9.0 mmol) in MeOH (4 mL). The reaction mixture was stirred at room temperature 
for 36 h. To the reaction mixture was added HCl/dioxane (4 M, 2 mL). The reaction mixture 
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was stirred for 36 h at room temperature and then concentrated in vacuo. The residue was 
redissolved in DCM (20 mL) and washed with sat. NaHCO3 solution (30 mL). The aqueous 
layer was reextracted with DCM (3x 20 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated to dryness under reduced pressure. The residue was purified 
by automated flash chromatography (gradient cyclohexane : ethylacetate 100:1 to 1:2, 
containing 0.1% triethylamine) to afford the product (4.11 mmol,1.75 g, 72%). 1H NMR (400 
MHz, DMSO-d6) δ 8.89 (t, J = 5.6 Hz, 1H), 8.10 – 7.89 (m, 1H), 7.68 – 7.47 (m, 6H), 7.34 – 
7.17 (m, 7H), 2.84 (d, J = 11.5 Hz, 1H), 2.67 – 2.51 (m, 2H), 2.37 (t, J = 12.4 Hz, 1H), 2.08 (t, 
J = 11.2 Hz, 1H), 1.60 (d, J = 13.0 Hz, 1H), 1.12 – 0.97 (m, 1H), 0.62 – 0.48 (m, 1H), 0.47 – 
0.36 (m, 1H). 13C NMR (101 MHz, DMSO-d6) δ 173.11, 155.19, 154.32, 152.61, 143.70, 
138.15, 131.13, 130.49, 130.22, 129.37, 129.03, 127.91, 127.51, 123.29, 122.95, 120.05, 
115.57, 84.79, 79.34, 63.36, 48.55, 37.71, 28.72, 27.85. LC-MS (ESI): calcd for C27H28N4O: 
425.23376 [M+H]+, found 425.17 [M+H]+, Rt = 5.15 min; HR-MS found 425.23359  [M+H]
+. 
 
tert-Butyl benzyl(2-cyclohexyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)acetyl)carbamate 
(50) To a solution of amide 48 (620 mg, 1.46 mmol) in DCM (5 mL) was added Boc-anhydride 
(639 mg, 2.92 mmol), triethylamine (405 µL, 2.92 mmol) and DMAP (179 mg, 1.46 mmol). 
The reaction mixture was stirred at room temperature for 5 h. After this time Boc-anhydride 
(639 mg, 2.92 mmol), triethylamine (405 µL, 2.92 mmol) and DMAP (179 mg, 1.46 mmol) 
were added to the reaction mixture and stirring was continued for an additional 12 h. The 
reaction mixture was concentrated to dryness under reduced pressure. Purification by automated 
flash chromatography using a gradient of cyclohexane : ethyl acetate 20:1 to 1:1 afforded the 
product (0.66 g, 1.26 mmol, 86%).  1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 7.4 Hz, 1H), 
7.82 – 7.73 (m, 1H), 7.56 – 7.48 (m, 2H), 7.47 – 7.39 (m, 3H), 7.34 – 7.24 (m, 2H), 7.24 – 7.15 
(m, 3H), 7.05 (d, J = 7.2 Hz, 2H), 6.38 (d, J = 10.6 Hz, 1H), 4.83 (d, J = 15.0 Hz, 1H), 4.68 (d, 
J = 14.9 Hz, 1H), 2.87 (d, J = 10.8 Hz, 1H), 1.84 – 1.68 (m, 2H), 1.72 – 1.50 (m, 2H), 1.38 – 
0.74 (m, 15H). 13C NMR (101 MHz, CDCl3) δ 173.81, 155.26, 152.49, 143.59, 137.78, 134.92, 
131.22, 130.10, 129.81, 128.75, 128.56, 127.55, 127.42, 123.03, 122.68, 120.04, 115.08, 84.19, 
64.13, 48.53, 39.52, 29.87, 29.66, 27.95, 26.38, 26.25, 26.16. LC-MS (ESI): calcd for 
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C33H37N3O3: 524.29077 [M+H]
+, found 524.18 [M+H]+, Rt = 11.55 min; HR-MS found 
524.29035 [M+H]+. 
 
tert-Butyl 4-(2-(benzyl(tert-butoxycarbonyl)amino)-2-oxo-1-(2-phenyl-1H-
benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (51) To a solution of amide 49 (300 
mg, 0.71 mmol) in DCM (5 mL) was added Boc-anhydride (463 mg, 2.13 mmol), triethylamine 
(293 µL, 2.13 mmol) and DMAP (86 mg, 0.71 mmol). The reaction mixture was stirred at room 
temperature for 5 h. Boc-anhydride (463 mg, 2.13 mmol), triethylamine (293 µL, 2.13 mmol) 
and DMAP (86 mg, 0.71 mmol) were added to the reaction mixture and stirring was continued 
for an additional 12 h. The reaction mixture was concentrated to dryness under reduced 
pressure. Purification by flash chromatography using a gradient of cyclohexane: ethyl acetate 
20:1 to 1:1 afforded the product (0.36 g, 0.58 mmol, 81%). 1H NMR (400 MHz, DMSO-d6) δ 
8.04 (d, J = 7.5 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.55 – 7.37 (m, 5H), 7.31 – 7.10 (m, 5H), 
7.04 (d, J = 7.2 Hz, 2H), 6.23 (d, J = 10.4 Hz, 1H), 4.77 (d, J = 15.5 Hz, 1H), 4.64 (d, J = 15.1 
Hz, 1H), 3.95 (d, J = 11.9 Hz, 1H), 3.82 (d, J = 11.2 Hz, 1H), 2.97 (d, J = 10.2 Hz, 1H), 2.86 – 
2.59 (m, 1H), 2.56 – 2.40 (m, 2H), 1.59 (d, J = 11.7 Hz, 1H), 1.47 – 1.24 (m, 10H), 1.25 – 1.05 
(m, 9H), 1.05 – 0.88 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 173.11, 155.19, 154.32, 
152.61, 143.70, 138.15, 131.13, 130.49, 130.22, 129.37, 129.03, 127.91, 127.51, 123.29, 
122.95, 120.05, 115.57, 84.79, 79.34, 63.36, 48.55, 37.71, 28.72, 27.85. LC-MS (ESI): calcd 
for C37H44N4O5: 625.33845 [M+H]
+, found 625.19 [M+H]+, Rt = 10.76 min; HR-MS found 
625.33840.   
 
2-Cyclohexyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethanol (52) A solution of Boc-
protected amide 50 (650 mg, 1.24 mmol) in EtOH:THF (1:5, 5 mL) was added to a suspension 
of NaBH4 (188 mg, 5 mmol) in THF (4 mL) at room temperature over 1 h. The reaction mixture 
was stirred at room temperature for 12 h. After this time NaBH4 (94 mg, 2.5 mmol) was added 
to the reaction mixture and stirring was continued for 3 h. To the reaction mixture was added a 
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NH4Cl-solution (15 mL), followed by DCM (20 mL). The pH of the aqueous layer was adjusted 
to 9 by addition of sat. NaHCO3-solution. The aqueous layers were extracted with DCM (2x 20 
mL). The combined organic layers were dried (Na2SO4), filtered and concentrated under 
reduced pressure and the residue was purified by flash chromatography (gradient cyclohexane: 
ethyl acetate 10:1 to 1:1) to afford the product (330 mg, 1.03 mmol, 83%).1H NMR (400 MHz, 
CDCl3) δ 7.73 – 7.61 (m, 3H), 7.52 (d, J = 8.1 Hz, 1H), 7.48 – 7.35 (m, 3H), 7.25 – 7.10 (m, 
2H), 4.36 – 4.21 (m, 2H), 4.06 – 4.02 (m, 1H), 3.13 (s, 1H), 2.18 – 2.05 (m, 1H), 1.80 (d, J = 
11.9 Hz, 1H), 1.67 (d, J = 13.6 Hz, 1H), 1.53 (d, J = 10.0 Hz, 1H), 1.41 (d, J = 12.5 Hz, 1H), 
1.31 – 1.10 (m, 1H), 1.04 – 0.77 (m, 4H), 0.57 – 0.37 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
156.21, 143.34, 133.52, 130.86, 130.56, 129.69, 128.63, 122.62, 122.51, 120.24, 112.34, 65.04, 
61.68, 37.67, 30.88, 29.62, 26.06, 25.87, 25.74. LC-MS (ESI): calcd for C37H44N4O5:  
321.19614 [M+H]+, found 321.18 [M+H]+, Rt = 6.24 min; HR-MS found 321.19642.  
 
tert-Butyl 4-(2-hydroxy-1-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-
carboxylate (53) A solution of Boc-protected amide 51 (1.0 g, 1.6 mmol) in EtOH:THF (1:5, 
15 mL) was added to a suspension of NaBH4 (242 mg, 6.4 mmol) in THF (15 mL) at room 
temperature over 1 h. The reaction mixture was stirred at room temperature for 12 h. NaBH4 
(120 mg, 3.2 mmol) was added to the reaction mixture and stirring was continued for 3 h. To 
the reaction mixture was added NH4Cl-solution (40 mL), followed by DCM (30 mL). The pH 
of the aqueous layer was adjusted to 8 by addition of sat. NaHCO3-solution. The aqueous layers 
were reextracted with DCM (3x 30 mL). The combined organic layers were concentrated in 
vacuo and the residue was purified by flash chromatography (gradient cyclohexane: ethyl 
acetate 10:1 to 1:2) to afford the product (538 mg, 1.27 mmol, 80%). 1H NMR (400 MHz, 
DMSO-d6) δ 7.87 – 7.78 (m, 1H), 7.74 (d, J = 3.6 Hz, 2H), 7.70 – 7.62 (m, 1H), 7.58 – 7.46 
(m, 3H), 7.26 – 7.11 (m, 2H), 5.29 – 5.07 (m, 1H), 4.30 – 4.07 (m, 2H), 4.04 – 3.73 (m, 2H), 
3.71 – 3.44 (m, 1H), 2.79 – 2.56 (m, 1H), 2.45 – 2.23 (m, 2H), 1.81 (d, J = 12.2 Hz, 1H), 1.46 
– 1.20 (m, 10H), 0.93 (d, J = 10.4 Hz, 1H), 0.68 – 0.38 (m, 2H). 13C NMR (101 MHz, DMSO-
d6) δ 155.95, 154.28, 143.86, 134.19, 131.67, 130.82, 130.09, 129.08, 122.74, 122.40, 120.11, 
113.62, 79.18, 64.71, 60.33, 35.71, 30.18, 29.06, 28.67.LC-MS (ESI): calcd for C25H31N3O3: 
422.24382 [M+H]+, found 422.20 [M+H]+, Rt = 6.31 min; HR-MS found 422.24271. 
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General Procedure C for the synthesis of phenol ethers via Mitsunobu reaction 
 
To a mixture of phenol, alcohol (1.0 eq) and tri-n-butyl phosphine (2 eq) in toluene (3 mL/mmol 
phenol) was added at 0°C TMAD (2 eq) in one portion. The resulting suspension was heated 
for 16 h at 60°C. If the reaction was not complete tri-n-butyl phosphine (1 eq) and TMAD (1 eq) 
were added at room temperature and the mixture was heated for 16 h at 60°C. The reaction 
mixture was diluted with DCM (20 mL/mmol phenol) and washed with sat. NaHCO3 (10 mL 
/mmol phenol). The aqueous phase was reextracted with DCM (3 x 20 mL/mmol phenol). The 
combined organic phases were dried (Na2SO4), filtered and concentrated in vacuo. The crude 
product was purified by column chromatography as described below. 
 
1-Benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethoxy)phenyl)-1H-
benzo[d]imidazole (54) The product was synthesized from phenol 32 (50 mg, 0.17 mmol) and 
alcohol 40 according to Procedure C for the synthesis of phenol ethers via Mitsunobu 
reaction. The crude product was purified by automated flash chromatography using a gradient 
of of cyclohexane: ethyl acetate 6:1 to 1:9 to yield the product (52 mg, 0.10 mmol, 59%). 1H 
NMR (400 MHz, DMSO-d6) δ 7.86 – 7.79 (m, 2H), 7.77 (d, J = 7.9 Hz, 1H), 7.70 – 7.62 (m, 
2H), 7.60 – 7.45 (m, 5H), 7.38 (d, J = 6.8 Hz, 1H), 7.33 – 7.13 (m, 7H), 6.96 (d, J = 7.2 Hz, 
2H), 6.86 (d, J = 8.7 Hz, 2H), 5.49 (s, 2H), 4.70 (t, J = 5.0 Hz, 2H), 4.36 (t, J = 5.1 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ 159.51, 154.48, 153.74, 143.35, 137.64, 136.56, 136.25, 
131.22, 131.09, 130.27, 129.45, 129.29, 128.10, 126.68, 123.36, 123.14, 123.10, 122.77, 
119.84, 119.71, 115.17, 111.94, 111.59, 66.71, 48.09, 44.41. LC-MS (ESI): calcd for 
C35H28N4O: 521.23359 [M+H]
+, found: 521.34 [M+H]+, Rt = 6.37 min; HR-MS found 
521.23314 [M+H]+. 
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1-Benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)pent-4-enyloxy)phenyl)-1H-
benzo[d]imidazole (55) The product was synthesized from phenol 32 (76 mg, 0.25 mmol) and 
alcohol 42 according to Procedure C for the synthesis of phenol ethers via Mitsunobu 
reaction. The crude product was purified by automated flash chromatography using a gradient 
of of cyclohexane: ethyl acetate 10:1 to 1:7 to yield the product (100 mg, 0.18 mmol, 72 %). 1H 
NMR (400 MHz, DMSO-d6) δ 7.99 – 7.89 (m, 1H), 7.75 – 7.63 (m, 4H), 7.57 (t, J = 11.0 Hz, 
2H), 7.54 – 7.43 (m, 3H), 7.38 (dt, J = 8.8, 4.5 Hz, 1H), 7.34 – 7.06 (m, 8H), 6.98 (dd, J = 7.7, 
5.4 Hz, 4H), 5.51 (s, 2H), 5.50 – 5.33 (m, 1H), 4.91 – 4.71 (m, 4H), 4.44 (dd, J = 10.1, 3.6 Hz, 
1H), 3.08 – 2.91 (m, 1H), 2.81 – 2.68 (m, 1H). 13C NMR (101 MHz, DMSO-d6) δ 159.51, 
155.59, 153.74, 143.91, 143.37, 137.66, 136.60, 133.94, 133.85, 131.47, 131.14, 130.59, 
130.20, 129.47, 129.18, 128.11, 126.66, 123.48, 123.12, 123.01, 122.78, 122.61, 120.29, 
119.73, 119.09, 115.33, 113.31, 111.59, 68.29, 56.84, 48.12, 33.72. LC-MS (ESI): calcd for 
C38H32N4O: 561.26489 [M+H]
+, found: 561.36 [M+H]+, Rt = 7.19 min; HR-MS found 
561.26523 [M+H]+. 
 
 
1-Benzyl-2-(4-(2-cyclohexyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethoxy)phenyl)-1H-
benzo[d]imidazole (56) The product was synthesized from phenol 32 (50 mg, 0.17 mmol) and 
alcohol 52  according to Procedure C for the synthesis of phenol ethers via Mitsunobu 
reaction. The crude product was purified by automated flash chromatography using a gradient 
of of cyclohexane: ethyl acetate 10:1 to 1:7 to yield the product (63 mg, 0.11 mmol, 63%). 1H 
NMR (600 MHz, DMSO-d6) δ 7.91 (d, J = 7.3 Hz, 1H), 7.73 (d, J = 6.9 Hz, 2H), 7.66 (td, J = 
7.1, 4.6 Hz, 2H), 7.58 (t, J = 10.6 Hz, 2H), 7.57 – 7.49 (m, 3H), 7.39 (d, J = 7.6 Hz, 1H), 7.28 
– 7.15 (m, 7H), 7.04 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 7.4 Hz, 2H), 5.51 (s, 2H), 4.85 (t, J = 9.9 
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Hz, 1H), 4.61 – 4.54 (m, 1H), 4.45 (t, J = 8.4 Hz, 1H), 2.37 (d, J = 10.8 Hz, 1H), 1.99 – 1.92 
(m, 1H), 1.64 (d, J = 13.2 Hz, 1H), 1.53 – 1.35 (m, 3H), 1.28 – 1.17 (m, 1H), 1.05 – 0.75 (m, 
4H), 0.59 – 0.49 (m, 1H). 13C NMR (151 MHz, DMSO-d6) δ 159.71, 155.88, 153.73, 143.76, 
143.29, 137.68, 136.58, 133.93, 131.13, 130.66, 130.27, 129.47, 129.28, 128.10, 126.64, 
123.39, 123.13, 123.06, 122.80, 122.63, 120.24, 119.68, 115.39, 113.35, 111.61, 109.99, 67.38, 
62.19, 48.08, 37.36, 30.74, 29.64, 26.11, 25.84, 25.79. LC-MS (ESI): calcd for C41H38N4O: 
603.31184 [M+H]+, found: 603.39 [M+H]+, Rt = 8.14 min; HR-MS found 603.31156 [M+H]
+. 
 
tert-Butyl-4-(2-(4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(2-phenyl-1H-
benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (57) The product was synthesized 
from phenol 32 (60 mg, 0.14 mmol) and alcohol 53 according to Procedure C for the synthesis 
of phenol ethers via Mitsunobu reaction. The crude product was purified by automated flash 
chromatography using a gradient of of cyclohexane: ethyl acetate 10:1 to 1:7 to yield the 
product (66 mg, 0.09 mmol, 66%). 1H NMR (400 MHz, DMSO-d6) δ 7.94 (d, J = 6.3 Hz, 1H), 
7.78 – 7.64 (m, 4H), 7.64 – 7.49 (m, 5H), 7.40 (d, J = 7.9 Hz, 1H), 7.31 – 7.15 (m, 7H), 7.04 
(d, J = 8.2 Hz, 2H), 6.97 (d, J = 7.2 Hz, 2H), 5.51 (s, 2H), 4.85 (d, J = 9.5 Hz, 1H), 4.58 (d, J = 
9.6 Hz, 1H), 4.48 (s, 1H), 3.91 (d, J = 12.6 Hz, 1H), 3.70 (s, 1H), 2.80 – 2.52 (m, 2H), 2.45 – 
2.31 (m, 1H), 1.92 (d, J = 11.6 Hz, 1H), 1.31 (s, 9H), 1.19-1.00 (d, J = 9.6 Hz, 2H), 0.92 – 0.63 
(m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 159.68, 155.83, 154.29, 153.69, 143.76, 143.18, 
137.64, 136.56, 131.16, 130.69, 130.31, 129.46, 129.29, 128.11, 126.66, 123.39, 123.17, 
122.84, 122.75, 120.29, 119.65, 115.42, 113.29, 111.62, 79.30, 67.12, 61.64, 48.13, 35.89, 
29.79, 29.08, 28.71. LC-MS (ESI): calcd for C45H45N5O3 : 704.35952 [M+H]
+, found: 704.31 
[M+H]+, Rt = 7.68 min; HR-MS found 704.36024  [M+H]
+. Chiral, analytical HPLC conditions: 
flow rate: 0.5 mL/min; solvent: 40 % ethanol in iso-hexane. (S)-8 Rt =90.1 min, (R)-8 100.9 
min. 
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tert-Butyl 4-(1-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(4-(1-(pyridin-2-ylmethyl)-1H-
benzo[d]imidazol-2-yl)phenoxy)ethyl)piperidine-1-carboxylate (58) The product was 
synthesized from phenol 36 (61 mg, 0.14 mmol) according to Procedure C for the synthesis of 
phenol ethers via Mitsunobu reaction. The crude product was purified by automated flash 
chromatography using a gradient of DCM:MeOH 100:1 to 5:1 to yield the product 
(60 mg, 0.08 mmol, 61%). 1H NMR (400 MHz, DMSO-d6) δ 8.45 – 8.34 (m, 1H), 8.30 – 8.22 
(m, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.78 – 7.39 (m, 10H), 7.30 – 7.14 (m, 6H), 7.06 (d, J = 8.6 
Hz, 2H), 5.57 (s, 2H), 4.86 (t, J = 9.8 Hz, 1H), 4.63 – 4.53 (m, 1H), 4.53 – 4.43 (m, 1H), 3.91 
(d, J = 12.2 Hz, 1H), 3.79 – 3.59 (m, 1H), 2.79 – 2.51 (m, 2H), 2.45 – 2.36 (m, 1H), 1.92 (d, J 
= 12.0 Hz, 1H), 1.30 (s, 9H), 1.18 – 0.93 (m, 1H), 0.88 – 0.55 (m, 2H). 13C NMR (101 MHz, 
DMSO-d6) δ 159.69, 155.85, 154.30, 153.72, 149.42, 148.39, 143.83, 143.36, 136.37, 134.58, 
133.82, 133.28, 131.38, 131.23, 130.69, 130.30, 129.56, 129.29, 128.87, 125.98, 124.45, 
123.38, 123.26, 123.15, 122.92, 122.72, 120.32, 119.81, 115.47, 113.30, 111.54, 79.30, 67.13, 
61.64, 45.89, 35.87, 29.08, 28.71.LC-MS (ESI): calcd for C44H44N6O3: 705.35477 [M+H]
+, 
found: 705.30 [M+H]+, Rt = 6.94 min; HR-MS found: 705.35474  [M+H]
+. 
 
 
tert-Butyl 4-(2-(4-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(2-phenyl-
1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (59) The product was synthesized 
from phenol 35 (50 mg, 0.12 mmol) according to Procedure C for the synthesis of phenol ethers 
via Mitsunobu reaction. The crude product was purified by automated flash chromatography 
using a gradient of cyclohexane: ethyl acetate 10:1 to 1:7 to yield the product 
(58 mg, 0.08 mmol, 66%). 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.79 (m, 2H), 7.71 (dd, J = 
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19.7, 5.3 Hz, 3H), 7.61 – 7.44 (m, 5H), 7.34 – 7.15 (m, 5H), 7.01 (p, J = 8.8 Hz, 4H), 6.92 (d, 
J = 8.4 Hz, 2H), 5.35 (s, 2H), 4.80 – 4.64 (m, 1H), 4.64 – 4.53 (m, 1H), 4.48 (d, J = 9.7 Hz, 
1H), 4.21 – 4.02 (m, 1H), 4.01 – 3.87 (m, 1H), 2.71 (t, J = 12.4 Hz, 1H), 2.64 – 2.37 (m, 2H), 
1.89 (d, J = 12.9 Hz, 1H), 1.34 – 1.19 (m, 10H), 1.02 – 0.79 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 163.67, 161.22, 159.53, 155.80, 154.75, 153.84, 143.82, 143.28, 136.12, 133.57, 
132.32, 132.29, 130.96, 130.82, 130.32, 130.08, 128.97, 127.85, 127.77, 123.43, 123.26, 
123.01, 122.81, 120.83, 120.09, 116.38, 116.16, 114.95, 112.06, 110.44, 79.94, 67.47, 61.70, 
47.92, 36.46, 30.16, 28.80, 28.60. LC-MS (ESI): calcd for C45H44FN5O3: 722.35009 [M+H]
+, 
found: 722.31 [M+H]+, Rt = 8.16 min; HR-MS found: 722.35052 [M+H]
+. 
 
tert-Butyl 4-(2-(4-(1-(3-methylbenzyl)-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(2-phenyl-
1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (60) The product was synthesized 
from phenol 34 (70 mg, 0.17 mmol) according to Procedure C for the synthesis of phenol ethers 
via Mitsunobu reaction. The crude product was purified by automated flash chromatography 
using a gradient of cyclohexane: ethyl acetate 10:1 to 1:7 to yield the desired compound 
(86 mg, 0.12 mmol, 70%). 1H NMR (400 MHz, cdcl3) δ 7.82 – 7.74 (m, 2H), 7.69 – 7.57 (m, 
4H), 7.55 – 7.48 (m, 2H), 7.47 – 7.39 (m, 3H), 7.24 – 7.08 (m, 7H), 7.05 – 6.99 (m, 1H), 6.87 
– 6.72 (m, 5H), 5.28 (s, 2H), 4.69 – 4.55 (m, 1H), 4.55 – 4.43 (m, 1H), 4.43 – 4.34 (m, 1H), 
4.12 – 3.95 (m, 1H), 3.91 – 3.73 (m, 1H), 2.63 (t, J = 12.8 Hz, 1H), 2.58 – 2.33 (m, 2H), 1.80 
(d, J = 12.6 Hz, 1H), 1.32 (s, 9H), 1.20 – 1.13 (m, 1H), 0.81 (dd, J = 24.7, 11.8 Hz, 2H).13C 
NMR (101 MHz, CDCl3) δ 159.63, 155.75, 154.75, 153.69, 143.70, 139.15, 136.34, 136.13, 
133.55, 131.10, 130.72, 130.53, 130.32, 130.11, 129.23, 128.98, 128.84, 126.63, 123.37, 
123.11, 123.07, 122.85, 120.77, 119.68, 114.97, 112.09, 110.75, 79.93, 67.47, 61.69, 48.62, 
36.45, 30.15, 28.80, 28.60, 21.67. LC-MS (ESI): calcd for C46H47N5O3: 718.37517 [M+H]
+, 
found: 718.33 [M+H]+, Rt = 8.17 min; HR-MS found: 718.37523 [M+H]
+. 
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tert-Butyl 4-(2-(4-(1-(2-methylbenzyl)-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(2-phenyl-
1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (61) The product was synthesized 
from phenol 33 (39 mg, 0.12 mmol)  according to Procedure C for the synthesis of phenol ethers 
via Mitsunobu reaction. The crude product was purified by automated flash chromatography 
using a gradient of cyclohexane: ethyl acetate 10:1 to 1:7 to yield the desired product (55 mg, 
64%). 1H NMR (400 MHz, CDCl3) δ 7.90 – 7.78 (m, 2H), 7.78 – 7.64 (m, 3H), 7.64 – 7.45 (m, 
5H), 7.35 – 7.17 (m, 6H), 7.16 – 7.06 (m, 2H), 6.93 – 6.83 (m, 2H), 6.74 (d, J = 7.6 Hz, 1H), 
5.31 (s, 2H), 4.70 (t, J = 8.2 Hz, 1H), 4.63 – 4.51 (m, 1H), 4.51 – 4.36 (m, 1H), 4.18 – 4.04 (m, 
1H), 4.02 – 3.74 (m, 1H), 2.70 (t, J = 12.0 Hz, 1H), 2.63 – 2.35 (m, 2H), 2.30 (s, 3H), 1.88 (d, 
J = 12.4 Hz, 1H), 1.44 – 1.30 (m, 9H), 1.29 – 1.18 (m, 1H), 1.00 – 0.73 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 159.50, 155.80, 154.75, 153.98, 143.82, 143.22, 136.42, 134.69, 134.43, 
130.83, 130.79, 130.48, 130.31, 130.07, 128.96, 127.84, 126.95, 125.39, 123.44, 123.18, 
123.02, 122.94, 122.80, 120.82, 119.98, 114.92, 112.06, 110.55, 79.92, 67.46, 61.68, 46.89, 
36.46, 30.15, 28.79, 28.60, 19.32. LC-MS (ESI): calcd for C46H47N5O3 : 718.37517 [M+H]
+, 
found: 718.32 [M+H]+, Rt = 8.16 min; HR-MS found: 718.37640 [M+H]
+. 
 
General Procedure D for the Boc-deprotection of piperidine-containing benzimidazoles 
 
To a solution of Boc-protected piperidine in DCM (1 mL / 20 µM protected piperidine) was 
added a 4 M HCl/dioxane solution to a final concentration of 2 M HCl. The reaction mixture 
was stirred at room temperature for 3 h. The solvent was removed in vacuo to afford the product 
in quantitative yield as an HCl-salt. Further purification, if required, is described below. 
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1-Benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethoxy)phenyl)-
1H-benzo[d]imidazole (62) The product was synthesized according to General Procedure (D) 
starting from 8 (32 mg, 0.046 mmol) to afford the HCl-salt in quantitative yield. The residue 
was dissolved in methanol (500 µL) and applied to a preparative C18-RP column eluting with 
a gradient (CH3CN: H2O 1:5 to 9:1 containing 0.1% TFA), to afford the desired piperdine (20 
mg, 0.033 mmol, 71%) as a TFA-salt. 1H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 6.8 Hz, 
1H), 7.77 – 7.71 (m, 2H), 7.69 – 7.63 (m, 2H), 7.63 – 7.49 (m, 5H), 7.41 – 7.36 (m, 1H), 7.30 
– 7.14 (m, 7H), 7.05 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 7.3 Hz, 2H), 5.51 (s, 2H), 4.86 (t, J = 9.9 
Hz, 1H), 4.62 – 4.52 (m, 1H), 4.47 (t, J = 8.5 Hz, 1H), 2.89 (d, J = 12.0 Hz, 1H), 2.68 (d, J = 
12.0 Hz, 1H), 2.46 – 2.34 (m, 1H), 2.28 – 2.11 (m, 1H), 1.89 – 1.80 (m, 1H), 1.13 – 0.98 (m, 
1H), 0.77 – 0.51 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 159.70, 155.88, 153.74, 143.78, 
143.36, 137.68, 136.61, 133.94, 131.49, 131.14, 130.68, 130.27, 129.46, 129.28, 128.10, 
126.65, 123.48, 123.10, 122.78, 122.66, 120.27, 119.71, 115.40, 113.27, 111.58, 67.15, 62.29, 
48.11, 46.11, 46.01, 36.24, 31.25, 29.88. LC-MS (ESI): calcd for C40H37N5O: 604.30709 
[M+H]+, found: 604.26 [M+H]+, Rt = 5.34 min; HR-MS found: 604.30716 [M+H]
+. [∝]𝐷
20 
: -140.0° for the (S)-enantiomer (c=0.6, DMSO, HCl salt). 
 
 
2-Phenyl-1-(1-(piperidin-4-yl)-2-(4-(1-(pyridin-2-ylmethyl)-1H-benzo[d]imidazol-2-
yl)phenoxy)ethyl)-1H-benzo[d]imidazole (63) The product was synthesized according to 
General Procedure (D) to afford the HCl-salt in quantitative yield. The residue was dissolved 
in methanol (500 µL) and applied to a preparative C18-RP column eluting with a gradient 
(CH3CN: H2O 1:5 to 9:1 containing 0.1% TFA), to afford the desired piperidine (27 mg, 
0.044 mmol, 74%) as a TFA-salt. 1H-NMR (600 MHz, DMSO-d6) δ 9.35 – 9.24 (m, 1H), 9.00 
– 8.86 (m, 1H), 8.72 – 8.65 (m, 2H), 8.34 – 8.26 (m, 1H), 8.03 – 7.96 (m, 1H), 7.93 – 7.85 (m, 
4H), 7.80 – 7.67 (m, 6H), 7.59 – 7.48 (m, 4H), 7.20 (d, J = 8.5 Hz, 2H), 5.84 (s, 2H), 4.92 – 
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4.86 (m, 1H), 4.75 (d, J = 8.3 Hz, 1H), 4.69 – 4.53 (m, 1H), 3.26 (d, J = 11.6 Hz, 1H), 3.04 (d, 
J = 12.1 Hz, 1H), 2.97 – 2.84 (m, 2H), 2.70 (d, J = 9.6 Hz, 1H), 2.09 (d, J = 12.5 Hz, 1H), 1.64 
– 1.53 (m, 1H), 1.28 – 1.18 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 161.32, 153.01, 151.57, 
133.82, 133.34, 132.85, 132.59, 131.32, 131.19, 130.03, 126.82, 126.49, 126.40, 126.12, 
116.84, 116.09, 115.73, 115.28, 113.69, 66.71, 62.57, 46.64, 42.93, 40.70, 33.41, 26.16, 
25.90. LC-MS (ESI): calcd for C39H36N6O: 605.30234 [M+H]
+, found: 605.28[H]+, Rt = 4.89 
min; HR-MS found 605.30247 [M+H]+. 
 
1-(4-Fluorobenzyl)-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-
yl)ethoxy)phenyl)-1H-benzo[d]imidazole (64) The product was synthesized according to 
General Procedure (D) to afford the HCl salt. The residue was dissolved in methanol (500 µL) 
and applied to a preparative C18-RP column eluting with a gradient (CH3CN: H2O 1:5 to 9:1 
containing 0.1% acetic acid), to afford the desired piperidine (16 mg, 65%),. 1H NMR (600 
MHz, DMSO-d6) δ 7.92 (d, J = 7.4 Hz, 1H), 7.73 (d, J = 6.9 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 
7.61 – 7.49 (m, 5H), 7.44 – 7.37 (m, 1H), 7.25 – 7.16 (m, 4H), 7.12 – 7.02 (m, 4H), 7.02 – 6.96 
(m, 2H), 5.49 (s, 2H), 4.85 (t, J = 9.9 Hz, 1H), 4.58 (d, J = 8.1 Hz, 1H), 4.46 (t, J = 8.6 Hz, 1H), 
2.92 (d, J = 12.1 Hz, 1H), 2.70 (d, J = 11.9 Hz, 1H), 2.26 – 2.15 (m, 1H), 1.88 (d, J = 11.9 Hz, 
1H), 1.12 – 0.99 (m, 1H), 0.78 – 0.59 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 173.50, 
162.82, 161.20, 159.69, 155.87, 153.67, 143.76, 143.32, 136.45, 133.85, 133.83, 131.43, 
131.16, 130.68, 130.30, 129.30, 128.80, 128.74, 123.39, 123.18, 123.12, 122.84, 122.70, 
120.28, 119.73, 116.36, 116.22, 115.41, 113.28, 111.57, 67.07, 62.18, 47.41, 45.64, 45.55, 
35.89, 30.68, 29.35, 22.85. LC-MS (ESI): calcd for C40H36FN5O: 622.29767 [M+H]
+, found: 
622.28[M+H]+, Rt = 5.70 min; HR-MS found 622.29806 [M+H]
+. 
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1-(3-Methylbenzyl)-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-
yl)ethoxy)phenyl)-1H-benzo[d]imidazole (65) The product was synthesized according to 
General Procedure (D) to afford the HCl salt. The residue is dissolved in methanol (500 µL) 
and applied to a preparative C18-RP column eluting with a gradient (ACN: H2O 1:5 to 9:1 
containing 0.1% acetic acid), to afford the desired piperidine (69%, 15 mg). 1H NMR (600 
MHz, DMSO-d6) δ 7.91 (d, J = 7.3 Hz, 1H), 7.77 – 7.67 (m, 2H), 7.70 – 7.62 (m, 2H), 7.58 (t, 
J = 8.3 Hz, 2H), 7.57 – 7.49 (m, 3H), 7.37 (d, J = 7.9 Hz, 1H), 7.25 – 7.10 (m, 5H), 7.09 – 7.00 
(m, 3H), 6.82 (s, 1H), 6.70 (d, J = 7.7 Hz, 1H), 5.45 (s, 2H), 4.85 (t, J = 10.0 Hz, 1H), 4.58 (d, 
J = 8.1 Hz, 1H), 4.46 (t, J = 8.5 Hz, 1H), 2.91 (d, J = 12.1 Hz, 1H), 2.70 (d, J = 12.1 Hz, 1H), 
2.25 – 2.16 (m, 1H), 1.94 – 1.83 (m, 1H), 1.16 – 1.00 (m, 1H), 0.83 – 0.56 (m, 2H). 13C NMR 
(151 MHz, DMSO-d6) δ 159.67, 155.86, 153.72, 151.53, 148.65, 143.75, 143.29, 138.64, 
137.61, 136.59, 133.86, 131.42, 131.12, 130.68, 130.30, 129.39, 129.30, 128.78, 127.20, 
123.66, 123.45, 123.12, 122.77, 122.69, 120.27, 119.68, 115.39, 113.27, 111.58, 67.07, 62.18, 
48.06, 45.63, 35.92, 30.73, 29.41, 22.5, 21.66. LC-MS (ESI): calcd for  C41H39N5O: 618.32274 
[M+H]+, found: 618.30[M+H]+, Rt = 5.79 min; HR-MS found 618.32299 [M+H]
+. 
 
1-(2-Methylbenzyl)-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-
yl)ethoxy)phenyl)-1H-benzo[d]imidazole (66) The product was synthesized according to 
General Procedure (D) (38 mg, 0.061 mmol) to afford the product as an HCl-salt in quantitative 
yield. 1H NMR (400 MHz, DMSO-d6) δ 8.64 (d, J = 10.7 Hz, 1H), 8.22 – 8.07 (m, 1H), 7.99 
(d, J = 5.1 Hz, 1H), 7.87 – 7.68 (m, 4H), 7.67 – 7.55 (m, 5H), 7.48 (d, J = 8.2 Hz, 1H), 7.42 (t, 
J = 7.6 Hz, 1H), 7.38 – 7.29 (m, 3H), 7.24 (d, J = 7.1 Hz, 1H), 7.20 – 7.07 (m, 3H), 7.02 (t, J = 
7.5 Hz, 1H), 6.49 (d, J = 7.7 Hz, 1H), 5.54 (s, 2H), 4.86 (t, J = 9.8 Hz, 1H), 4.64 (d, J = 10.3 
Hz, 1H), 4.58 – 4.42 (m, 1H), 3.27 (d, J = 11.7 Hz, 1H), 3.06 (d, J = 11.5 Hz, 1H), 2.94 – 2.60 
(m, 3H), 2.27 (s, 3H), 2.08 (d, J = 12.8 Hz, 1H), 1.41 (d, J = 12.5 Hz, 1H), 1.19 – 0.90 (m, 2H). 
13C NMR (101 MHz, DMSO-d6) δ 160.65, 158.66, 152.61, 135.68, 135.15, 134.48, 133.14, 
131.49, 131.15, 131.00, 130.80, 129.84, 129.52, 128.21, 127.00, 125.23, 124.98, 123.94, 
123.71, 119.60, 117.61, 115.81, 113.67, 112.75, 66.96, 61.61, 47.16, 43.20, 33.49, 26.65, 25.93, 
19.34.LC-MS (ESI): calcd for C41H39N5O:  618.32274 [M+H]
+, found: 618.26 [M+H]+, Rt = 
5.85 min; HR-MS found 618.32318 [M+H]+. 
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Procedures for the labeling of benzimidazole 55 with biotin 
 
4-(4-(1-Benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-3-(2-phenyl-1H-benzo[d]imidazol-1-
yl)butanoic acid (67) To a suspension of 55 (20 mg, 36 µmol) in a mixture of CCl4, acetonitrile 
and water 1:1:1.5 (2 mL) was added sodium periodate (31 mg, 140 µM) and RuCl3 (0.3 mg). 
After 24h of stirring, sodium periodate (31 mg, 140 µM) and RuCl3 (0.3 mg) were added. The 
reaction mixture was stirred for an additional 2 d. The reaction mixture was concentrated in 
vacuo. The aqueous residue was extracted with DCM (3x10 mL). The combined organic phases 
were dried (Na2SO4), filtered and concentrated in vacuo. The crude reaction mixture was 
subjected to automated flash chromatography (gradient DCM: MeOH 100:1 to 15:1) to afford 
compound 67 (13 mg, 22 µmol, 62%). 1H NMR (400 MHz, DMSO-d6) δ 7.91 (d, J = 7.1 Hz, 
1H), 7.76 (dd, J = 7.2, 2.0 Hz, 2H), 7.65 (dd, J = 10.7, 4.8 Hz, 2H), 7.56 (d, J = 8.7 Hz, 2H), 
7.48 (dd, J = 8.2, 2.8 Hz, 3H), 7.39 (d, J = 6.4 Hz, 1H), 7.32 – 7.14 (m, 7H), 6.96 (t, J = 8.0 Hz, 
4H), 5.50 (s, 2H), 5.23 (s, 1H), 4.71 (t, J = 9.9 Hz, 1H), 4.39 (dd, J = 10.7, 4.0 Hz, 1H), 3.25 – 
3.14 (m, 2H).13C NMR (101 MHz, DMSO-d6) δ 159.42, 155.70, 153.73, 143.95, 143.35, 
137.67, 136.57, 133.90, 131.60, 131.12, 130.59, 130.07, 129.47, 128.95, 128.11, 126.68, 
123.49, 123.11, 122.77, 122.60, 120.24, 119.72, 115.25, 113.18, 111.60, 68.23, 53.52, 48.10, 
34.96, 29.68. LC-MS (ESI): calcd for C37H30N4O3: 579.23907 [M+H]+, found: 579.36 [M+H]+, 
Rt = 6.26 min; HR-MS found 579.23912 [M+H]+.  
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N-(18-(4-(1-Benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-15-oxo-17-(2-phenyl-1H-
benzo[d]imidazol-1-yl)-4,7,10-trioxa-14-azaoctadecyl)-5-((3aS,4S,6aR)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamide (68) To a mixture of acid 67 (13 mg, 22 µmol), 
Biotin-PEG-NH2
.TFA (38 mg, 67 µmol) in DMF (1 mL) at room temperature was added 
DIPEA (32 µL, 180 µmol) and PyBOP (54 mg, 100 µmol). The reaction mixture was stirred at 
room temperature for 2 d and then concentrated in vacuo. The residue was dissolved in 
methanol (500 µL) and applied to a preparative C18-RP column eluting with a gradient 
(CH3CN:H2O 1:4 to 9:1 containg 0.1% TFA), to afford the product as a mixture of 
diastereoisomers (16 mg, 16 µmol, 71%). 1H NMR (400 MHz, DMSO-d6) δ 8.12 (d, J = 7.3 
Hz, 1H), 8.06 (t, J = 5.6 Hz, 1H), 7.91 – 7.84 (m, 2H), 7.84 – 7.74 (m, 2H), 7.75 – 7.62 (m, 
4H), 7.62 – 7.54 (m, 3H), 7.53 – 7.39 (m, 4H), 7.35 – 7.22 (m, 3H), 7.14 – 7.01 (m, 4H), 6.40 
(s, 2H), 5.64 (s, 2H), 5.35 (s, 1H), 4.83 – 4.74 (m, 1H), 4.47 (dd, J = 11.0, 3.7 Hz, 1H), 4.28 
(dd, J = 7.8, 5.0 Hz, 1H), 4.10 (dd, J = 7.7, 4.5 Hz, 1H), 3.51 – 3.38 (m, 6H), 3.38 – 3.30 (m, 
4H), 3.30 – 3.20 (m, 1H), 3.18 – 3.10 (m, 3H), 3.10 – 2.97 (m, 4H), 2.96 – 2.86 (m, 1H), 2.83 
– 2.73 (m, 1H), 2.55 (d, J = 12.4 Hz, 1H), 2.51 – 2.44 (m, 2H), 2.10 – 1.96 (m, 2H), 1.68 – 1.54 
(m, 3H), 1.54 – 1.36 (m, 5H), 1.36 – 1.15 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 172.62, 
168.60, 163.40, 160.84, 159.10, 158.76, 153.98, 151.92, 135.88, 134.17, 132.06, 131.90, 
130.91, 129.60, 129.45, 128.65, 127.04, 125.90, 125.68, 125.22, 118.05, 117.71, 116.58, 
115.82, 115.36, 114.63, 113.38, 70.41, 70.37, 70.20, 70.14, 68.78, 68.27, 61.74, 59.90, 56.10, 
54.84, 48.86, 36.41, 36.36, 35.89, 35.21, 30.09, 29.71, 28.89, 28.72, 25.98. LC-MS (ESI): calcd 
for C57H66N8O7S: 1007.48479 [M+H]
+, found: 1007,60 [M+H]+, Rt = 5.89 min; HR-MS found 
1007.48529 [M+H]+. 
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1-Benzyl-2-(4-(3-methyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)butoxy)phenyl)-1H-
benzo[d]imidazole (69) The product was synthesized by Carsten Schultz-Fademrecht, LDC 
Dortmund. 1H NMR (400 MHz, CD3OD) δ 7.95 - 7.86 (m, 1H), 7.79 (d, J = 5.0 Hz, 2H), 7.73 
(d, J = 8.0 Hz, 2H), 7.63 - 7.53 (m, 6H), 7.44 - 7.23 (m, 8H), 7.08 - 7.01 (m, 3H), 5.52 (s, 2H), 
4.69 - 4.45 (m, 3H), 2.82 (s, 1H), 1.16 (d, J = 6.5 Hz, 3H), 0.64 (d, J = 6.6 Hz, 3H). LC-MS: 
5min_A: tR=1.98min, 10min_C: tR=4.39min. MS (ES) C38H34N4O calcd: 562, found: 563 
[M+H]+. LC-MS (ESI): calcd for C38H34N4O: 563.28054 [M+H]+, found 563.28190 [M+H]+. 
 
1-Benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-3-yl)ethoxy)phenyl)-
1H-benzo[d]imidazole (diastereoisomer 1) (70) The product was synthesized by Carsten 
Schultz-Fademrecht, LDC Dortmund. 1H NMR (400 MHz, CD3OD) δ 7.95 (d, J = 7.6 Hz, 1H), 
7.83 - 7.71 (m, 4H), 7.69 - 7.58 (m, 5H), 7.53 - 7.33 (m, 5H), 7.28 (m, 3H), 7.14 (d, J = 8.5 Hz, 
2H), 7.06 (d, J = 6.6 Hz, 2H), 5.59 (s, 2H), 4.81 (m, 1H), 4.68 (d, J = 9.8 Hz, 1H), 3.67 (d, J = 
13.0 Hz, 1H), 3.30 (m, 2H), 3.09 (m, 1H), 2.91 (t, J = 12.1 Hz, 1H), 2.83 (dt, J = 2.7 Hz, J = 
12.7 Hz, 1H), 1.74 (d, J = 14.3 Hz, 1H), 1.54 (q, J = 14.0 Hz, 1H), 1.18 (d, J = 12.1 Hz, 1H), 
1.09 (q, J = 11.2 Hz, 1H). LC-MS:5min_A: tR=1.65min, 10min_C: tR= 3.37min. LC-MS (ESI) 
C40H37N5O calcd: 603, found: 604 [M+H]+.LC-MS (ESI, HR-MS): calcd for C40H37N5O: 
604.30709. [M+H]+ found 604.30876 [M+H]+. 
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1-Benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-3-yl)ethoxy)phenyl)-
1H-benzo[d]imidazole (diastereoisomer 2) (71) The product was synthesized by Carsten 
Schultz-Fademrecht, LDC Dortmund. 1H NMR (400 MHz, CD3OD) δ 8.05 (d, J = 7.6 Hz, 1H), 
7.79 (m, 3H), 7.74 (d, J = 7.3 Hz, 1H), 7.68 - 7.63 (m, 5H), 7.60 - 7.33 (m, 5H), 7.30 (m, 3H), 
7.12 (d, J = 8.5 Hz, 2H), 7.07 (dd, J = 2.4 Hz, J = 7.7 Hz, 2H), 5.62 (s, 2H), 4.77 (m, 1H), 4.71 
(d, J = 10.1 Hz, 1H), 3.32 (m, 1H), 3.14 (m, 1H), 2.85 (dt, J = 2.9 Hz, J = 13.2 Hz, 1H), 2.69 
(d, J = 12.8 Hz, 1H), 2.55 (m, 1H), 2.22 (d, J = 10.5 Hz, 1H), 1.89 (d, J =15.0 Hz, 1H), 1.84 (m, 
1H), 1.40 (m, 2H). LC-MS: 5min_A: tR=1.61min, 10min_C: tR=3.26min. MS (ESI) C40H37N5O 
calcd: 603, found: 604 [M+H]+. LC-MS (ESI, HR-MS): calcd for C40H37N5O: 604.30709. 
[M+H]+ found 604.30839 [M+H]+. 
 
1-Benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-3-(piperidin-4-
yl)propoxy)phenyl)-1H-benzo[d]imidazole (72) The product was synthesized by Carsten 
Schultz-Fademrecht, LDC Dortmund.1H NMR (400 MHz, CD3OD, 300K) δ 7.89 (d, J = 8.2 
Hz, 1H), 7.83 (m, 2H), 7.72 (m, 2H), 7.59 (m, 5H), 7.44 - 7.23 (m, 8H), 7.06 (d, J = 8.6 Hz, 
2H), 7.02 (d, J = 6.9 Hz, 2H), 5.52 (s, 2H), 5.09 (m, 1H), 4.93 (t, J = 10.1 Hz, 1H), 4.53 (dd, J 
= 4.2 Hz, 10.1 Hz, 1H), 3.17 (m, 3H), 2.72 (m, 2H), 2.41 (t, J = 11.5 Hz, 1H), 1.86 (m, 1H), 
1.52 (d, J = 15.4 Hz, 1H), 1.31 (m, 2H), 1.16 (m, 1H). LC-MS: 5min_A: tR=1.60min, 10min_C: 
tR= 3.23min. MS (ESI) C41H39N5Ocalcd: 617, found: 618 [M+H]+.LC-MS (ESI, HR-MS): calcd 
for C41H39N5O: 618.32479 [M+H]+, found 618.30839 [M+H]+. 
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Procedures for the synthesis of benzimidazole fragments  
 
Ethyl 1-(1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate (77) To a solution of 2-chloro 
benzimidazole (6.0 g, 39.3 mmol) in NMP (40 mL) was added 4-carboxyethyl piperidine (16.5 
g, 105 mmol) and diisopropylethylamine (13.4 mL, 78.2 mmol). The reaction mixture was 
heated to 90°C and stirred for 16 h. Water (100 mL) was added and stirring was continued for 
an additional 20 min. The precipitate was collected by filtration and washed with water (3x 100 
mL) and EtOAc (3x 30 mL) to yield the desired compound (8.67 g, 81% mmol). 1H NMR (400 
MHz, CDCl3) δ 7.33 – 7.08 (m, 2H), 7.03 – 6.81 (m, 2H), 4.18 – 3.98 (m, 4H), 3.20 – 3.00 (m, 
2H), 2.52 – 2.38 (m, 1H), 1.94 (d, J = 12.5 Hz, 2H), 1.83 – 1.66 (m, 2H), 1.29 – 1.07 (m, 
3H). 13C NMR (101 MHz, CDCl3) δ 174.59, 156.47, 120.45, 60.73, 46.33, 41.05, 27.65, 
14.39. LC-MS (ESI): calcd for  C15H19N3O2:  274.15500 [M+H]
+, found: 274.16 [H]+, Rt = 5.75 
min; HR-MS found 274.15523 [M+H]+. 
 
Ethyl 1-(1-benzyl-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate (78) The product 
was synthesized by procedure A starting from compound 77 (140 mg, 0.38 mmol, 85%).1H 
NMR (400 MHz, DMSO-d6) δ 7.46 – 6.96 (m, 9H), 5.25 (s, 2H), 4.15 – 3.99 (m, 2H), 3.41 (d, 
J = 12.3 Hz, 2H), 2.95 (t, J = 11.2 Hz, 2H), 2.60 – 2.50 (m, 1H), 1.93 – 1.62 (m, 4H), 1.16 (t, J 
= 6.9 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 174.73, 158.51, 141.99, 137.66, 135.78, 
129.37, 128.02, 127.09, 121.93, 121.50, 118.02, 110.43, 60.61, 50.42, 47.53, 40.57, 28.09, 
14.77. LC-MS (ESI): calcd for C22H25N3O: 364.19 [M+H]+, found: 364.22 [H]+, Rt = 8.01 min. 
 
Ethyl 1-(1-(2-chloro-6-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate 
(79) The product was synthesized from ethyl 1-(1H-benzo[d]imidazol-2-yl)piperidine-4-
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carboxylate (77) (100 mg, 0.37 mmol) according to General Procedure A for the alkylation of 
benzimidazoles. The crude product was purified by automated flash chromatography using a 
gradient of cyclohexane and ethyl acetate 20:1 to 1:2 to yield compound 79 
(141 mg, 0.34 mmol, 92%). 1H NMR (400 MHz, DMSO-d6) δ 7.42 – 7.33 (m, 2H), 7.31 – 7.26 
(m, 1H), 7.25 – 7.17 (m, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.95 – 6.90 (m, 2H), 5.39 (s, 2H), 4.08 
(q, J = 7.1 Hz, 2H), 3.43 – 3.37 (m, 2H), 3.01 – 2.89 (m, 2H), 2.58 – 2.49 (m, 1H), 1.95 – 1.83 
(m, 2H), 1.80 – 1.67 (m, 2H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 
174.81, 161.97 (C-FJ = 249.2 Hz), 159.01, 142.06, 135.14 (C-FJ=5.4 hz), 134.52, 131.53(C-
FJ=9.9 Hz), 126.60 (C-FJ=3.2 Hz), 122.17 (C-FJ=16.5 Hz), 121.72, 121.42, 118.33, 115.41(C-
FJ=22.2 Hz), 109.94, 60.61, 50.59, 28.22, 14.79.LC-MS (ESI): calcd for  C22H23ClFN3O2: 
416.15356 [M+H]+, found: 416.13 [H]+, Rt = 7.03 min; HR-MS found 416.15341 [M+H]
+. 
 
Ethyl 1-(1-(thiophen-3-ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate 
(80) To a mixture of benzimidazole (2.0 g, 7.3 mmol), 3-hydroxymethyl thiophene 
(2.5 g, 22.0 mmol) and tri-n-butyl phosphine (5.4 mL, 22.0 mmol) in THF (20 mL) was added 
at 0°C TMAD (3.8 g, 22.0 mmol) in one portion. The resulting suspension was allowed to warm 
to room temperature and stirred at this temperature for 3 h. The reaction mixture was 
concentrated in vacuo and the residue was purified by column chromatography (petroleum ether 
: ethyl acetate 5:1 to 1:1) to afford the desired compound (61%, 1.6 g). 1H NMR (400 MHz, 
CDCl3) δ 7.62 (dt, J = 7.9, 1.0 Hz, 1H), 7.32 (dd, J = 5.0, 3.0 Hz, 1H), 7.21 – 7.16 (m, 1H), 
7.12 – 7.09 (m, 2H), 7.02 (dd, J = 3.0, 1.3 Hz, 1H), 6.96 (dd, J = 5.0, 1.3 Hz, 1H), 5.18 (s, 2H), 
4.16 (q, J = 7.1 Hz, 2H), 3.49 (dt, J = 6.7, 3.1 Hz, 2H), 3.02 (td, J = 12.5, 2.7 Hz, 2H), 2.48 (tt, 
J = 11.1, 4.1 Hz, 1H), 2.05 – 1.95 (m, 2H), 1.95 – 1.79 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 174.81, 158.38, 141.80, 137.71, 135.44, 127.28, 126.23, 122.15, 
121.71, 121.70, 118.40, 109.49, 60.77, 50.73, 44.18, 41.10, 28.32, 14.45 LC-MS (ESI): calcd 
for  C20H23N3O2S: 370.15837 [M+H]
+, found:  370.13 [M+H]+, Rt = 6.60 min; HR-MS found 
370.15890 [M+H]+. 
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1-(1-Benzyl-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylic acid (81) To ester 78 
(1.10 g, 3.0 mmol) in MeOH/H2O (30 mL, 10/1 vol/vol) was added KOH (0.84 g, 15 mmol) at 
room temperature. The resulting reaction mixture was stirred at room temperature for 5 h. The 
pH was adjusted with 20% acetic acid in H2O to 6 and the aqeous phase was extracted with 
DCM (4x 30 mL). The combined organic phases were dried over Na2SO4,filtered and 
concentrated in vacuo to afford 81 (0.93 g, 92 %).  1H NMR (400 MHz, DMSO-d6) δ 12.17 (s, 
1H), 7.43 (d, J = 7.8 Hz, 1H), 7.31 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.3 Hz, 1H), 7.16 (d, J = 7.5 
Hz, 3H), 7.09 (t, J = 7.4 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 5.27 (s, 2H), 3.49 – 3.40 (m, 2H), 
3.04 – 2.90 (m, 2H), 2.47 – 2.39 (m, 1H), 1.88 – 1.80 (m, 2H), 1.78 – 1.63 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 176.35, 172.61, 137.46, 135.50, 129.38, 128.06, 127.08, 122.17, 121.72, 
117.56, 110.55, 50.42, 47.68, 28.12, 21.71. LC-MS (ESI): calcd for  C20H21N3O2:  336.17065 
[M+H]+, found: 336.17 [M+H]+, Rt = 5.82 min; HR-MS found 336.17101 [M+H]
+.  
 
1-(1-(Thiophen-3-ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylic acid (82) 
To ester 80 (1.6 g, 4.5 mmol) in MeOH/H2O (40 mL, 10/1 vol/vol) was added KOH (1.3 g, 23 
mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 
5 h. The pH was adjusted with 20% acetic acid in H2O to 6 and the aqueous phase was extracted 
with DCM (4 x 40 mL). The combined organic phases were dried over Na2SO4 and concentrated 
in vacuo to afford the desired compound (1.4 g, 89 %,). 1H NMR (400 MHz, DMSO-d6) δ 
12.23 (s, 1H), 7.49 (dd, J = 5.0, 3.0 Hz, 1H), 7.40 (d, J = 7.1 Hz, 1H), 7.29 (s, 1H), 7.23 (d, J = 
7.5 Hz, 1H), 7.08 – 7.00 (m, 2H), 6.94 (d, J = 4.9 Hz, 1H), 5.21 (s, 2H), 3.47 – 3.41 (m, 2H), 
3.00 – 2.89 (m, 2H), 2.47 – 2.39 (m, 1H), 1.93 – 1.83 (m, 2H), 1.82 – 1.69 (m, 2H). 13C NMR 
(151 MHz, DMSO) δ 176.50, 158.34, 138.47, 135.64, 127.85, 127.34, 125.99, 123.01, 121.88, 
121.46, 117.96, 110.40, 50.59, 43.63, 28.22, 21.73. LC-MS (ESI): calcd for C18H19N3O2S: 
342.12707 [M+H]+, found:  342.10 [M+H]+, Rt = 5.74 min; HR-MS found 342.12747 [M+H]
+. 
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1-(1-(2-Chloro-6-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylic acid 
(83) To a solution of the ester 79 (0.82 g, 2.0 mmol) in HCl/dioxane (4 M, 10 mL) was added 
water until the formation of a precipitate was observed. The reaction mixture was stirred at 
room temperature for 2 d, concentrated in vacuo, the pH of the aqueous residue was adjusted to 
6 with sat. NaHCO3 and the aqueous layer was extracted with DCM (5 x 40 mL). The combined 
organic phases were dried (Na2SO4), filtered and concentrated in vacuo to afford the desired 
product (0.65 g, 85%). 1H NMR (400 MHz, DMSO-d6) δ 7.41 – 7.34 (m, 2H), 7.29 (d, J = 7.8 
Hz, 1H), 7.21 (t, J = 9.1 Hz, 1H), 7.04 – 6.97 (m, 1H), 6.97 – 6.90 (m, 2H), 5.40 (s, 2H), 3.46 
– 3.37 (m, 2H), 3.02 – 2.87 (m, 2H), 2.47 – 2.39 (m, 1H), 1.90 (dd, J = 13.2, 3.2 Hz, 2H), 1.80 
– 1.64 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 176.51, 163.22, 160.74, 159.08, 142.07, 
135.18, 135.12, 134.53, 131.56, 131.46, 126.60, 126.57, 122.26, 122.10, 121.72, 121.40, 
118.32, 115.51, 115.29, 109.94, 67.04, 50.74, 28.31. LC-MS (ESI): calcd for  C20H19ClFN3O2: 
388.12226 [M+H]+, found: 388.10 [M+H]+, Rt = 6.27 min; HR-MS found 388.12330 [M+H]+. 
General Procedure E for esterification of two benzimidazole units 
 
To a mixture of carboxylic acid, alcohol (1.0 eq) and polymer bound triphenylphosphine 
(3 meq) in THF/toluene (1:1, 3 mL/ mmol benzimidazole) was added at 0°C di-tert-butyl 
azodicarboylate (3eq). The reaction mixture is stirred at room temperature for 16 h, diluted with 
DCM (15 mL/mmol benzimidazole) and filtered. The filtrate was concentrated in vacuo and 
purified by automated flash chromatography as described below.  
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2-Cyclohexyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl) ethyl 1-(1-benzyl-1H-
benzo[d]imidazol-2-yl)piperidine-4-carboxylate (84) The product was synthesized from 
alcohol 52 (40 mg, 0.12 mmol) and carboxylic acid 81 according to Procedure E for the 
esterification via Mitsunobu reaction. The crude product was purified by automated flash 
chromatography using a gradient of cyclohexane and ethyl acetate 50:1 to 1:2 to yield the 
product (57 mg, 0.09 mmol, 61%). 1H NMR (600 MHz, DMSO-d6) δ 8.03 (s, 1H), 7.77 – 7.69 
(m, 3H), 7.66 – 7.56 (m, 3H), 7.54 (t, J = 7.8 Hz, 1H), 7.42 – 7.21 (m, 10H), 5.38 (s, 2H), 4.84 
(t, J = 10.7 Hz, 1H), 4.62 – 4.52 (m, 1H), 4.43 (t, J = 8.0 Hz, 1H), 3.66 – 3.55 (m, 1H), 3.56 – 
3.43 (m, 1H), 3.28 – 3.10 (m, 2H), 2.62 – 2.52 (m, 1H), 2.40 (d, J = 10.4 Hz, 1H), 1.87 (d, J = 
10.8 Hz, 1H), 1.72 – 1.57 (m, 3H), 1.57 – 1.32 (m, 4H), 1.32 – 1.14 (m, 1H), 1.09 – 0.83 (m, 
4H), 0.73 – 0.57 (m, 1H). 13C NMR (151 MHz, DMSO-d6) δ 173.73, 159.32, 159.09, 158.86, 
158.63, 154.12, 153.28, 135.48, 132.98, 131.61, 130.74, 129.67, 129.63, 128.58, 126.89, 
125.00, 124.71, 124.46, 118.46, 117.82, 115.87, 114.20, 113.41, 112.03, 109.99, 63.47, 62.19, 
49.29, 48.97, 39.23, 37.42, 30.54, 29.64, 27.43, 27.36, 26.01, 25.75. LC-MS (ESI): calcd for 
C41H43N5O2: 638.34895 [M+H]
+, found: 638.34 [M+H]+, Rt = 7.79 min; HR-MS found 
638.34934 [M+H]+.  
 
2-Cyclohexyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl 1-(1-(2-chloro-6-fluorobenzyl)-
1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate (85) The product was synthesized from 
alcohol 52 (40 mg, 0.12 mmol) and carboxylic acid 83 according to Procedure E for the 
esterification via Mitsunobu reaction. The crude product was purified by automated flash 
chromatography using a gradient of cyclohexane and ethyl acetate 20:1 to 1:2 to yield the 
product (56 mg, 0.08 mmol, 56%). 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.77 (m, 1H), 7.70 (d, 
J = 5.5 Hz, 2H), 7.61 – 7.44 (m, 5H), 7.33 – 7.24 (m, 3H), 7.24 – 7.07 (m, 3H), 7.06 – 6.83 (m, 
3H), 5.31 (s, 2H), 4.87 – 4.70 (m, 1H), 4.56 (dd, J = 11.7, 3.7 Hz, 1H), 4.49 (td, J = 10.3, 3.9 
Hz, 1H), 3.47 – 3.11 (m, 2H), 3.09 – 2.84 (m, 2H), 2.48 – 2.15 (m, 2H), 1.98 – 1.83 (m, 1H), 
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1.86 – 1.51 (m, 7H), 1.29 – 0.93 (m, 5H), 0.80 – 0.53 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
174.36, 163.26, 160.77, 158.67, 141.76, 135.72, 135.67, 133.90, 130.46, 130.37, 130.18, 
129.93, 128.83, 126.08, 126.05, 122.94, 122.66, 121.89, 121.71, 121.61, 121.45, 120.64, 
118.66, 114.77, 114.54, 112.11, 109.78, 63.70, 61.52, 50.93, 50.70, 40.95, 40.00, 39.96, 38.37, 
31.14, 30.40, 29.78, 28.08, 28.00, 26.05, 25.94, 25.84. LC-MS (ESI): calcd for C41H41ClFN5O2:  
690.30056 [M+H]+, found: 690.30 [M+H]+, Rt = 7.81 min; HR-MS found 690.30137 [M+H]
+. 
 
 
2-Cyclohexyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl 1-(1-(thiophen-3-ylmethyl)-
1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate (86) The product was synthesized from 
alcohol 52 (40 mg, 0.12 mmol) and carboxylic acid 82 according to Procedure E for the 
esterification via Mitsunobu reaction. The crude product was purified by automated flash 
chromatography using a gradient of cyclohexane and ethyl acetate 20:1 to 1:2 to yield the 
product (52 mg, 0.08 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.4 Hz, 1H), 7.72 
– 7.63 (m, 2H), 7.63 – 7.42 (m, 4H), 7.34 – 7.21 (m, 4H), 7.21 – 7.15 (m, 1H),   7.14 – 7.05 (m, 
2H), 7.01 – 6.97 (m, 1H), 6.92 (d, J = 5.0 Hz, 1H), 5.11 (s, 2H), 4.84 – 4.72 (m, 1H), 4.61 – 
4.39 (m, 2H), 3.46 – 3.24 (m, 2H), 3.04 – 2.71 (m, 2H), 2.39 – 2.11 (m, 2H), 1.97 – 1.81 (m, 
1H), 1.84 – 1.47 (m, 7H), 1.34 – 0.92 (m, 5H), 0.81 – 0.62 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 174.29, 158.15, 141.72, 137.61, 135.39, 130.18, 129.95, 128.83, 127.29, 126.22, 
122.94, 122.66, 122.16, 121.75, 121.73, 120.65, 118.40, 109.49, 63.65, 61.45, 50.56, 50.38, 
44.10, 40.90, 38.39, 31.12, 29.80, 27.97, 27.94, 26.05, 25.94, 25.84.LC-MS (ESI): calcd for 
C39H41N5O2S: 644.30537 [M+H]
+, found: 644.31 [M+H]+, Rt = 7.53 min; HR-MS found 
644.30594 [M+H]+. 
 
tert-butyl 4-(2-(1-(1-benzyl-1H-benzo[d]imidazol-2-yl)piperidine-4-carbonyloxy)-1-(2-
phenyl-1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (87) The product was 
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synthesized from alcohol 53 (63 mg, 0.15 mmol) and carboxylic acid 81 according to Procedure 
E for the esterification via Mitsunobu reaction. The crude product was purified by automated 
flash chromatography using a gradient of cyclohexane and ethyl acetate 20:1 to 1:2 to yield the 
desired product (70 mg, 0.10 mmol, 64%). 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 
1H), 7.63 – 7.50 (m, 3H), 7.50 – 7.38 (m, 4H), 7.31 – 7.16 (m, 5H), 7.15 – 6.98 (m, 4H), 6.95 
(d, J = 7.8 Hz, 1H), 5.08 (s, 2H), 4.75 (t, J = 10.2 Hz, 1H), 4.51 – 4.30 (m, 2H), 4.14 – 3.96 (m, 
1H), 3.95 – 3.69 (m, 1H), 3.41 – 3.14 (m, 2H), 2.97 – 2.72 (m, 2H), 2.63 (t, J = 12.0 Hz, 1H), 
2.51 – 2.14 (m, 3H), 1.84 – 1.41 (m, 4H), 1.39 – 1.04 (m, 10H), 1.04 – 0.63 (m, 3H).13C NMR 
(101 MHz, CDCl3) δ 174.16, 158.09, 155.58, 154.75, 143.80, 136.34, 135.40, 133.42, 130.67, 
130.15, 130.10, 129.23, 128.99, 127.93, 126.24, 123.18, 122.92, 122.34, 121.91, 120.87, 
118.24, 111.79, 109.67, 79.97, 63.33, 60.90, 50.50, 50.35, 47.86, 40.80, 36.99, 30.13, 28.82, 
28.60, 27.92, 27.88. LC-MS (ESI): calcd for C45H50N6O4: 739.39663 [M+H]
+, found: 739.39 
[M+H]+, Rt = 7.38 min; HR-MS found 739.39738 [M+H]
+. Chiral HPLC conditions: flow rate: 
0.35 mL/min; solvent: 75 % ethanol in iso-hexane. RT: (R)-26.5 min, (S)-56.8 min. 
 
tert-Butyl 4-(2-(1-(1-(2-chloro-6-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-
carbonyloxy)-1-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (88) 
The product was synthesized from alcohol 53 (75 mg, 0.18 mmol) and carboxylic acid 
83  according to Procedure E for the esterification via Mitsunobu reaction. The crude product 
was purified by automated flash chromatography using a gradient of cyclohexane and 
ethyl acetate 20:1 to 1:2 to yield the desired compound (86 mg, 0.11 mmol, 61%). 1H NMR 
(400 MHz, CDCl3) δ 7.91 – 7.77 (m, 1H), 7.76 – 7.63 (m, 2H), 7.63 – 7.41 (m, 5H), 7.35 – 7.24 
(m, 2H), 7.24 – 7.06 (m, 3H), 7.05 – 6.87 (m, 3H), 5.31 (s, 2H), 4.84 (t, J = 10.1 Hz, 1H), 4.61 
– 4.44 (m, 2H), 4.23 – 4.06 (m, 1H), 4.00 – 3.85 (m, 1H), 3.42 – 3.24 (m, 2H), 3.06 – 2.88 (m, 
2H), 2.71 (t, J = 12.2 Hz, 1H), 2.53 – 2.31 (m, 3H), 1.92 – 1.58 (m, 4H), 1.42 (s, 9H), 1.31 – 
1.14 (m, 2H), 1.09 – 0.79 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 174.29, 163.25, 160.76, 
158.60, 155.61, 154.76, 143.79, 141.68, 135.70, 135.65, 133.87, 133.43, 130.66, 130.50, 
130.40, 130.16, 130.13, 129.00, 126.09, 126.05, 123.20, 122.94, 121.94, 121.76, 121.58, 
121.42, 120.87, 118.64, 114.78, 114.55, 111.84, 109.82, 79.98, 63.35, 60.95, 50.88, 50.68, 
40.93, 40.00, 39.96, 36.99, 30.14, 28.82, 28.60, 28.08, 28.00, 27.13. LC-MS (ESI): calcd for 
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C45H48ClFN6O4: 791.34824 [M+H]
+, found: 791.30 [M+H]+, Rt = 8.00 min; HR-MS found 
791.34737 [M+H]+. 
 
tert-Butyl 4-(1-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(1-(1-(thiophen-3-ylmethyl)-1H-
benzo[d]imidazol-2-yl)piperidine-4-carbonyloxy)ethyl)piperidine-1-carboxylate (89) The 
product was synthesized from alcohol 53 (80 mg, 0.19 mmol) and carboxylic acid 82 according 
to Procedure E for the esterification via Mitsunobu reaction. The crude product was purified by 
automated flash chromatography using a gradient of cyclohexane and ethyl acetate 20:1 to 1:2 
to afford the desired compound (95 mg, 0.13 mmol, 67%). 1H NMR (400 MHz, CDCl3) δ 7.82 
(d, J = 7.7 Hz, 1H), 7.66 (s, 2H), 7.59 (t, J = 8.4 Hz, 1H), 7.57 – 7.45 (m, 4H), 7.36 – 7.22 (m, 
3H), 7.23 – 7.14 (m, 1H), 7.14 – 7.05 (m, 2H), 6.97 (d, J = 1.6 Hz, 1H), 6.91 (d, J = 5.0 Hz, 
1H), 5.11 (s, 2H), 4.83 (t, J = 10.0 Hz, 1H), 4.59 – 4.42 (m, 2H), 4.15 (d, J = 11.3 Hz, 1H), 4.03 
– 3.86 (m, 1H), 3.50 – 3.23 (m, 2H), 3.02 – 2.79 (m, 2H), 2.78 – 2.62 (m, 1H), 2.54 – 2.25 (m, 
3H), 1.85 (d, J = 11.8 Hz, 1H), 1.79 – 1.53 (m, 4H), 1.40 (s, 9H), 1.23 (d, J = 11.9 Hz, 1H), 
1.00 (d, J = 26.4 Hz, 1H), 0.92 (d, J = 9.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 174.21, 
158.07, 155.60, 154.75, 143.82, 141.66, 137.58, 135.36, 133.42, 130.69, 130.16, 130.12, 
129.00, 127.32, 126.20, 123.18, 122.93, 122.20, 121.79, 121.72, 120.88, 118.39, 111.79, 
109.50, 79.98, 63.31, 60.90, 50.53, 50.36, 44.10, 40.88, 37.01, 30.13, 28.83, 28.60, 27.97, 
27.93. LC-MS (ESI): calcd for C43H48N6O4S:  745.35305 [M+H]
+, found: 745.33  [M+H]+, Rt 
= 7.35 min; HR-MS found 745.35302 [M+H]+. Chiral HPLC conditions: flow rate: 
0.35 mL/min; solvent: 75 % ethanol in iso-hexane. RT: (R)-26.8 min, (S)-54.6 min. 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl 1-(1-benzyl-1H-
benzo[d]imidazol-2-yl)piperidine-4-carboxylate (90) The product was synthesized according 
to General Procedure (D) starting from the protected piperidine 87 (15 mg,0.02 mmol) to afford 
the HCl-salt in quantitative yield. The residue was dissolved in methanol (500 µL) and applied 
to a preparative C18-RP column eluting with a gradient (CH3CN: H2O 1:5 to 9:1 containing 
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0.1% TFA), to afford piperidine 90 (9 mg, 0.01 mmol, 71%) as a TFA-salt. 1H NMR (600 MHz, 
DMSO-d6) δ 9.08 (s, 1H), 8.78 (s, 1H), 8.07 (s, 1H), 7.81 – 7.72 (m, 3H), 7.72 – 7.59 (m, 3H), 
7.56 (d, J = 7.8 Hz, 1H), 7.43 (s, 2H), 7.39 – 7.30 (m, 5H), 7.28 (t, J = 7.7 Hz, 1H), 7.24 (d, J 
= 7.5 Hz, 2H), 5.39 (s, 2H), 4.83 (t, J = 10.4 Hz, 1H), 4.57 (d, J = 11.3 Hz, 1H), 4.54 – 4.43 (m, 
1H), 3.65 (d, J = 12.1 Hz, 1H), 3.57 (d, J = 11.9 Hz, 1H), 3.33 – 3.17 (m, 3H), 3.04 (d, J = 11.3 
Hz, 1H), 2.85 – 2.72 (m, 2H), 2.72 – 2.54 (m, 2H), 1.97 (d, J = 12.3 Hz, 1H), 1.69 – 1.58 (m, 
2H), 1.58 – 1.44 (m, 2H), 1.40 (d, J = 10.8 Hz, 1H), 1.28 – 1.07 (m,2H). LC-MS (ESI): calcd 
for C40H42N6O2: 639.34420 [M+H]
+, found: 639.36 [M+H]+, Rt = 5.41 min; HR-MS found 
639.34491 [M+H]+. 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl 1-(1-(2-chloro-6-
fluorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate (91) The product was 
synthesized according to General Procedure (D) starting from the protected piperidine 
88 (15 mg,0.02 mmol) to afford the HCl-salt in quantitative yield. The residue was dissolved 
in methanol (500 µL) and applied to a preparative C18-RP column eluting with a gradient 
(CH3CN: H2O 1:5 to 9:1 containing 0.1% TFA), to afford the product (9 mg, 0.01 mmol, 65%) 
as the TFA-Salt. 1H NMR (400 MHz, DMSO-d6) δ 9.58 – 9.37 (m, 1H), 9.34 – 9.07 (m, 1H), 
8.38 – 8.20 (m, 1H), 7.98 – 7.81 (m, 3H), 7.80 – 7.71 (m, 3H), 7.64 – 7.55 (m, 3H), 7.49 – 7.37 
(m, 1H), 7.37 – 7.15 (m, 5H), 7.16 – 7.01 (m, 1H), 5.54 (s, 2H), 4.94 – 4.78 (m, 1H), 4.77 – 
4.46 (m, 2H), 3.88 – 3.73 (m, 2H), 3.40 – 3.32 (m, 2H), 3.32 – 3.15 (m, 1H), 3.07 – 2.96 (m, 
1H), 2.96 – 2.77 (m, 2H), 2.77 – 2.57 (m, 2H), 2.09 – 1.88 (m, 1H), 1.80 – 1.40 (m, 4H), 1.40 
– 1.12 (m, 3H). 13C NMR (101 MHz, DMSO-d6) δ 173.66, 162.99, 160.51, 153.22, 152.23, 
134.92, 134.87, 133.23, 132.54, 132.44, 131.22, 131.03, 130.15, 129.97, 126.92, 126.61, 
125.28, 124.71, 120.13, 119.98, 116.37, 115.90, 115.68, 115.39, 113.45, 111.98, 72.84, 71.20, 
67.03, 62.98, 62.16, 60.84, 49.58, 49.24, 44.31, 42.94, 39.16, 27.72, 26.20, 25.68. LC-MS 
(ESI): calcd for C40H40ClFN6O2: 691.29581 [M+H]
+, found: 691.26 [M+H]+, Rt = 5.63 min; 
HR-MS found 691.29659 [M+H]+. 
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2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl 1-(1-(thiophen-3-
ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate (92) The product was 
synthesized according to General Procedure (D) starting from the protected piperidine 
(61 mg, 0.08 mmol) to afford the HCl-salt in quantitative yield. The residue was dissolved in 
methanol (500 µL) and applied to a preparative C18-RP column eluting with a gradient 
(CH3CN: H2O 1:5 to 9:1 containing 0.1% acetic acid), to afford free piperidine 92 (33 
mg, 0.005 mmol, 59%). 1H NMR (600 MHz, DMSO-d6) δ 7.84 (d, J = 6.0 Hz, 1H), 7.69 – 7.62 
(m, 3H), 7.58 – 7.50 (m, 3H), 7.51 – 7.46 (m, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.26 – 7.17 (m, 4H), 
7.08 – 6.99 (m, 2H), 6.92 – 6.87 (m, 1H), 5.15 (s, 2H), 4.89 – 4.77 (m, 1H), 4.54 (dd, J = 12.0, 
3.5 Hz, 1H), 4.48 – 4.34 (m, 1H), 3.32 (d, J = 12.6 Hz, 1H), 3.24 (d, J = 12.5 Hz, 1H), 3.01 – 
2.78 (m, 4H), 2.72 (d, J = 11.8 Hz, 1H), 2.45 – 2.36 (m, 1H), 2.26 – 2.18 (m, 1H), 1.80 – 1.76 
(m, 1H), 1.64 – 1.38 (m, 4H), 1.14 – 1.05 (m, 1H), 0.86 – 0.70 (m, 2H). 13C NMR (151 MHz, 
DMSO-d6) δ 174.30, 158.13, 155.48, 143.70, 141.96, 138.43, 135.64, 133.83, 131.19, 130.50, 
130.37, 129.35, 127.87, 127.28, 123.22, 122.93, 122.78, 121.88, 121.47, 120.28, 117.96, 
113.16, 110.36, 109.99, 63.22, 61.45, 50.12, 45.73, 45.62, 43.61, 36.18, 29.43, 27.81, 
27.68. LC-MS (ESI): calcd for C38H40N6O2S: 645.30062 [M+H]
+, found: 645.27 [M+H]+, Rt = 
5.31 min; HR-MS found 645.30123 [M+H]+. 
 
3-Methyl-2-(2-phenyl-1H-benzo[d]imidazol-1-yl)butyl 1-(1-benzyl-1H-benzo[d]imidazol-
2-yl)piperidine-4-carboxylate (93) The product was synthesized by Carsten Schultz-
Fademrecht, LDC Dortmund. 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 7.8 Hz, 1H), 7.67 (m, 
2H), 7.62 (t, J = 7.9 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.50 - 7.46 (m, 3H), 7.34 - 7.23 (m, 5H), 
7.19 (t, J = 7.8 Hz, 1H), 7.14 (d, J = 7.4 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 7.02 (d, J = 8.0 Hz, 
1H), 5.15 (s, 2H), 4.77 (m, 1H), 4.53 (dd, J = 3.8 Hz, J = 12.2 Hz, 1H), 4.39 (dt, J = 3.8 Hz, J = 
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10.2 Hz, 1H), 3.39 (d, J = 12.2 Hz, 1H), 3.32 (d, J = 12.6 Hz, 1H), 2.91 (m, 2H), 2.64 (m, 1H), 
2.31 (m, 1H), 1.75 - 1.52 (m, 4H), 1.09 (d, J = 6.6 Hz, 3H), 0.68 (d, J = 6.6 Hz, 3H).LC-MS: 
5min_B: tR=2.88min, 10min_D: tR= 4.54min.MS (ES) C38H39N5O2 calcd: 597, found: 598 
[M+H]+. LC-MS: 5min_B: Rt=2.88min, 10min_D: Rt=4.54min.MS (ESI) C38H39N5O2 calcd: 
597, found: 598 [M+H]+. LC-MS (ESI, HR-MS): calcd for C38H39N5O2: 598.31765. [M+H]+ 
found 598.31918 [M+H]+. 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-3-yl)ethyl 1-(1-benzyl-1H-
benzo[d]imidazol-2-yl)piperidine-4-carboxylate (diastereoisomer 1) (94) The product was 
synthesized by Carsten Schultz-Fademrecht, LDC Dortmund.1H NMR (400 MHz, CDCl3) δ 
7.80 (d, J = 7.9 Hz, 1H), 7.68 (m, 2H), 7.62 (d, J = 7.7 Hz, 1H), 7.57 (d, J = 6.7 Hz, 1H), 7.49 
(m, 3H), 7.29 (m, 5H), 7.18 (t, J = 7.6 Hz, 1H), 7.13 (d, J = 7.1 Hz, 2H), 7.09 (t, J = 7.5 Hz, 
1H), 7.02 (d, J = 7.9 Hz, 1H), 5.15 (s, 2H), 4.79 (t, J = 10.5 Hz, 1H), 4.55 (t, J = 10.5 Hz, 1H), 
4.49 (dd, J = 3.9 Hz, J = 11.5 Hz, 1H), 3.36 (dd, J = 14.4 Hz, J = 14.0 Hz, 2H), 3.27 (d, J = 10.2 
Hz, 1H), 2.91 (m, 3H), 2.46 (m, 3H), 2.32 (m, 1H) 1.71 (m, 3H), 1.60 (t, J = 12.9 Hz, 1H), 1.44 
(m, 1H), 1.28 (m, 2H), 0.86 (m, 1H). LC-MS: 5min_B: Rt=1.98min, 10min_D: Rt =3.33min. 
LC-MS (ESI) C40H42N6O2 calcd: 638, found: 639 [M+H]+.LC-MS (ESI, HR-MS): calcd for 
C40H42N6O2: 639.34402. [M+H]+ found 639.34605 [M+H]+. 
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2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-3-yl)ethyl 1-(1-benzyl-1H-
benzo[d]imidazol-2-yl)piperidine-4-carboxylate (diastereoisomer 2) (95) The product was 
synthesized by Carsten Schultz-Fademrecht, LDC Dortmund.1H NMR (400 MHz, CDCl3) δ 
7.79 (d, J = 7.1 Hz, 1H), 7.72 (m, 2H), 7.62 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.48 
(m, 3H), 7.34 - 7.24 (m, 5H), 7.18 (dt, J = 1.1 Hz, J = 7.7 Hz, 1H), 7.13 (d, J = 8.0 Hz, 2H), 
7.09 (dt, J =1.1 Hz, J = 7.3 Hz, 1H), 7.02 (d, J = 8.0 Hz, 1H), 5.15 (s, 2H), 4.76 (t, J = 10.4 Hz, 
1H), 4.58 (t, J = 9.9 Hz, 1H), 4.51 (dd, J = 3.5 Hz, J = 11.6 Hz, 1H), 3.39 (d, J = 12.4 Hz, 1H), 
3.32 (d, J = 12.3 Hz, 1H), 2.91 (m, 3H), 2.50 (m, 3H), 2.30 (m, 1H), 2.15 (t, J = 10.9 Hz, 1H), 
2.00 (m, 1H), 1.74 - 1.49 (m, 6H), 1.23 (m, 1H).LC-MS: 5min_B: Rt=1.98min, 10min_D: Rt 
=3.14min. MS (ESI) C40H42N6O2 calcd: 638, found: 639 [M+H]+.LC-MS (ESI, HR-MS): calcd 
for C40H42N6O2: 639.34402 [M+H]+ found 639.34598 [M+H]+. 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(pyrrolidin-3-yl)ethyl 1-(1-benzyl-1H-
benzo[d]imidazol-2-yl)piperidine-4-carboxylate (diastereoisomer 1) (96) The product was 
synthesized by Carsten Schultz-Fademrecht, LDC Dortmund. 1H NMR (400 MHz, DMSO-d6) 
δ 7.90 (dd, J = 3.0 Hz, J = 6.3 Hz, 1H), 7.73 (m, 2H), 7.67 (dd, J = 2.7 Hz, J = 6.3 Hz, 1H), 7.52 
(m, 3H), 7.42 (d, J = 7.5 Hz, 1H), 7.34 - 7.34 (m, 5H), 7.13 (m, 3H), 7.07 (dt, J = 1.2 Hz, J = 
7.5 Hz, 1H), 7.02 (dt, J = 1.1 Hz, J = 7.6 Hz, 1H), 5.22 ( s, 2H), 4.79 (t, J = 11.5 Hz, 1H), 4.54 
(dt, J = 3.0 Hz, J = 9.7 Hz, 1H), 4.46 (dd, J = 4.0 Hz, J = 12.1 Hz, 1H), 3.25 (m, 1H), 3.10 (m, 
1H), 2.85 (m, 4H), 2.42 (m, 3H), 2.16 (t, J = 9.5 Hz, 1H), 1.99 (m, 1H), 1.63 - 1.41 (m, 5H).LC-
MS: 5min_B: tR=1.78min, 10min_D: tR=2.86min. LC-MS (ES) C39H40N6O2 calcd: 624, found: 
625 [M+H]+. LC-MS (ESI, HR-MS): calcd for C39H40N6O2: 625.32855 [M+H]+ found 
625.33015 [M+H]+. 
 EXPERIMENTAL SECTION 
167 
 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(pyrrolidin-3-yl)ethyl 1-(1-benzyl-1H-
benzo[d]imidazol-2-yl)piperidine-4-carboxylate (diastereoisomer 2) (97) The product was 
synthesized by Carsten Schultz-Fademrecht, LDC Dortmund.1H NMR (400 MHz, DMSO-d6) 
δ 7.89 (m, 1H), 7.69 (m, 3H), 7.53 (m, 3H), 7.42 (d, J = 8.1 Hz, 1H), 7.34 - 7.23 (m, 5H), 7.13 
(m, 3H), 7.07 (dt, J = 1.2 Hz, J = 7.5 Hz, 1H), 7.02 (dt, J = 1.1 Hz, J = 7.5 Hz, 1H), 5.22 (s, 2H), 
4.82 (t, J = 10.8 Hz, 1H), 4.56 (t, J = 10.8 Hz, 1H), 4.40 (dd, J = 3.4 Hz, J = 12.0 Hz, 1H), 3.34 
(d, J = 13.1 Hz, 1H), 3.27 (d, J = 11.4 Hz, 1H), 3.12 (m, 2H), 2.88 (q, J = 12.0 Hz, 2H), 2.67 
(m, 2H), 2.43 (m, 1H), 1.67 - 1.43 (m, 4H), 1.27 (m, 2H), 1.03 (m, 1H). LC-MS:5min_B: 
tR=1.86min, 10min_D: tR=3.03min. LC-MS (ESI, HR-MS): calcd for C39H40N6O2: 625.32855. 
[M+H]+ found 625.33000 [M+H]+. 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-3-(piperidin-4-yl)propyl 1-(1-benzyl-1H-
benzo[d]imidazol-2-yl)piperidine-4-carboxylate (98) The product was synthesized by 
Carsten Schultz-Fademrecht, LDC Dortmund.1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 7.2 
Hz, 1H), 7.67 (m, 2H), 7.62 (d, J = 8.0 Hz, 1H), 7.54 - 7.46 (m, 4H), 7.34 - 7.25 (m, 5H), 7.18 
(dt, J = 1.3 Hz, J = 7.6 Hz, 1H), 7.14 (d, J = 8.2 Hz, 2H), 7.09 (dt, J = 1.1 Hz, J = 7.6 Hz, 1H), 
7.02 (d, J = 7.9 Hz, 1H), 5.16 (s, 2H), 4.91 (m, 1H), 4.80 (t, J = 10.5 Hz, 1H), 4.44 (dd, J = 4.8 
Hz, J = 11.4 Hz, 1H), 3.41 (d, J = 12.4 Hz, 1H), 3.34 (d, J = 12.6 Hz, 1H), 2.92 (m, 4H), 2.36 
(m, 3H), 2.18 (m, 2H), 1.83 - 1.58 (m, 5H), 1.34 (d, J = 13.5 Hz, 1H), 1.11 (m, 1H), 0.95 (m, 
2H). LC-MS: 5min_B: tR=2.13min, 10min_D: tR=3.17min. MS (ESI) C41H44N6O2 calcd: 652, 
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found: 653 [M+H]+.LC-MS (ESI, HR-MS): calcd for C41H44N6O2: 653.35985 [M+H]
+, found 
653.36179 [M+H]+.  
 
Synthesis of amide-linked bis-benzimidazoles 
 
tert-Butyl 4-(2-(1,3-dioxoisoindolin-2-yl)-1-(2-phenyl-1H-benzo[d]imidazol-1-
yl)ethyl)piperidine-1-carboxylate (99) To a mixture of tert-butyl 4-(2-hydroxy-1-(2-phenyl-
1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate1 (300 mg, 0.71 mmol), phthalimide 
(157 mg, 1.07 mmol), polymer-bound triphenylphosphine (474 mg, 3 mmol/g) and toluene (5 
mL) at 0°C was added di-tert-butyl azodicarboxylate (327 mg, 1.42 mmol). After 10 min the 
reaction mixture was allowed to warm to room temperature and stirred for 16 h. Due to 
incomplete conversion phthalimide (300 mg, 0.71 mmol), polymer-bound triphenylphosphine 
(400 mg) and di-tert-butyl azodicarboxylate (330 mg, 1.44 mmol) were added to the reaction 
mixture at room temperature. The mixture was stirred for an additional 16 h and filtered. The 
polymer resin was washed with a mixture of DCM and ethyl acetate (50:50 vol%, 100 mL) and 
the combined filtrates were concentrated in vacuo. After purification by column 
chromatography (gradient cyclohexane : ethyl acetate 5:1 to 1:2) the desired compound was 
isolated (320 mg, 0.58 mmol, 82 %). 1H NMR (400 MHz, CDCl3) δ 7.87 – 7.74 (m, 1H), 7.73 
– 7.59 (m, 5H), 7.41 – 7.29 (m, 3H), 7.24 – 7.06 (m, 4H), 4.53 – 4.43 (m, 1H), 4.41 – 4.31 (m, 
1H), 4.24 (d, J = 13.0 Hz, 1H), 4.13 – 3.94 (m, 2H), 2.80 (t, J = 12.4 Hz, 1H), 2.65 – 2.39 (m, 
2H), 2.08 (d, J = 13.0 Hz, 1H), 1.56 – 1.29 (m, 10H), 1.29 – 1.10 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 167.19, 155.21, 154.83, 143.82, 134.32, 133.99, 131.86, 130.11, 129.85, 129.71, 
128.66, 123.59, 123.21, 122.92, 120.90, 111.92, 79.95, 60.92, 38.19, 37.84, 30.68, 29.07, 28.64, 
27.12. LC-MS (ESI): calcd for C33H34N4O4: 551.26528 [M+H]
+, found: 551.20 [M+H]+, Rt = 
8.41 min; HR-MS found 551.26641 [M+H]+. 
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tert-Butyl 4-(2-amino-1-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-
carboxylate (100) To a solution of phthalimide 99 (300 mg, 0.54 mmol) in EtOH (3 mL) was 
added hydrazine hydrate (0.22 mL, 0.44 mmol). The reaction mixture was stirred at room 
temperature for 72 h. The reaction mixture was concentrated in vacuo, and co-evaporated with 
EtOH (3x 5 mL). The colorless residue was taken up in DCM (10 mL). To the resulting 
suspension was added sat. NaHCO3 solution (10 mL). The aqueous layer was extracted with 
DCM (3x 15mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuoto afford the product (200 mg, 0.47 mmol, 87%). 1H NMR (400 MHz, 
DMSO-d6) δ 7.86 – 7.74 (m, 3H), 7.69 – 7.62 (m, 1H), 7.57 – 7.46 (m, 3H), 7.26 – 7.14 (m, 
2H), 4.13 – 4.00 (m, 1H), 3.85 (d, J = 13.2 Hz, 1H), 3.70 – 3.51 (m, 1H), 3.51 – 3.37 (m, 1H), 
3.14 (d, J = 10.1 Hz, 1H), 2.74 – 2.52 (m, 1H), 2.38 – 2.11 (m, 2H), 1.77 (d, J = 13.1 Hz, 1H), 
1.28 (s, 9H), 0.96 – 0.78 (m, 1H), 0.64 – 0.41 (m, 2H). LC-MS (ESI): calcd for C25H32N4O2: 
421.25980 [M+H]+, found: 421.16  [M+H]+; HR-MS found 421.25938 [M+H]+. 
 
tert-Butyl 4-(1-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(1-(1-(thiophen-3-ylmethyl)-1H-
benzo[d]imidazol-2-yl)piperidine-4-carboxamido)ethyl)piperidine-1-carboxylate (101) 
To a mixture of acid 83 (122 mg, 0.36 mM), amine 100 (100 mg, 0.24 mM) in DMF (2 mL) at 
room temperature was added DIPEA (51 µL, 0.36 mM) and PyBOP (185 mg, 0.36 mmol). The 
reaction mixture was stirred at room temperature for 2 d and then concentrated in vacuo. The 
residue was dissolved in methanol (500 µL) and applied to a preparative C18-RP column 
eluting with a gradient (CH3CN:H2O 1:4 to 9:1 containing 0.1% TFA), to afford  the product 
(119 mg, 0.16 mmol, 67%). 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.7 Hz, 1H), 7.58 – 7.46 
(m, 4H), 7.44 – 7.36 (m, 3H), 7.30 – 7.19 (m, 3H), 7.17 – 7.12 (m, 1H), 7.08 (dd, J = 3.9, 2.1 
Hz, 2H), 6.97 – 6.94 (m, 1H), 6.91 (dd, J = 5.0, 1.2 Hz, 1H), 5.12 (s, 2H), 4.37 (td, J = 10.3, 
3.5 Hz, 1H), 4.29 – 4.19 (m, 1H), 4.09 (t, J = 11.1 Hz, 1H), 3.98 – 3.76 (m, 1H), 3.72 – 3.57 
(m, 1H), 3.37 (d, J = 12.3 Hz, 2H), 2.83 – 2.72 (m, 2H), 2.66 (t, J = 12.3 Hz, 1H), 2.40 (t, J = 
11.2 Hz, 1H), 2.26 (d, J = 11.2 Hz, 1H), 2.12 – 2.02 (m, 2H), 2.01 – 1.91 (m, 1H), 1.79 – 1.63 
(m, 3H), 1.56 – 1.47 (m, 1H), 1.38 (s, 9H), 1.33 – 1.19 (m, 2H). 13C NMR (101 MHz, CDCl3) 
δ 175.14, 158.10, 155.72, 154.74, 143.65, 141.45, 137.57, 135.28, 133.31, 130.23, 130.20, 
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130.03, 129.02, 127.30, 126.22, 123.31, 123.10, 122.23, 121.84, 121.72, 120.71, 118.19, 
111.91, 109.56, 79.86, 62.31, 50.62, 44.13, 42.72, 39.83, 38.14, 30.11, 28.88, 28.75, 28.59, 
28.32. LC-MS (ESI): calcd for C43H49N7O3S: 744.36904 [M+H]
+, found: 744.36824 [M+H]+; 
HR-MS found 744.36824 [M+H]+. 
 
 
N-(2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl)-1-(1-(thiophen-3-
ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxamide (102) The product was 
synthesized according to General Procedure (D) starting from the protected piperidine 101 
(61 mg, 0.13 mmol) to afford the HCl-salt in quantitative yield. The residue was dissolved in 
methanol (500 µL) and applied to a preparative C18-RP column eluting with a gradient 
(CH3CN: H2O 1:5 to 9:1 containing 0.1% TFA), to afford the desired piperidine as a TFA salt 
(66 mg, 0.010 mmol, 59%). 1H NMR (400 MHz, DMSO-d6) δ 9.19 (s, 1H), 8.99 (s, 1H), 8.29 
(t, J = 5.7 Hz, 1H), 8.15 (d, J = 7.9 Hz, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 7.5 Hz, 2H), 
7.70 (t, J = 7.4 Hz, 1H), 7.64 (t, J = 7.5 Hz, 2H), 7.62 – 7.53 (m, 4H), 7.49 – 7.47 (m, 1H), 7.38 
(t, J = 7.1 Hz, 1H), 7.36 – 7.32 (m, 1H), 7.31 – 7.27 (m, 1H), 7.08 – 7.04 (m, 1H), 5.39 (s, 2H), 
4.19 (t, J = 8.8 Hz, 1H), 3.94 (dd, J = 11.7, 7.0 Hz, 1H), 3.77 (d, J = 9.6 Hz, 2H), 3.61 – 3.53 
(m, 3H), 3.33 – 3.16 (m, 4H), 3.03 (dt, J = 12.3, 7.3 Hz, 2H), 2.90 – 2.61 (m, 4H), 2.28 (t, J = 
10.8 Hz, 1H), 2.16 (d, J = 13.4 Hz, 1H), 1.76 – 1.71 (m, 2H), 1.71 – 1.62 (m, 1H), 1.62 – 1.45 
(m, 3H), 1.44 – 1.29 (m, 3H), 1.16 – 1.09 (m, 1H). 13C NMR (151 MHz, DMSO-d6) δ 174.60, 
152.43, 136.25, 132.57, 131.05, 129.92, 128.50, 127.09, 125.08, 124.53, 123.57, 115.17, 
112.92, 112.06, 67.69, 64.33, 49.49, 49.32, 46.14, 45.95, 43.20, 43.12, 39.11, 34.30, 28.61, 
27.51, 26.84, 25.80, 25.64. LC-MS (ESI): calcd for C38H41N7OS : 644.31661 [M+H]
+, found: 
644.32 [M+H]+, Rt = 5.30 min; HR-MS found 644.31661 [M+H]
+. 
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Synthesis of carbamate-linked bis-benzimidazoles 
 
 
1-(2-(4-(1-Benzyl-1H-benzo[d]imidazol-2-yl)piperazine-1-carbonyloxy)-1-(1-(tert-
butoxycarbonyl)piperidin-4-yl)ethyl)-2-phenyl-1H-benzo[d]imidazol-6-ylium (105) To 4-
nitrophenyl chloroformate (65 mg, 0.32 mmol) in THF (1 mL) was added pyridine (26 µL, 0.32 
mmol) and the mixture was stirred at room temperature for 30 min. The tert-butyl 4-(2-hydroxy-
1-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (90 mg, 0.21 mmol) 
was added and the reaction mixture was stirred at room temperature for 16 h. 4-Nitrophenyl 
chloroformate (65 mg, 0.32 mmol) and pyridine (26 µL, 0.32 mmol) were added and stirring 
was continued for 16 h. The reaction mixture was concentrated in vacuo, the residue dissolved 
in DCM (10 mL) and extracted with a sat. NH4Cl-solution (10 mL). The aqueous layer was 
reextracted with DCM (3 x 10 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo. To a solution of HOBT (48 mg, 0,32 mmol) in DCM (3 mL) 
molecular sieves (4 Angstrom, 50 mg) were added and the mixture was stirred for 5 min. After 
5 min 1-benzyl-2-(piperazin-1-yl)-1H-benzo[d]imidazole125 (94 mg, 0,32 mmol) was added and 
the resulting mixture was stirred for 16 h. The reaction mixture was concentrated in vacuo, the 
residue dissolved in DCM (5 mL) and extracted with sat. NaHCO3. The aqueous layer was 
reextracted with DCM (3x 10 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash chromatography (gradient 
cyclohexane: ethyl acetate 10:1 to 1:2.5) to afford the product (71 mg, 46%). 1H NMR (400 
MHz, CDCl3) δ 7.81 (d, J = 7.4 Hz, 1H), 7.65 – 7.56 (m, 3H), 7.56 – 7.40 (m, 4H), 7.35 – 7.22 
(m, 5H), 7.18 (t, J = 7.6 Hz, 1H), 7.14 – 7.06 (m, 3H), 7.02 (d, J = 7.8 Hz, 1H), 5.18 (s, 2H), 
4.76 – 4.60 (m, 2H), 4.49 (t, J = 11.5 Hz, 1H), 4.19 – 4.05 (m, 1H), 3.98 – 3.76 (m, 1H), 3.55 
– 2.95 (m, 6H), 2.77 – 2.59 (m, 1H), 2.53 – 2.30 (m, 2H), 1.89 (d, J = 11.8 Hz, 1H), 1.40 (s, 
9H), 1.32 – 1.17 (m, 1H), 1.08 – 0.84 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 157.39, 154.75, 
154.59, 141.42, 136.21, 135.53, 130.59, 130.13, 130.00, 129.31, 128.95, 128.06, 126.19, 
123.16, 122.89, 122.41, 122.08, 120.82, 118.49, 111.81, 109.68, 79.92, 64.24, 61.30, 50.40, 
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47.73, 43.56, 37.03, 30.24, 28.80, 28.60, 27.12. LC-MS (ESI): calcd for C44H49N7O4:740.39188 
[M+H]+, found: 740.33 [M+H]+, Rt = 7.84 min; HR-MS found 740.39234 [M+H]
+. 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl 4-(1-benzyl-1H-
benzo[d]imidazol-2-yl)piperazine-1-carboxylate (106) The product was synthesized 
according to General Procedure (D) starting from the protected piperidine 105 
(30 mg,0.040 mmol) to afford the HCl-salt in quantitative yield. The residue was dissolved in 
methanol (500 µL) and applied to a preparative C18-RP column eluting with a gradient 
(CH3CN: H2O 1:5 to 9:1 containing 0.1% TFA), to afford the product (17  mg, 0.026 mmol, 
66%) as the TFA-salt. 1H NMR (400 MHz, DMSO-d6) δ 7.87 – 7.79 (m, 1H), 7.71 – 7.63 (m, 
1H), 7.63 – 7.55 (m, 2H), 7.56 – 7.46 (m, 3H), 7.43 (d, J = 7.2 Hz, 1H), 7.35 – 7.27 (m, 2H), 
7.27 – 7.20 (m, 3H), 7.20 – 7.11 (m, 3H), 7.11 – 6.98 (m, 2H), 5.28 (s, 2H), 4.69 (t, J = 10.8 
Hz, 1H), 4.58 (d, J = 8.2 Hz, 1H), 4.45 – 4.35 (m, 1H), 3.42 – 2.76 (m, 10H), 2.94 – 2.81 (m, 
1H), 2.70 (d, J = 13.6 Hz, 1H), 2.45 – 2.33 (m, 2H), 2.18 (t, J = 10.2 Hz, 1H), 1.80 (d, J = 10.9 
Hz, 1H), 1.07 (d, J = 9.5 Hz, 1H), 0.91 – 0.71 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 
157.01, 154.82, 153.80, 143.05, 141.12, 136.82, 135.03, 133.32, 130.53, 129.67, 128.68, 
128.58, 127.39, 126.54, 122.49, 122.03, 121.34, 121.03, 119.62, 117.54, 112.47, 109.90, 72.16, 
70.51, 63.46, 61.28, 60.19, 49.73, 46.71, 45.56, 45.44, 42.84, 35.86, 30.93, 29.32. LC-MS 
(ESI): calcd for C39H41N7O2: 640.33945 [M+H]
+, found: 640.29 [M+H]+, Rt = 5.62 min; HR-
MS found 640.33988 [M+H]+. 
 
Enantioselctive synthesis of bis-benzimidazoles 
 
tert-butyl (R)-4-(1-(((benzyloxy)carbonyl)amino)-2-methoxy-2-oxoethyl)piperidine-1-
carboxylate (113) The compound was synthesized in an analogous fashion to the literature 
method.91 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.29 (m, 5H), 5.35 (d, J = 9.0 Hz, 1H), 5.09 (s, 
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2H), 4.40 – 4.30 (m, 1H), 4.20 – 4.02 (m, 2H), 3.73 (s, 3H), 2.74 – 2.56 (m, J = 9.1 Hz, 2H), 
1.96 – 1.83 (m, 1H), 1.70 – 1.45 (m, 2H), 1.44 (s, 9H), 1.35 – 1.18 (m, 2H). ; [∝]𝐷
20 : -22.0° (Lit 
-20.7°, c=1.0, CHCl3); Chiral HPLC (isohexane:isopropylalcohol:TFA 9:1:0.1): Rt 11.0 min, 
88% ee (Lit: 94%). LC-MS (ESI): calcd for C21H30N2O6: 407.21 [M+H]
+, found: 406.75 
[M+H]+, Rt = 7.53 min.  
tert-Butyl 4-((S)-1-azido-2-oxo-2-((S)-2-oxo-4-phenyloxazolidin-3-yl)ethyl)piperidine-1-
carboxylate (116) The product was synthesized according to literature methods.90 1H NMR 
(400 MHz, CDCl3) δ 7.45 – 7.27 (m, 5H), 5.45 (dd, J = 8.7, 4.0 Hz, 1H), 4.98 (d, J = 7.8 Hz, 
1H), 4.75 (t, J = 8.9 Hz, 1H), 4.33 (dd, J = 9.0, 4.0 Hz, 1H), 4.23 – 4.06 (m, 2H), 2.74 – 2.59 
(m, 2H), 2.11-1.97 (m, 1H), 1.84-1.74 (m, 1H), 1.53-1.63 (m, 1H), 1.45 (s, 9H), 1.41-1.32 (m, 
2H). Analytical data are consistent with literature data. 
 
(S)-tert-Butyl 4-(2-hydroxy-1-(2-nitrophenylamino)ethyl)piperidine-1-carboxylate (107) 
Synthesis starting from azide 116: To a solution of azide 116 (2.0 g, 4.7 mmol) in MeOH (5 mL) 
was added NaBH4 (530 mg, 14.1 mmol) at room temperature. The reaction mixture was stirred 
at room temperature for 2 h and NaBH4 (530 mg, 14.1 mmol) was added to the reaction mixture. 
After stirring for an additional 12 h sat. NH4Cl-solution (20 mL) was added, followed by DCM 
(30 mL). The aqueous layer was extracted with DCM (3x 30 mL). The combined organic layers 
were dried (Na2SO4), filtered, evaporated to dryness and the residue was purified by flash 
chromatography (gradient cyclohexane : ethyl acetate 10:1 to 1:1). To a solution of the 
intermediate azido alcohol (1.0 g, 3.67 mmol) in degassed ethanol was added palladium on 
carbon (5%, 100 mg). The reaction vessel was evacuated and then refilled with argon three 
times. The reaction mixture was stirred under H2 (1 atm) for 2 h at room temperature. The 
reaction vessel was then evacuated and refilled with argon, ethyl acetate (50 mL) was added 
and filtered over Celite. The filter cake was washed with ethanol and ethyl acetate (100 mL, 
respectively), evaporated to dryness and used without any further purification (LC-MS:ESI 
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244.89 [M+H]+). To a solution of the free amine in NMP (10 mL) was added 1-fluoro-2-
nitrobenzene (0.66 mL, 6.14 mmol), and DIPEA (0.35 mL, 2 mmol). The reaction mixture was 
heated to 90°C for 8 h, cooled to room temperature and diluted with DCM (50 mL). To the 
reaction mixture was added a sat. of NH4Cl solution (40 mL). The aqueous layer was extracted 
with DCM (2x 50 mL). The combined organic layers were dried over MgSO4,filtered and then 
evaporated to dryness. The crude product was purified by column chromatography to yield the 
desired compound (1.35 g, 3.7 mmol, 45%). 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 9.1 Hz, 
1H), 8.09 (dd, J = 8.6, 1.5 Hz, 1H), 7.33 (dd, J = 8.4, 7.2 Hz, 1H), 6.85 (d, J = 8.8 Hz, 1H), 
6.57 (dd, J = 8.4, 7.2 Hz, 1H), 4.19 – 3.97 (m, 2H), 3.77 (dd, J = 11.2, 4.2 Hz, 1H), 3.70 (dd, J 
= 11.1, 5.3 Hz, 1H), 3.59 – 3.48 (m, 1H), 2.61 (t, J = 12.3 Hz, 2H), 2.00-1.96 (m, 1H), 1.87 – 
1.57 (m, 4H), 1.37 (s, 9H), 1.31 – 1.10 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 154.92, 145.89, 
136.52, 132.42, 127.38, 115.81, 114.42, 79.82, 62.56, 58.73, 38.44, 29.21, 28.74, 28.64. LC-
MS (ESI): calcd for C18H27N3O5: 388.18429 [M+Na]
+, Rt = 9.41 min; HR-MS found 388.18459 
[M+Na]+; [∝]𝐷
20 : -243.0° (c=1.6, DCM).  
 
 
(S)-tert-Butyl 4-(2-(4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(2-
nitrophenylamino)ethyl)piperidine-1-carboxylate ((S)-117) The product was synthesized 
according to Procedure C for the connection of two benzimidazoles via Mitsonobu reaction 
starting from alcohol (S)-53 (30 mg. 0.10 mmol). The crude product was purified by automated 
flash chromatography using a gradient of of cyclohexane: ethyl acetate 20:1 to 1:2 to yield the 
desired compound (45 mg, 0.07 mmol, 70%). 1H NMR (400 MHz, CDCl3) δ 8.36 (d, J = 9.1 
Hz, 1H), 8.17 (dd, J = 8.6, 1.6 Hz, 1H), 7.83 (t, J = 7.3 Hz, 1H), 7.63 – 7.58 (m, 2H), 7.45 – 
7.39 (m, 1H), 7.36 – 7.26 (m, 4H), 7.24 – 7.15 (m, 2H), 7.13 – 7.07 (m, 2H), 6.97 – 6.89 (m, 
3H), 6.70 – 6.62 (m, 1H), 5.42 (s, 2H), 4.35 – 4.01 (m, 3H), 3.97 – 3.77 (m, 1H), 2.72 (t, J = 
12.0 Hz, 2H), 2.10 – 1.99 (m, 1H), 1.90 (d, J = 12.6 Hz, 1H), 1.77 (d, J = 12.7 Hz, 1H), 1.49 – 
1.21 (m, 12H). 13C NMR (101 MHz, CDCl3) δ 159.86, 154.88, 154.08, 145.31, 143.28, 136.66, 
136.51, 136.32, 132.56, 131.01, 129.29, 127.98, 127.45, 126.10, 123.34, 123.12, 122.87, 
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119.96, 115.91, 115.04, 114.10, 110.60, 79.84, 67.75, 56.27, 48.58, 38.80, 29.21, 28.70, 
28.65. [∝]𝐷
20 : -62.5° (c=1.5, DCM). 
 
(S)-tert-Butyl 4-(2-(4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(2-phenyl-1H-
benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (S)-(57) To a solution of (S)-
117 (40 mg, 0.066 mmol) in MeOH, H2O and DMSO (8:2:1, 2 mL) was added  benzaldehyde 
(18 µL, 0.18 mmol)  and sodium dithionite (23 mg, 0.14 mmol). The reaction mixture was 
heated to 65°C and after 0.5, 1, and 2 h sodium dithionite  (3x 23 mg, 0.14 mmol) was added. 
After 6 h the reaction mixture was allowed to cool to room temperature. The reaction mixture 
was concentrated under reduced pressure and then extracted with DCM (3x 20 mL). The 
combined organic phases were dried (Na2SO4), filtered and concentrated to dryness. 
Purification by flash chromatography (gradient cyclohexane : ethyl acetate 5:1 to 1:5) afforded 
enantiomerically pure (S)-89 (25 mg, 0.035mmol, 53%).  
 
(S)-tert-Butyl 4-(1-(2-nitrophenylamino)-2-(1-(1-(thiophen-3-ylmethyl)-1H-
benzo[d]imidazol-2-yl)piperidine-4-carbonyloxy)ethyl)piperidine-1-carboxylate ((S)-118) 
The product was synthesized according to Procedure E for the connection of two 
benzimidazoles via Mitsunobu reaction starting from alcohol (1.0 g. 2.74 mmol). The crude 
product was purified by automated flash chromatography using a gradient of cyclohexane: ethyl 
acetate 20:1 to 1:2 to yield the desired compound (1.33 g, 1.94 mmol, 71%).1H NMR (400 
MHz, CDCl3) δ 8.19 – 8.13 (m, 2H), 7.63 – 7.58 (m, 1H), 7.43 – 7.38 (m, 1H), 7.33 (dd, J = 
5.0, 3.0 Hz, 1H), 7.22 – 7.16 (m, 1H), 7.13 – 7.10 (m, 2H), 7.04 – 6.99 (m, 1H), 6.97 – 6.89 (m, 
2H), 6.64 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 5.16 (s, 2H), 4.30 – 4.08 (m, 4H), 3.79 (td, J = 11.5, 
5.5 Hz, 1H), 3.45 (d, J = 12.5 Hz, 2H), 2.96 (dd, J = 16.8, 7.0 Hz, 2H), 2.70 (t, J = 12.1 Hz, 
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2H), 2.47 (tt, J = 11.2, 4.1 Hz, 1H), 1.98 – 1.69 (m, 6H), 1.37 – 1.17 (m, 3H).13C NMR (101 
MHz, CDCl3) δ 174.55, 158.15, 154.85, 145.39, 141.69, 137.65, 136.53, 135.40, 132.60, 
127.42, 127.32, 126.25, 122.20, 121.78, 121.74, 118.37, 116.08, 114.18, 109.52, 79.91, 64.16, 
55.71, 50.60, 50.53, 44.17, 41.00, 38.96, 29.11, 28.65, 28.13. LC-MS (ESI): calcd for 
C18H27N3O5: 689.31158 [M+H]
+, found: 689.29 [M+H]+ , Rt = 8.47 min; HR-MS found 
689.31133 [M+H]+; [∝]𝐷
20 : -50.0° (c=1.8, DCM). 
 
(S)-tert-Butyl 4-(1-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(1-(1-(thiophen-3-ylmethyl)-
1H-benzo[d]imidazol-2-yl)piperidine-4-carbonyloxy)ethyl)piperidine-1-carboxylate ((S)-
89) To a solution of (S)-118 (30 mg, 0,044 mmol) in MeOH, H2O and DMSO (8:2:1, 3 mL) was 
added benzaldehyde (9µL, 0.09 mmol) and sodium dithionite (23 mg, 0.14 mmol). The reaction 
mixture was heated to 65°C and after 0.5, 1, and 2 h sodium dithionite  (3x 23 mg, 0.14 mmol) 
was added. After 5 h the reaction mixture was allowed to cool to room temperature. The reaction 
mixture was concentrated under reduced pressure and then extracted with DCM (3x 20 mL). 
The combined organic phases were dried (Na2SO4), filtered and concentrated to dryness. 
Purification by flash chromatography (gradient cyclohexane : ethyl acetate 5:1 to 1:5) afforded 
enantiomerically pure (S)-89 (20 mg, 0.031mmol, 61%).  
General procedure F for the cyclisation of nitro anilines to benzimidazoles 
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To a solution of (S)-118 (20 mg, 0.029 mmol) in MeOH, H2O and DMSO (8:2:1, 2 mL) was 
added the corresponding aldehyde (0.06 mmol)  and sodium dithionite (12 mg, 0.007 mmol). 
The reaction mixture was heated to 65°C and after 0.5, 1, and 2 h sodium dithionite  (3x 12 mg) 
was added. The reaction was followed by TLC and LC-MS and was allowed to cool to room 
temperature upon completion. The reaction mixture was then concentrated under reduced 
pressure and extracted with DCM (3x 20 mL). The combined organic phases were dried 
(Na2SO4), filtered and concentrated to dryness. Purification by automated flash 
chromatography (gradient cyclohexane : ethyl acetate 5:1 to 1:5) afforded the Boc-protected 
intermediates. The Boc protected intermediates were then deprotected with HCl/dioxane as 
described and purified by preparative C18-RP column eluting with a gradient (CH3CN: H2O 
1:5 to 9:1 containing 0.1% TFA), to afford the desired piperidines as TFA salts.  
 
(S)-2-(2-Isopropyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl 1-(1-(thiophen-3-
ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate ((S)-127) The compound 
was synthesized according to General procedure F. Yield (10 mg, 56 %)1H NMR (600 MHz, 
DMSO-d6) δ 8.82 – 8.76 (m, 1H), 8.54 – 8.44 (m, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 7.4 
Hz, 1H), 7.57 – 7.55 (m, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.44 – 7.31 (m, 4H), 7.31 – 7.22 (m, 
2H), 7.02 – 6.97 (m, 1H), 5.30 (s, 2H), 4.87 – 4.73 (m, 2H), 4.57 – 4.54 (m, 1H), 3.60 – 3.52 
(m, 2H), 3.47 (d, J = 13.1 Hz, 1H), 3.39 (d, J = 12.0 Hz, 1H), 3.22 – 3.07 (m, 3H), 2.95 – 2.84 
(m, 1H), 2.82 – 2.64 (m, 2H), 2.09 (d, J = 13.3 Hz, 1H), 1.76 – 1.64 (m, 2H), 1.61 – 1.49 (m, 
2H), 1.42 – 1.33 (m, 7H), 1.09 (d, J = 13.4 Hz, 1H).13C NMR (151 MHz, DMSO-d6) δ 173.71, 
160.64, 159.34, 159.12, 158.90, 158.68, 153.72, 136.56, 133.15, 131.60, 128.35, 127.10, 
124.54, 124.04, 123.40, 118.33, 117.34, 116.36, 114.02, 111.77, 62.69, 59.83, 49.11, 49.08, 
45.57, 43.36, 43.31, 39.44, 33.55, 27.41, 27.38, 26.48, 26.01, 25.85, 21.91. LC-MS (ESI, HR-
MS): calcd for C35H42N6O2S: 611.31627 [M+H]+, found 611.31707 [M+H]+. [∝]𝐷
20 : 12.6° 
(c=0.6, DMSO).  
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(S)-2-(2-Cyclopropyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl 1-(1-(thiophen-3-
ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate ((S)-128) The compound 
was synthesized according to General procedure F. Yield (10 mg, 57 %) 1H NMR (600 MHz, 
DMSO-d6) δ 8.73 – 8.64 (m, 1H), 8.44 – 8.32 (m, 1H), 7.97 – 7.89 (m, 1H), 7.63 – 7.58 (m, 
1H), 7.58 – 7.55 (m, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.44 – 7.24 (m, 6H), 7.02 – 6.97 (m, 1H), 
5.30 (s, 2H), 4.95 – 4.89 (m, 1H), 4.81 – 4.72 (m, 1H), 4.65 – 4.56 (m, 1H), 3.37 (d, J = 11.3 
Hz, 1H), 3.24 – 3.09 (m, 3H), 2.96 – 2.82 (m, 1H), 2.82 – 2.64 (m, 2H), 2.59 – 2.47 (m, 4H), 
2.41 – 2.33 (m, 1H), 2.11 (d, J = 13.0 Hz, 1H), 1.73 – 1.58 (m, 3H), 1.53 – 1.14 (m, 8H).13C 
NMR (151 MHz, DMSO-d6) δ 173.72, 159.35, 159.13, 158.91, 158.69, 157.38, 153.26, 136.28, 
132.83, 131.85, 131.28, 128.44, 127.04, 124.89, 124.53, 124.38, 123.44, 118.26, 116.95, 
116.30, 113.60, 111.90, 62.47, 60.33, 49.03, 45.75, 43.25, 39.32, 33.38, 27.35, 26.39, 25.93, 
10.30, 9.33, 7.66. LC-MS (ESI): calcd for C35H40N6O2S: 609.30062 [M+H]+, found 609.30079 
[M+H]+. [∝]𝐷
20 : 8.0° (c=0.4, DMSO). 
.  
(S)-2-(2-Ethyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl 1-(1-(thiophen-3-
ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate ((S)-129) The compound 
was synthesized according to general procedure F. Yield (11 mg, 64 %)1H NMR (600 MHz, 
DMSO-d6) δ 8.71 (d, J = 9.8 Hz, 1H), 8.40 (d, J = 10.3 Hz, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.72 
(d, J = 7.4 Hz, 1H), 7.58 – 7.54 (m, 1H), 7.51 – 7.23 (m, 7H), 7.00 (d, J = 5.0 Hz, 1H), 5.31 (s, 
2H), 4.79 – 4.71 (m, 2H), 4.61 – 4.51 (m, 1H), 3.23 – 3.02 (m, 5H), 2.95 – 2.82 (m, 1H), 2.83 
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– 2.67 (m, 2H), 2.56 – 2.49 (m, 1H), 2.08 (d, J = 13.5 Hz, 1H), 1.72 – 1.58 (m, 3H), 1.54 – 1.44 
(m, 1H), 1.43 – 1.29 (m, 5H), 1.12 (d, J = 13.6 Hz, 1H).13C NMR (151 MHz, DMSO-d6) δ 
173.66, 159.39, 159.16, 158.94, 158.72, 157.08, 153.23, 136.29, 132.83, 131.22, 128.43, 
127.03, 125.59, 125.36, 124.88, 124.37, 123.44, 116.42, 114.35, 113.56, 111.90, 62.53, 60.48, 
49.02, 45.74, 43.26, 39.30, 33.30, 27.33, 26.25, 25.81, 20.22, 11.85. LC-MS (ESI, HR-MS): 
calcd for C34H40N6O2S: 597.30062 [M+H]+, found 597.30139 [M+H]+. [∝]𝐷
20 : 15.0° 
(c=0.5, DMSO). 
 
(S)-2-(2-Methyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethyl 1-(1-(thiophen-3-
ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carboxylate ((S)-130) The compound 
was synthesized according to General procedure F. Yield (4 mg, 24 %) 1H NMR (600 MHz, 
DMSO-d6) δ 8.74 – 8.56 (m, 1H), 8.39 – 8.21 (m, 1H), 8.03 (d, J = 7.8 Hz, 1H), 7.76 – 7.65 
(m, 1H), 7.58 – 7.52 (m, 1H), 7.51 – 7.41 (m, 3H), 7.41 – 7.24 (m, 4H), 6.99 (d, J = 4.9 Hz, 
1H), 5.31 (s, 2H), 4.75 – 4.68 (m, 2H), 4.61 – 4.54 (m, 1H), 2.92 – 2.84 (m, 2H), 2.81 – 2.69 
(m, 5H), 2.58 – 2.51 (m, 1H), 2.08 (d, J = 13.3 Hz, 1H), 1.70 – 1.61 (m, 3H), 1.54 – 1.12 (m, 
5H). LC-MS (ESI, HR-MS): calcd for C33H38N6O2S : 583.28487 [M+H]+, found 583.28497 
[M+H]+.[∝]𝐷
20 : 15.3° (c=0.5, DMSO). 
 
2-(2-Phenyl-1H-imidazol-1-yl)ethyl 1-(1-benzyl-1H-benzo[d]imidazol-2-yl)piperidine-4-
carboxylate (131) The product was synthesized by Carsten Schultz-Fademrecht, LDC. 1H 
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NMR (400MHz, CDCl3) δ 7.64 (d, J = 8.0 Hz, 1H), 7.57 (dd, J = 1.4 Hz, J = 8.0 Hz, 2H), 7.47 
- 7.38 (m, 3H), 7.37 - 7.25 (m, 3H), 7.23 - 7.13 (m, 4H), 7.10 (dt, J = 1.1 Hz, J = 7.2 Hz, 1H), 
7.05 (d, J = 1.3 Hz, 1H), 7.03 (d, J = 7.9 Hz, 1H), 5.20 (s, 2H), 4.31 (s, 4H), 3.44 (dt, J =12.8 
Hz, J = 3.5 Hz, 2H), 2.97 (dt, J = 2.6 Hz, 12.0 Hz, 2H), 2.36 (m, 1H), 1.91 - 1.70 (m, 4H).LC-
MS: 5min_A: Rt =1.51min, 10min_C: Rt=2.94min.LC-MS (ESI) C31H31N5O2 calcd: 505, 
found: 506 [M+H]+. LC-MS (ESI, HR-MS): calcd for C31H31N5O2: 506.25505 [M+H]+, found 
506.25570 [M+H]+. 
 
2-(2-Methyl-1H-benzo[d]imidazol-1-yl)ethyl 1-(1-benzyl-1H-benzo[d]imidazol-2-
yl)piperidine-4-carboxylate (132) The product was synthesized by Carsten Schultz-
Fademrecht, LDC Dortmund. 1H NMR (400MHz, CDCl3)δ 7.67 (m, 1H), 7.62 (d, J = 7.9 Hz, 
1H), 7.34 - 7.27 (m, 3H), 7.23 - 7.18 (m, 3H), 7.17 - 7.13 (m, 3H), 7.10 (dt, J = 1.2 Hz, J = 7.6 
Hz, 1H), 7.03 (d, J = 8.0 Hz, 1H), 5.17 (s, 2H), 4.40 (m, 4H), 3.40 (dt, J = 13.0 Hz, J = 3.3 Hz, 
2H), 2.93 (dt, J = 2.6 Hz, J = 12.1Hz, 2H), 2.64 (s, 3H), 2.37 (m, 1H), 1.84 - 1.62 (m, 4H). LC-
MS: 5min_A: Rt =1.52min, 10min_C: Rt =2.94min. MS (ES) C31H31N5O2 calcd: 493, found: 
494 [M+H]+. LC-MS (ESI, HR-MS): calcd for C30H31N5O2: 494.25505 [M+H]+, found 
494.25563 [M+H]+. 
 
2-(2-Phenyl-1H-benzo[d]imidazol-1-yl)ethyl 1-(1-benzyl-1H-benzo[d]imidazol-2-
yl)piperidine-4-carboxylate (133) The product was synthesized by Carsten Schultz-
Fademrecht, LDC. 1H NMR (400MHz, CDCl3) δ 7.82 (m, 1H), 7.73 (dd, J = 1.6 Hz, J = 7.9 Hz, 
2H), 7.63 (d, J = 7.9 Hz, 1H), 7.53 - 7.48 (m, 3H), 7.44 (m, 1H), 7.35 - 7.25 (m, 5H), 7.19 (dt, 
J = 1.0 Hz, J = 7.6 Hz, 1H), 7.14 (d, J = 7.0 Hz, 2H), 7.09 (dt, J = 0.8 Hz, J = 7.6 Hz, 1H), 7.02 
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(d, J = 7.9 Hz, 1H), 5.16 (s, 2H), 4.55 (t, J = 5.6 Hz, 2H), 4.35 (t, J = 5.6 Hz, 2H), 3.37 (dt, J = 
12.8 Hz, J = 3.1 Hz, 2H), 2.88 (dt, J = 2.8 Hz, J = 12.0 Hz, 2H), 2.19 (m, 1H), 1.71 - 1.55 (m, 
4H).LC-MS:5min_A: Rt =1.72min, 10min_C: Rt =3.59min.MS (ES) C35H33N5O2 calcd: 555, 
found: 556 [M+H]+.LC-MS (ESI, HR-MS): calcd for C35H33N5O2: 556.27070. [M+H]+ found 
556.27199 [M+H]+. 
 
1-Benzyl-2-(4-(2-(2-phenyl-1H-imidazol-1-yl)ethoxy)phenyl)-1H-benzo[d]imidazole (134) 
The product was synthesized by Carsten Schultz-Fademrecht, LDC Dortmund. 1H NMR (400 
MHz, CDCl3) δ 7.85 (d, J = 7.4 Hz, 1H), 7.61 (m, 4H), 7.50 - 7.40 (m, 3H), 7.39 - 7.27 (m, 4H), 
7.22 (dd, J = 8.2 Hz, 1.4 Hz, 2H), 7.17 (d, J = 13.0 Hz, 2H), 7.11 (d, J = 6.5 Hz, 2H), 6.88 (d, 
J = 8.8 Hz, 2H), 5.43 (s, 2H), 4.43 (t, J = 5.4 Hz, 2H), 4.24 (t, J = 5.4 Hz, 2H).LC-MS:5min_A: 
tR=1.57min, 10min_C: Rt =3.11min. LC-MS (ES) C31H26N4O calcd: 470, found: 471 [M+H]+. 
LC-MS (ESI, HR-MS): calcd for C31H27N4O: 471.21794 [M+H]+, found 471.21850 [M+H]+. 
 
1-Benzyl-2-(4-(2-(2-methyl-1H-benzo[d]imidazol-1-yl)ethoxy)phenyl)-1H-
benzo[d]imidazole (135) The product was synthesized by Carsten Schultz-Fademrecht, LDC 
Dortmund. 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 7.9 Hz, 2H), 7.74 - 7.67 (m, 2H), 7.57 
(d, J = 8.8 Hz, 2H), 7.40 - 7.15 (m, 7H), 7.07 (d, J = 7.5 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 5.38 
(s, 2H), 4.54 (t, J = 5.3 Hz, 2H), 4.32 (t, J = 5.3 Hz, 2H), 2.72 (s, 3H). LC-MS: 5min_A: Rt 
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=1.57min, 10min_C: Rt =3.12min. MS (ES) C30H26N4O calcd: 458, found: 459 [M+H]+.LC-
MS (ESI, HR-MS): calcd for C30H26N4O: 459.21794 [M+H]+, found 459.21835 [M+H]+. 
 
Synthesis of benzimidazole-pyrrole hybrid compounds 
 
(E)-3-(1H-Benzo[d]imidazol-2-yl)-1-phenylprop-2-en-1-one (148) To a suspension of 2-
formyl benzimidazole (500 mg, 3.42 mmol) in DMF (40 mL) was added 
(benzoylmethylene)triphenylphosphorane (1.3 g, 3.42 mmol). The reaction mixture was stirred 
overnight at 600C. The solvent was removed in vacuo and the residue purified by automated 
flash chromatography (DCM:MeOH 100:1 to 10:1) to yield the desired product (612 mg, 
72%).1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 15.6 Hz, 1H), 7.98 (d, J = 15.6 Hz, 1H), 7.89 
– 7.82 (m, 2H), 7.71 – 7.62 (m, 2H), 7.54 – 7.47 (m, 1H), 7.38 – 7.25 (m, 4H).13C NMR (101 
MHz, cdcl3) δ 190.24, 148.82, 137.21, 133.85, 132.22, 129.00, 128.86, 127.01, 124.46. LC-MS 
(ESI): calcd for C16H12N2O: 249.10224 [M+H]
+, HR-MS found: 249.10269 [M+H]+. 
 
 
3-(1H-Benzo[d]imidazol-2-yl)-5-methyl-1-phenylhexane-1,4-dione (151) To a mixture of 
isobutyraldehyde (184 µL,2.0 mmol) and benzimidazole 90 (100 mg,  0.4 mmol) in ethanol (4 
mL) was added triethylamine (40 µL, 0.8 mmol) and then3-Ethyl-5-(2-hydroxyethyl)-4-
methylthiazolium bromide (101 mg, 0.40 mmol). The reaction mixture is heated in a closed 
system to 70°C and stirred overnight. The reaction mixture is allowed to cool to 
roomtemperature. To the reaction mixture is added DCM (15 mL) the reaction mixture is 
extracted with saturated ammonium chloride solution ( 5 mL). The organic phase is extracted 
with brine (5 mL), dried over magnesium sulfate, filtered and evaporated to dryness. The crude 
product is purified by automated flash chromatography (cyclohexane: EtOAc 100:1 to 1:1) to 
yield the desired product (58 mg, 45%).1H NMR (400 MHz, DMSO-d6) δ 12.53 (s, 1H), 8.07 
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– 7.94 (m, 2H), 7.71 – 7.39 (m, 5H), 7.21 – 7.04 (m, 2H), 4.88 (dd, J = 9.4, 4.5 Hz, 1H), 4.13 – 
3.95 (m, 1H), 3.53 (dd, J = 18.2, 4.6 Hz, 1H), 2.90 (hept, J = 6.9 Hz, 1H), 1.14 (d, J = 6.9 Hz, 
3H), 0.86 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 209.83, 197.96, 151.88, 
136.81, 134.12, 129.46, 128.65, 122.80, 46.61, 39.47, 39.38, 19.53, 18.61. LC-MS (ESI): calcd 
for C20H20N2O5: 321.15975 [M+H]
+, HR-MS found: 321.16019 [M+H]+. 
 
(3-(2-Methyl-1H-imidazol-1-yl)propyl)-5-phenyl-1H-pyrrol-3-yl)-1H-benzo[d]imidazole 
(153) To a mixture of diketone 151 (60 mg, 0.19 mmol) and 1-(3-Aminopropyl)-2-methyl-1H-
imidazole (152) (57 mg, 0.41 mmol) in toluene (1 mL) was added acetic acid (106  µL, 
1.87 mmol). The reaction mixture is heated in a closed microwave vial to 100°C for 3 h. The 
reaction mixture was cooled to RT and extracted with NaHCO3 (10 mL). The aqueous phase is 
extracted with DCM (2x 10 mL), the combined organic phases were dried over MgSO4, filtered 
and evaporated to dryness. The crude product was dissolved was in EtOAc (1 mL), and 
cyclohexane was added (1 mL). The mixture was heated at 60°C for 10 min, the mixture 
allowed then to cool to room temperature and the colorless solid was collected by filtration (69 
mg, 87%). 1H NMR (400 MHz, DMSO-d6) δ 12.10 (s, 1H), 7.59 – 7.50 (m, 1H), 7.47 – 7.32 
(m, 6H), 7.13 – 7.04 (m, 2H), 6.88 (d, J = 1.2 Hz, 1H), 6.66 (d, J = 1.2 Hz, 1H), 6.63 (s, 1H), 
4.10 – 3.97 (m, 2H), 3.97 – 3.83 (m, 1H), 3.77 (t, J = 6.7 Hz, 2H), 2.09 (s, 3H), 1.87 – 1.76 (m, 
2H), 1.41 (d, J = 7.1 Hz, 6H).13C NMR (101 MHz, DMSO-d6) δ 150.67, 144.80, 144.10, 
140.41, 134.73, 133.60, 133.33, 129.38, 129.25, 127.99, 127.01, 121.84, 121.43, 120.15, 
118.63, 111.10, 110.99, 109.99, 43.05, 42.37, 32.65, 25.82, 21.62, 13.05. LC-MS (ESI): calcd 
for C27H29N5: 424.24957 [M+H]+, found: 424.28 [M+H]+, Rt = 4.67 min. HR-MS found: 
424.24905 [M+H]+, 
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1-(Cyclopropylmethyl)-2-(2-isopropyl-1-(3-(2-methyl-1H-imidazol-1-yl)propyl)-5-
phenyl-1H-pyrrol-3-yl)-1H-benzo[d]imidazole (154) To a suspension of benzimidazole 153 
(20 mg, 0.05 mmol) in MeCN (1 mL) was added caesiumcarbonate (18 mg, 0.06 mmol) and 
(iodomethyl)cyclopropane (13 mg, 0.07 mmol). The reaction mixture was stirred at room 
temperature for 6 hours. The reaction temperature was then raised to 50°C and stirring was 
continued at this temperature for an additional 18 hours. The reaction mixture was cooled to RT 
diluted with DCM (10 mL) and extracted with NaHCO3 (10 mL). The aqueous phase was 
extracted with DCM twice (2x 10 mL), the combined organic phases were dried over MgSO4, 
filtered and evaporated to dryness. The crude was purified by automated flash chromatography 
(DCM: MeOH 100 :1 to 10:1 with 0.1% triethylamine) to yield the final product (11 mg, 
48%).1H NMR (400 MHz, DMSO-d6) δ 7.63 – 7.59 (m, 2H), 7.44 – 7.34 (m, 5H), 7.25 – 7.15 
(m, 2H), 6.92 – 6.88 (m, 1H), 6.69 – 6.67 (m, 1H), 6.28 (s, 1H), 4.09 (d, J = 6.8 Hz, 2H), 4.08 
– 3.99 (m, 2H), 3.77 (t, J = 6.9 Hz, 2H), 3.21 – 3.09 (m, 1H), 2.12 (s, 3H), 1.91 – 1.82 (m, 2H), 
1.17 (d, J = 7.0 Hz, 6H), 1.12 – 1.06 (m, 1H), 0.45 – 0.38 (m, 2H), 0.29 – 0.23 (m, 2H).13C 
NMR (101 MHz, DMSO-d6) δ 151.33, 144.06, 143.33, 140.32, 135.75, 133.56, 133.05, 129.37, 
129.31, 127.89, 127.03, 122.28, 121.85, 120.07, 119.30, 111.21, 110.85, 109.85, 48.58, 43.04, 
41.88, 32.76, 26.34, 22.79, 13.03, 11.92, 4.61. LC-MS (ESI): calcd for C31H35N5: 478.29652 
[M+H]+,HR-MS found 478.29638[M+H]+. 
 
1-(Cyclopentylmethyl)-2-(2-isopropyl-1-(3-(2-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-
1H-pyrrol-3-yl)-1H-benzo[d]imidazole (155) To a suspension of benzimidazole 153 (20 
mg, 0.05 mmol) in MeCN (1 mL) was added caesiumcarbonate (18 mg, 0.06 mmol) and 
(iodomethyl)cyclopentane (13 mg, 0.06 mmol). The reaction mixture was stirred at 50°C for 5 
days. The reaction mixture was allowed to cool to room temperature and caesiumcarbonate 
(18 mg, 0.06 mmol) and (iodomethyl)cyclopentane (13 mg, 0.06 mmol) were added again. The 
reaction mixture was stirred at 50°C overnight. The reaction mixture was cooled to RT, diluted 
with DCM (10 mL) and extracted with NaHCO3 (10 mL). The aqueous phase was extracted 
with DCM (2x 10 mL), the combined organic phases were dried over MgSO4, filtered and 
evaporated to dryness. The crude product was dissolved in methanol and purified by reverse 
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phase chromatography (CH3CN: H2O 1:5 to 9:1 containing 0.1% TFA) and obtained as a TFA 
salt (5.5 mg, 23%).1H NMR (600 MHz, DMSO-d6) δ 7.99 (d, J = 6.7 Hz, 1H), 7.81 (d, J = 7.2 
Hz, 1H), 7.57 – 7.51 (m, 2H), 7.47 (d, J = 2.0 Hz, 1H), 7.44 – 7.33 (m, 6H), 6.48 (s, 1H), 4.30 
(d, J = 7.7 Hz, 2H), 4.11 – 4.04 (m, 2H), 4.02 (t, J = 6.7 Hz, 2H), 3.28 – 3.17 (m, 1H), 2.41 – 
2.35 (m, 1H), 2.33 (s, 3H), 1.89 – 1.82 (m, 2H), 1.56 – 1.46 (m, 4H), 1.45 – 1.39 (m, 2H), 1.20 
– 1.16 (m, 8H). 13C NMR (151 MHz, DMSO-d6) δ 144.46, 141.55, 134.68, 132.60, 129.49, 
129.44, 128.68, 122.47, 118.83, 111.15, 49.77, 44.67, 41.89, 31.02, 30.37, 26.45, 24.72, 22.54, 
10.62. LC-MS (ESI): calcd for C33H39N5: 506.32782 [M+H]+, found: 506.38 [M+H]+, Rt = 5.49 
min, HR-MS found 506.32798 [M+H]+. 
 
1-Benzyl-2-(2-isopropyl-1-(3-(2-methyl-1H-imidazol-1-yl)propyl)-5-phenyl-1H-pyrrol-3-
yl)-1H-benzo[d]imidazole (156) To a suspension of benzimidazole 153 (30 mg, 0.06 mmol) 
in acetontrile (1 mL) was added caesium carbonate (18 mg, 0.06 mmol). After half an hour 
benzylbromide (7 µL, 0.06 mmol) was added to the reaction mixture. The reaction mixture was 
stirred at RT for 2 days. Methanol was added  and directly applied to reverse phase 
chromatography (CH3CN: H2O 1:5 to 9:1 containing 0.1% TFA) yielding the desired product 
(16 mg, 45%).1H NMR (600 MHz, DMSO-d6) δ 7.82 – 7.75 (m, 2H), 7.51 – 7.43 (m, 3H), 7.40 
– 7.32 (m, 6H), 7.30 – 7.23 (m, 3H), 7.10 – 7.06 (m, 2H), 6.39 (s, 1H), 5.59 (s, 2H), 4.01 (t, J 
= 6.8 Hz, 4H), 3.15 – 3.10 (m, 1H), 2.33 (s, 3H), 1.88 – 1.79 (m, 2H), 1.04 (d, J = 7.0 Hz, 6H). 
LC-MS (ESI): calcd for  C34H35N5: 514.29652 [M+H]
+, HR-MS found: 514.29644 [M+H]+. 
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Synthesis of labeled bis-benzimidazoles 
 
(S)-tert-Butyl 4-(1-(2-(3-cyanophenyl)-1H-benzo[d]imidazol-1-yl)-2-(1-(1-(thiophen-3-
ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-carbonyloxy)ethyl)piperidine-1-
carboxylate ((S)-136) To a solution of  (100 mg, 0.15 mmol) in MeOH, H2O and DMSO (8:2:1, 
5 mL) was added 3-cyano benzaldehyde (43 mg, 0.33 mmol) and sodium dithionite (81 mg, 
0.46 mmol). The reaction mixture was heated to 65°C and after 0.5, 1, and 2 h sodium 
dithionite  (3x 81 mg, 0.46 mmol) was added. After 5 h the reaction mixture was allowed to 
cool to room temperature. The reaction mixture was concentrated under reduced pressure and 
then extracted with DCM (3x 50 mL). The combined organic phases were dried (Na2SO4), 
filtered and concentrated to dryness. Purification by flash chromatography (gradient 
cyclohexane : ethyl acetate 5:1 to 1:5) afforded (S)-136 (74 mg, 0.010 mmol, 64%). 1H NMR 
(400 MHz, CDCl3) δ 8.06 – 7.95 (m, 2H), 7.87 (dd, J = 12.8, 5.8 Hz, 2H), 7.74 (t, J = 7.4 Hz, 
2H), 7.60 (d, J = 5.1 Hz, 1H), 7.46 – 7.27 (m, 5H), 7.17 (d, J = 7.9 Hz, 1H), 7.08 (d, J = 1.4 Hz, 
1H), 6.93 (d, J = 5.0 Hz, 1H), 5.20 (s, 2H), 5.04 – 4.91 (m, 1H), 4.62 (dd, J = 11.9, 3.8 Hz, 1H), 
4.38 (t, J = 7.9 Hz, 1H), 4.17 (d, J = 13.3 Hz, 1H), 4.00 – 3.83 (m, 1H), 3.77 – 3.56 (m, 2H), 
3.42 – 3.22 (m, 2H), 2.70 (t, J = 12.3 Hz, 1H), 2.62 – 2.34 (m, 3H), 2.00 – 1.79 (m, 3H), 1.79 
– 1.53 (m, 2H), 1.40 (s, 9H), 1.24 (t, J = 10.1 Hz, 1H), 0.96 – 0.67 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 173.09, 161.89, 161.53, 154.66, 153.12, 152.33, 141.54, 134.45, 134.10, 
133.52, 132.74, 132.02, 130.82, 130.63, 130.54, 128.67, 125.59, 125.53, 124.92, 124.74, 
124.36, 122.56, 120.44, 118.01, 117.93, 115.05, 113.60, 112.28, 110.59, 80.21, 63.52, 61.71, 
49.35, 46.05, 39.68, 37.35, 29.93, 28.83, 28.57, 27.50. LC-MS (ESI): calcd for C18H27N3O5: 
689.31158 [M+H]+, found: 689.29 [M+H]+, Rt = 8.47 min; HR-MS found 689.31133 [M+H]+. 
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2-(3-(3,12-dioxo-5,8-dioxa-2,11-diazatridecyl)phenyl)-1H-enzo[d]imidazol-1-yl)-2-
(piperidin-4-yl)ethyl 1-(1-(thiophen-3-ylmethyl)-1H-benzo[d]imidazol-2-yl)piperidine-4-
carboxylate = TAMRA-(S)-92. Raney Nickel (Aldrich, W.R. Grace and Co. Raney®2800, 
slurry, in H2O, 40 mg) was added to an argon filled flask containing ammonia in ethanol (2.0 
M, 1 mL). After 5 minutes of stirring the liquid was removed via syringe. The flask was 
evacuated and flushed with argon. Ammonia in ethanol (2.0 M, 4 mL) was then added, followed 
by compound (S (15 mg, 19 µmol). The solution was purged with argon for 2 minutes and kept 
under an atmosphere of hydrogen (1 atm, balloon). The resulting reaction mixture was stirred 
at room temperature for 3 h to afford the free amine (LC-MS: 6.36 min retention time, [M+H]+ 
774.36). The reaction mixture was filtered over a pad of Celite, the filter cake was washed with 
EtOH (30 mL) and ethylacetate (20 ml) and the filtrate was concentrated under reduced 
pressure. To the crude amine in DMF (1 mL) was added PyBOP (12 mg, 23 µmol) and TAMRA-
PEG-COOH (13 mg, 23 µmol). The reaction mixture was stirred at room temperature overnight. 
The reaction mixture was concentrated under reduced pressure. To the residue was added HCl 
in dioxane (4 M) and the mixture was stirred for 2 h at room temperature. The reaction mixture 
was concentrated under reduced pressure, the residue was dissolved in methanol and purified 
by reverse phase chromatography to yield TAMRA-(S)-92 (7 mg, 6 µmol, 29 %). 1H NMR (400 
MHz, DMSO-d6) δ 8.95 (t, J = 5.5 Hz, 1H), 8.63 (s, 1H), 8.54 – 8.46 (m, 1H), 8.46 – 8.38 (m, 
1H), 8.30 – 8.23 (m, J = 8.1 Hz, 1H), 8.11 – 7.98 (m, 1H), 7.84 (d, J = 7.6 Hz, 1H),7.67 – 7.60 
(m, 2H), 7.58 – 7.39 (m, 6H), 7.35 – 7.22 (m, 4H), 7.22 – 7.11 (m, 2H), 7.06 – 6.87 (m, 6H), 
5.23 (s, 2H), 4.89 (s, 1H), 4.56-4.38 (m, J = 45.4, 9.5 Hz, 3H), 3.97 (s, 2H), 3.08 – 2.90 (m, 
3H), 2.88 – 2.76 (m, 1H), 2.75 – 2.61 (m, 1H) 2.08 – 1.91 (m, 2H), 1.71 – 1.27 (m, 7H), 1.27 – 
1.13 (m, 2H), 1.15 – 0.91 (m, 3H).  LC-MS (ESI): found: 1231.58 [M+H]+, Rt = 5.76 min; HR-
MS calcd for C70H74N10O9S: 411.18597 [M+3H]3+, found 411.18576 [M+3H]3+. 
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(S)-3-(1-(2-(4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(piperidin-4-yl)ethyl)-1H-
benzo[d]imidazol-2-yl)benzonitrile ((S)-169) The desired product was synthesized according 
to the procedure for (S)-136 starting from (S)-117(15 mg, 60%).1H NMR (400 MHz, CDCl3) δ 
8.09 (s, 1H), 7.98 (d, J = 7.7 Hz, 1H), 7.80 – 7.71 (m, 3H), 7.63 – 7.51 (m, 4H), 7.31 – 7.20 (m, 
6H), 7.18 – 7.10 (m, 2H), 7.03 – 6.97 (m, 2H), 6.85 (d, J = 8.8 Hz, 2H), 5.33 (s, 2H), 4.72 (t, J 
= 9.2 Hz, 1H), 4.49 – 4.34 (m, 2H), 4.17 – 4.02 (m, 1H), 3.92 – 3.72 (m, 1H), 2.64 (t, J = 12.5 
Hz, 1H), 2.56 – 2.31 (m, 2H), 1.85 (d, J = 12.9 Hz, 1H), 1.33 (s, 9H), 1.26 – 1.11 (m, 1H), 0.86 
– 0.74 (m, 2H). LC-MS (ESI): calcd for C46H45N6O3 729.25 [M+H]+, found: 729.31 [M+H]+. 
 
(S)-N-(2-(2-(2-(3-(1-(2-(4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(piperidin-4-
yl)ethyl)-1H-benzo[d]imidazol-2-yl)benzylamino)-2-oxoethoxy)ethoxy)ethyl)-3',6'-
bis(dimethylamino)-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxamide 
(S)-137 (TAMRA-Deltarasin) The desired product was synthesized according to the procedure 
for TAMRA-(S)-92 starting from (S)-169 (5 mg, 20%).1H NMR (400 MHz, DMSO) δ 8.94 (t, 
J = 5.5 Hz, 1H), 8.70 – 8.58 (m, 2H), 8.40 (t, J = 6.2 Hz, 1H), 8.24 (dd, J = 8.0, 1.7 Hz, 1H), 
8.19 – 8.02 (m, 1H), 7.95 (d, J = 7.0 Hz, 1H), 7.78 – 7.57 (m, 6H), 7.57 – 7.41 (m, 4H), 7.41 – 
7.19 (m, 6H), 7.15 – 6.87 (m, 9H), 5.55 (s, 2H), 4.86 (t, J = 9.6 Hz, 1H), 4.67 – 4.48 (m, 2H), 
4.43 (d, J = 6.0 Hz, 2H), 3.94 (s, 2H), 2.79 – 2.63 (m, 2H), 2.10 (d, J = 12.5 Hz, 1H), 1.50 – 
1.34 (m, 1H), 1.11 – 0.87 (m, 2H). LC-MS (ESI): calcd for C72H71N9O8: 1190.54 [M+H]+, 
found: 1190.1 [M+H]+. 
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N-(3-(1-((R)-2-(4-(1-Benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-1-(piperidin-4-yl)ethyl)-
1H-benzo[d]imidazol-2-yl)benzyl)-1-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)-3,6,9,12-tetraoxapentadecan-15-amide (170) To the 
hydrogenated product of (S)-169 (65 mg, 0.09 mmol) was added Biotin-PEG-COOH (44 mg, 
0.09 mmol), DIPEA  (79 µL, 0.44 mmol) and HATU (34  mg,0.09 mmol). The reaction mixture 
was stirred at room temperature for 18 h. Water (2 mL) was added to the reaction mixture, the 
precipitate was collected and washed with water (2x 4 mL). The solid was dissolved in DCM  
(1 mL), HCl/dioxane (1 mL, 4 M) was added and the reaction mixture was stirred at room 
temperature for 3 h. The solvent is removed in vacuo, redissolved in MeOH and purified by 
reverse phase chromatography to yield the desired compound as an TFA salt (48 mg, 45%).1H 
NMR (400 MHz, DMSO-d6) δ 8.64 – 8.53 (m, 1H), 8.49 (t, J = 5.8 Hz, 1H), 8.17 – 8.02 (m, 
1H), 7.97 (d, J = 7.6 Hz, 1H), 7.84 – 7.73 (m, 2H), 7.71 – 7.63 (m, 4H), 7.60 – 7.49 (m, 2H), 
7.49 – 7.42 (m, 1H), 7.41 – 7.25 (m, 6H), 7.17 – 7.10 (m, 2H), 7.08 – 7.01 (m, 2H), 6.47 – 6.23 
(m, 2H), 5.59 (s, 2H), 4.87 (t, J = 9.7 Hz, 1H), 4.64 (d, J = 7.8 Hz, 1H), 4.59 – 4.50 (m, 1H), 
4.46 – 4.33 (m, 2H), 4.31 – 4.25 (m, 1H), 4.10 – 4.07 (m, 1H), 3.59 (t, J = 6.3 Hz, 2H), 3.48 – 
3.26 (m, 16H), 3.18 – 3.11 (m, 2H), 3.09 – 3.01 (m, 2H), 2.94 – 2.63 (m, 5H), 2.38 (t, J = 6.2 
Hz, 2H), 2.10 (d, J = 13.0 Hz, 1H), 2.04 (t, J = 7.5 Hz, 2H), 1.64 – 1.53 (m, 1H), 1.51 – 1.37 
(m, 4H), 1.33 – 1.19 (m, 2H), 1.11 – 0.92 (m, 2H). LC-MS (ESI): calcd for  C62H75N9O8S: 
1106.55321 [M+H]+, found: 1106.44 [M+H]+, HR-MS found 1106.55238 [M+H]+. 
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Synthesis of lipidated N-terminal Lyn peptide 
 
Mono lipidated N-terminal Lyn peptide 179 (Fmoc)-Boc-Lys-Allyl was synthesized and 
immobilized as previously described.40 N-terminal elongation was achieved by cycles of N-
deprotection and peptide bond formation using Fmoc-(Trt)-SerOH, Fmoc-(Mtt)-Lys-OH, 
Fmoc-Ile-OH, Fmoc-Gly-OH and myristoic acid. Deprotection was achieved using 5 mL of 
20% piperidine and 2% DBU in DMF twice for 10 minutes. Subsequently the resin was washed 
5 times with DMF. All amino acids were coupled twice employing 4 eq of amino acid, 4 eq of 
HCTU and 8 eq of DIPEA in 5 ml DMF. Double couplings were carried out at 60°C for 15 
minutes each cycle. The C-terminal allyl group was deprotected with 0.05 eq Pd(PPh3)4 and 10 
eq of PhSiH3 in THF for 2 hours. The allyl deportected building block was coupled Fmoc-PEG-
NH2 (1eq) using PyBop (2 eq) and NMM (2eq), deprotected and treated with 2 eq FITC. 
Cleavage from the solid support and side chain deprotection was performed by treating the resin 
with 15 mL of 5 % TFA in dry DCM containing 2 % TES for 1 hour. The solvent was evaporated 
and redissolved in MeOH. The resulting solution was filtered, and the filtrate purified by 
preparative HPLC using a C18 column (Yield 8%).1H NMR (400 MHz, dmso) δ 10.11 (s, 2H), 
9.97 (s, 1H), 8.22 (s, 1H), 8.19 – 8.11 (m, 2H), 8.05 (t, J = 5.6 Hz, 2H), 8.00 – 7.85 (m, 3H), 
7.81 (d, J = 8.2 Hz, 1H), 7.78 – 7.56 (m, 9H), 7.16 (d, J = 8.3 Hz, 1H), 6.66 (d, J = 2.2 Hz, 2H), 
6.63 – 6.51 (m, 4H), 5.17 (s, 1H) 4.44 – 4.31 (m, 1H), 4.30 – 4.18 (m, 2H), 4.12 (t, J = 7.6 Hz, 
2H), 3.73 – 3.46 (m, 17H), 3.09 – 3.02 (m, 2H), 2.83 – 2.62 (m, 5H), 2.10 (t, J = 7.5 Hz, 2H), 
1.85 – 1.36 (m, 18H), 1.33 – 1.20 (m, 20H), 1.13 – 0.98 (m, 1H), 0.91 – 0.74 (m, 9H). LC-MS 
(ESI): calcd for C71H109N11O17S: 1420.77 [M+H]+, found 1421.57 [M+H]+, Rt = 6.76 min.  
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Double lipidated N-terminal Lyn 180 The peptide was synthesiszed in an analogous fashion 
to the mono lipidated peptide 179. The racemization-prone hexadecylated cysteine126 building 
block was coupled twice at room temperature for 5 h.(Yield 4%). 1H NMR (400 MHz, dmso) δ 
10.11 (s, 2H), 10.03 – 9.90 (m, 1H), 8.22 (s, 1H), 8.19 – 8.09 (m, 2H), 8.09 – 8.02 (m, 2H), 
8.02 – 7.93 (m, 4H), 7.89 (d, J = 8.1 Hz, 1H), 7.84 – 7.58 (m, 10H), 7.16 (d, J = 8.4 Hz, 1H), 
6.66 (d, J = 2.2 Hz, 2H), 6.63 – 6.46 (m, 4H), 5.18 (s, 1H), 4.50 – 4.41 (m, 1H), 4.29 – 4.17 (m, 
2H), 4.17 – 4.05 (m, 2H), 3.74 – 3.39 (m, 15H), 3.13 – 3.02 (m, 3H), 2.81 – 2.58 (m, 6H), 2.10 
(t, J = 7.5 Hz, 2H), 1.87 – 1.36 (m, 18H), 1.36 – 1.12 (m, 60H), 0.87 – 0.74 (m, 13H). LC-MS 
(ESI): calc for C87H141N11O16S2 1661.00 found: 1661.70 [M+H]
+, Rt = 7.36 min.
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7 APPENDIX 
KD,app values determined by Alpha technology (COMAS).
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 KD values of sulfonamides in nM, determined by means of fluorescence polarization 
assays (average of triplicate determination) 
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8 ZUSAMMENFASSUNG 
Ras-Proteine sind molekulare Schalter, die in gesunden Zellen Wachstum und Teilung 
regulieren. Mutationen in Ras-Genen können zu einem dauerhaft angeschalteten Zustand 
führen und im ungünstigsten Fall zur Entstehung von Tumoren durch permantes Zellwachstum 
beitragen. Da fast jeder dritte Tumor eine Mutation in einem der Ras-Proteine aufweist, 
befinden sich diese Proteine seit Jahren im Fokus der Wirkstoffentwicklung. Von 
herausragendem Interesse ist dabei die besonders aggressive K-Ras Isoform. Die Lokalisation 
von K-Ras in der Zelle ist eng mit der biologischen Schalterfunktion verknüpft, da K-Ras nur 
an der Plasmamembran aktiv die Signaltransduktion beeinflussen kann.  
Das Transport-Protein PDEδ reguliert die zelluläre Lokalisation von K-Ras und damit die K-
Ras abhängige Signaltransduktion. Im Gegensatz zu K-Ras selbst weist PDEδ eine große 
hydrophobe Bindungstasche auf, die es erlaubt mittels kleinen synthetischen Molekülen die 
Signaltransduktion von Ras zu beeinflussen. Wichtigstes Ziel dieser Arbeit war deshalb die 
Identifikation und Optimierung von Inhibitoren der K-Ras-PDEδ-Wechselwirkung.  
Identifkation und Optimierung von Benzimidazole basierten K-Ras-PDEδ Inhibitoren 
Für die biochemische Hochdurchsatztestung von Inhibitoren wurde ein C-terminales K-Ras-
Peptid synthesiert und PDEδ heterolog in E.Coli produziert. Eine 40000 Moleküle umfassende 
Substanzbibliothek wurde dann mittels Alpha screen bezüglich ihrer Wirkung auf die K-Ras-
PDEδ-Interaktion untersucht. Dabei wurde das Benzimidazolfragment 10 identifiziert als 
nanomolarer Inhibitor der K-Ras-PDEδ-Interaktion identifiziert (Abbildung 1, a). Durch 
Kokristallisation des Benzimidazolfragments mit PDEδ und isothermaler Titrationskalorimetrie 
(ITC) konnte die Bindung von zwei Benzimidazol-Fragmenten 10 an das Protein nachgewiesen 
werden (Abbildung 1, b). In ITC-Messungen wurde dabei eine stark Enthalpie getriebene 
Interaktion der Benzimidazole mit PDEδ festgestellt, welche sich auf die Ausbildung von zwei 
Wasserstoffbrücken zu jedem der Benzimidazolfragmente (Arg61 und Tyr149, Abbildung 1, b) 
zurückführen lässt. Um die Affinität und damit auch die Spezifität der Benzimidazol-Liganden 
zu verbessern, wurden die zwei Fragmente des Benzimidazoles 10 miteinander verknüpft. Die 
besten Phenylether-verbrückten bis-Benzimidazole wiesen KD Werte bis zu 16 nM auf und 
zeigten damit eine deutliche bessere Affinität als das Fragment 10. In der Kristallstruktur des 
bis-Benzimidazols 55 mit PDEδ (Abbildung 1, c) zeigt die Allylgruppe in Richtung der 
Carbonylfunktion des Rückgratamids von Cys56. Deshalb wurden in der Folge Moleküle zu 
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synthetisiert, welche eine weitere Wasserstoffbrücke zur Carbonylgruppe von Cys56 ausbilden 
können. Dazu wurde die verbrückende Phenylether-Einheit durch einen flexibleren Piperidyl-
Ester ersetzt (Abbildung 1, a, rechts) und die Allylgruppe durch ein Piperidin substituiert.       
           
   
Abbildung 1 Strukturen und Bindungsaffinitäten der synthetisierten Benzimidazole bestimmt durch 
Verdrängungstirationen von Fluorescein-Atorvastatin.79 a) Strukturen der Benzimidazol-basierten Inhibitoren; b) 
Kokristallstruktur von Benzimidazolfragment 10 mit PDEδ (gelb). Überlagert ist die Struktur der vorher 
bestimmten Kristallstruktur von farnesyliertem Rheb-Peptid  mit PDEδ (cyan). Das Benzimidazolfragment 10 
(grün) und die Farnesylgruppe (rot) sind als Stäbchenmodell dargestellt. Wasserstoffbrückenbindungen zwischen 
den zwei Benzimidazolfragmenten 10 und dem Protein sind hervorgehoben; c) Struktur von (rac)-55 (orange) im 
Komplex mit PDEδ. Überlagert sind die zwei Benzimidazolfragemente 10 (schwach graue Stäbchen); d) Die 
Kokristallstuktur von (S)-90 und PDEδ bestätigt die erwartete Wasserstoffbrücke zwischen der Piperidingruppe 
und dem Rückgratcarbonyl von Cys56. Die Kokristallstrukturen wurden von Dr. Shehab Ismail gelöst. 
Die Ester-verbrückten bis-Benzimidazole 90 und 92 wiesen dabei verbesserte Affinitäten auf. 
Die durch Computermodellierung vorhergesagte Wasserstoffbrücke zu Cys56 konnte durch 
eine Kokristallstruktur verifiziert werden (Abbildung 1, d). Direkte Titrationen der 
fluoreszenzmarkierten Moleküle TAMRA-(S)-62-Deltarasin und TAMRA-(S)-92 mit 
a 
b c d 
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PDEbestätigten die hohe Affinität der bis-Benzimidazole (KD-Werte 5-7 nM). Hingegen 
konnte keine Interaktion mit den Lipid-bindenden Proteinen UNC119a/HRG4, UNC119b and 
Galectin 1/3 beobachtet werden, was auf eine sehr gute Selektivität der bis-Benzimidazole 
hindeutet. Durch zeitaufgelöste Fluoreszenzanisotropie-Messungen konnte die Kinetik der 
Interaktion zwischen fluoreszenzmarkierten bis-Benzimidazolen und PDE untersucht werden. 
Dabei wurden fürden TAMRA-(S)-92-PDE-Komplex Dissoziations-Halbwertszeiten im 
Stundenbereich gemessen. Mittels Oberflächenplasmonenresonanz (SPR) konnten sowohl die 
sehr langsame Dissoziation der bis-Benzimidazol-PDE-Komplexe als auch die sehr niedrigen 
KD-Werte verifiziert werden. Für den nicht fluoreszenzmarkierten Ester (S)-90 konnte dabei aus 
kinetischen Messdaten eine Affinität von 77 pM berechnet werden. 
Inhibitoren der K-Ras-PDEδ-Wechselwirkung hemmen die onkogene Ras-
Signaltransduktion 
Da die sehr potenten Esterverbindungen jedoch potentiell empfindlich gegenüber Hydrolasen 
sind, wurde in zellulären Experimente nur mit Ether-verknüpften bis-Benzimidazolen 
gearbeitet. Das gut lösliche bis-Benzimidazole (S)-62 Deltarasin wurde deshalb bezüglich 
seines Effekts auf PDEδ in Zellen untersucht. Sowohl für immobilisiertes als auch für freies 
Deltarasin konnte die Interaktion mit PDEδ in Zellysaten mittels Western Blot nachgewiesen 
werden. Björn Papke konnte zeigen, dass Deltarasin auch die Wechselwirkung zwischen K-Ras 
und PDEδ in lebenden Zellen inhibitiert. Darüberhinaus hemmt Deltarasin die Erk-
Phosyphorylierung und stoppt selektiv das Wachstum von Ras-abhängigen Zelllinien, sowohl 
in cellulo als auch in vivo im Maus-Xenograft-Modell. 
Optimierung und Identifikation neuer Substanzklassen von PDEδ Inhibitoren   
Durch weitere strukturbasierte Optimierung konnte das Molekulargewicht und die 
Hydrophobizität der bis-Benzimidazole gesenkt werden, wobei die Affinität für das PDEδ 
erhalten blieb. In einem weiteren Ansatz konnte der literaturbekannte PDEδ-Inhibitor 
Atorvastatin rational modifiziert werden und die Affinität um fast zwei Größenordnungen 
verbessert werden. Durch Hochdurchsatztestung identifizierte bis-Sulfonamide wurden durch 
eine kommerziell erhältliche Bibliothek von 56 Derivaten ergänzt. Diese Verbindungen zeigten 
sehr hohe Affinitäten im niedrig nanomolaren Bereich. 
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Allosterische Verdrängung von PDEδ Inhibitoren durch Arl2/3.  
Obwohl Deltarasin und andere Inhibitoren eine nanomolare Potenz in biochemischen Assays 
aufwiesen, konnten keine Inhibitoren mit nanomolarer Aktivität in zellulären Testsystemen 
identifiziert werden. Dies deutet auf einen Chemotyp-unabhängigen Mechanismus hin, der die 
Wirkung der Inhibitoren blockiert. Die GTPasen Arl2/3 regulieren die K-Ras-PDEδ Interaktion 
allosterisch durch Bildung eines transienten ternären Komplexes. Die allosterische Regulation 
wurde deshalb im Rahmen dieser Arbeit auch für die hoch affinen Sonden TAMRA-(S)-62-
Deltarasin und TAMRA-(S)-92 untersucht. Dabei konnte festgestellt werden, dass sowohl Arl2 
als auch Arl3 das fluoreszenzmarkierte (S)-62 Deltarasin aus der Bindungstasche verdrängen, 
während der stärker bindende Ester TAMRA-(S)-92 nur von Arl3 aus der Bindungstasche 
entfernt werden konnte. Interessanterweise zeigte sich in zeitaufgelösten 
Verdrängungsexperimenten, dass Arl3 eine sehr viel höhere Affinität gegenüber PDEδ aufweist 
als Arl2. Diese Messdaten deuten auf zwei untschiedliche Funktionen von Arl2 und Arl3 in der 
Zelle hin. Demnach kontrolliert Arl2 die Lokalisation von relativ schwach bindenden, 
prenylierten GTPasen wie Ras im Zytoplasma. Arl3 hingegen lokalisiert hauptsächlich im 
primären Cilium, wo es hochaffine Binder wie die Inositol-Phosphatase INPP5E aus der 
Farnesylbindungstasche von PDEδ verdrängt. 
Prenylspezifität der Bindung von Proteinen an PDEδ 
PDEδ transportiert farnesylierte Proteine wie K-Ras in der Zelle. Die Interaktion mit 
geranylgeranylierten Proteinen hingegen wird in der Literatur kontrovers diskutiert. Gerade im 
Hinblick auf mögliche Nebenwirkungen von Inhibitoren der K-Ras-PDEδ-Wechselwirkung ist 
die Prenylspezifität jedoch von entscheidender Bedeutung. Im Rahmen dieser Arbeit wurde 
erstmals eine Peptidsequenz untersucht, welche sowohl geranylgeranyliert als auch farnesyliert 
vorlag. Dabei konnte eine leichte Präferenz (Faktor 2.5) von PDEδ für farnesylierte Peptide 
abgeleitet werden. Die gemessene Selektivität liegt weit unterhalb der Literaturwerte, die einen 
dramatischen Affinitätsunterschied (mindestens Faktor 100) zwischen geranylgeranylierten und 
farnesylierten Peptiden suggerieren. 
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Rationales Design von UNC119a/b Inhibitoren   
UNC119a und UNC119b sind myristoyl-bindende Proteine, die eine hohe Sequenzidentiät mit 
PDEδ aufweisen. Die Lipidbindungstasche befindet sich jedoch auf der anderen Seite der -
Fass-Struktur der Proteine. Basierend auf der literaturbekannten Kokristallstruktur von 
UNC119a mit dem N-Terminus von Transducin- wurde versucht rational Inhibtoren in silico 
zu entwerfen. In vorherigen ITC Messungen konnte die Lipidabhängigkeit der Interaktion 
zwischen N-terminalen Transducin--Peptiden und UNC119a gezeigt werden. Eine Analyse 
der Kokristallstruktur von UNC119a/Tranducin- zeigte darüberhinaus die Interaktion von 
Ser218 (UNC119a) mit der Carbonylfunktion des N-terminalen Amids von Tranducin-. 
Deshalb wurden lipidierte Moleküle mit starken Wasserstoffbrückenakzeptoren bezüglich ihrer 
Bindung an UNC119a und UNC119b untersucht. Dabei wurde festgestellt, dass das lipidierte, 
-Lacton Palmostatin B an UNC119a mit einer mikromolaren Affinität bindet. 
In einem weiteren Ansatz wurde die helikale Sekundärstruktur des N-Terminus von Transducin-
im Komplex mit UNC119a/b für das Design von stabilen Peptidmakrozyklen ausgenutzt. 
Dabei wurde der myristoylierte N-Terminus von Transducin-durch lipidierte 
Peptidmakrozyklen ersetzt. Die Peptidmakrozyklen zeigten dabei Affinitäten für UNC119a/b 
im niedrig nanomolaren Bereich und sind deshalb sehr gut zur Untersuchung des Transports 
von myristoylierten Proteinen im Zytoplasma und im primären Cilium geeignet.   
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9 LIST OF ABBREVIATIONS 
Alpha  amplified luminescent proximity homogeneous assay 
Arl    Arf-like  
Arf   ADP ribosylation factors 
Arg   arginine 
aq   aqueous 
au   arbitrary units 
Bn   benzyl 
Boc    tert-butyl carboxycarbonyl 
   chemical shift in ppm (NMR) 
Cbz   caboxylbenzyl 
Cps   counts per second  
Cpd   compound 
Cys   cysteine 
Da   dalton 
DIPEA  diisopropyl ethyl amine 
DCM  dichloromethane 
DMAP  4-dimethylaminopyridine 
DMF   N, N-dimethylformamide 
DMSO  dimethylsulfoxide 
ee   enantiomeric excess 
eq   equivalents 
ESI   electro spray ionization 
Et   ethyl 
EtOH  ethanol 
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EtOAc   ethyl acetate 
FACS  fluorescence-activated cell sorting 
Far   farnesyl 
FITC   fluorescein isothiocyanate 
FLIM  fluorescence lifetime imagining 
FP   fluorescence polarization 
FRET  Förster resonance energy transfer 
g   gram 
GppNHp  5'-guanylyl imidodiphosphate 
GDP   guanosine diphosphate 
Gli   transcription factor identified in Glioblastoma 
GTP   guanosine triphosphate 
GTPase   guanosine triphosphatase 
h   hour 
HCTU O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
His   histidine 
HPLC  high performance liquid chromatography 
HR-MS  high resolution mass spectrometry 
Hz   hertz 
ITC   isothermal titration calorimetry 
J   coupling constant 
KD   thermodynamic equilibrium constant 
kcal   kilocalorie 
L   liter 
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m   multiplet 
MDCK  Madin-Darby canine kidney 
Me   methyl 
MeCN  acetonitrile 
MeOH  methanol 
MORM  mental retardation, truncal obesity, retinal dystrophy and micropenis 
Mtt   4-methyl trityl 
m/z   mass to charge ratio 
n-BuLi  n-butyl lithium 
nd   not determined 
NMM  N-methyl morpholine 
NMP   N-methyl pyrrolidone 
OD   optical density (absorbance) 
P   power 
PAMPA  parallel artificial membrane permeability assay 
PDAC  pancreatic ductual adenocarcinoma  
PDEδ  non catalytic δ-subunit of phosphodiesterase 6, prenyl binding protein PrBP/δ 
PEG   polyethylene glycol 
PMSF  phenylmethanesulfonylfluoride 
Ph   phenyl 
PM   plasma membrane 
RMSD  root square mean deviation 
Ras   rat sarcoma (protein) 
Rheb   ras homologue enriched in brain 
RhoGDI  ras homologue guanosine diphosphate dissociation inhibitor 
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RT   room temperature 
RTCA  real time cell analysis 
s   singlet 
si-RNA  small interefering ribonucleic acid 
SPR   surface plasmon resonance 
Tm   protein melting point 
TAMRA  tetramethylrhodamine 
TES   triethylsilane 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TMAD  N,N,N',N'-tetramethylazodicarboxamide 
 UNC  uncoordinated (protein) 
 Ser   serine 
 Tyr   tyrosine 
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